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CD23/FceRII is the low affinity receptor for IgE on B lymphocytes and the 
counterstructure for the complement receptor type 2, (CR2, CD21, EBV receptor); it is 
the interaction of CD23 with CR2 that has been the subject of this study. Recombinant 
CD23 fragment comprising the entire extracellular domain of human CD23 was expressed 
in E. coli and large amounts of the protein were obtained and purified. An optimal 
protocol for refolding of denatured inactive protein expressed in bacterial cells has been 
developed. The major molecular form of the recombinant soluble CD23 was found to be 
a dimer but there also appears to exist an equilibrium between dimer and trimer, as well 
as between monomer and dimer. A model has been proposed in which the transition of 
CD23 dimer into trimer occurs at the protein concentration of 10' M. It has been further 
demonstrated that the recombinant dimeric CD23 binds to CR2 on B cells and also 
interacts with recombinant soluble CR2 expressed in insect cells. Moreover, it has been 
shown that CD23 can crosslink IgE and CR2 in vitro. The functional consequence of 
CD23-CR2 interaction has been studied; CD23 expressed together with the low affinity 
receptor for IgG (CD32) in a fibroblast cell line was found to be stimulatory for tonsillar 
B cells in as much as it: (i) lowered the threshold for activation of cells by a factor of 10- 
100, (ii) enhanced the cellular response to antigen receptor ligation and (iii) modulated 
B cell response to CD19 ligation. In addition to the adhesion type interaction with CR2 
that has been shown responsible for the stimulatory effects of CD23, there also appears 
to be a synergistic interaction between CD23 and CD32, tile manner of which resembles 
the synergistic interaction of CR2 and CD19 with antigen receptor. Thus, CD23 must now 
be added to the list of CR2 ligands (Od, EBV) and antibodies that can induce 
proliferation of B cells through this receptor. 
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CHAPTER 1: INTRODUCTION 
1.1. Introduction to CD23 
1.1.1. IgE and IgE system 
Immunoglobulin E (IgE) is one of the five classes of immunoglobulins in humans (the 
others being IgM, IgD, IgG and IgA) and it is generally known for its principal role in 
mediating allergic disorders such as asthma, rhinitis (hay fever), atopic dermatitis, food 
allergy and anaphylaxis. Allergy is certainly one of the major environmental diseases of 
modem time and considerable efforts have been made over the past two decades towards 
understanding the molecular mechanisms involved in allergic reactions. The allergic 
reaction generally requires three components: allergen, specific antibody and the effector 
cell. The allergens are multivalent antigens present in our environment in numerous and 
very different forms, while the antibody is IgE. The third component of the allergic 
reaction is the effector cell such as mast or basophil cell, which is capable of binding IgE 
via its high affinity receptor, FcFRl. The binding of the allergen to the IgE/receptor 
complex on the surface of these cells activates a signal transduction mechanism leading 
to the degranulation of the cell and release of histamine and a number of lymphokines, 
including interleukin-4 (IL-4), (Paul, 1991). IL-4 activates IgE production via a complex 
regulatory mechanism that culminates in immunoglobulin class switching from IgM to IgE 
(Finkelman et al., 1990; de Vries et al., 1991) and requires contact between B cell and 
CD4+ T cell through the interaction of CD40 and CD40L (CD40-ligand), (Armitage et 
al., 1992). 
The newly synthesised IgE binds to its high affinity receptor on mast cells enabling them 
to bind more allergen which in turn, stimulates them to release more histamine and IL-4, 
thus creating a local feedback loop. The switched B cells would normally produce 
predominantly nonspecific IgE capable of binding to mast cells but not able to initiate 
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their activation; therefore, a threshold level of allergen specific B cells is required for the 
synthesis of allergen-specific IgE for the repeated contact with the allergen, to maintain 
the feedback loop (Scharenberg and Kinet, 1994). 
The recruitment and activation of the inflami-natory cells by the products of degranulation 
of mast cells induces the expression of the low affinity receptor for IgE (CD23, FcCRH) 
which is responsible for IgE-dependent cytotoxic activities of the inflammatory cells, such 
as phagocytosis of the immune complexes by monocytes (Kikutani and Kishimoto, 1990). 
Apart from this activity CD23 facilitates a number of other IgE dependent or independent 
activities through the interaction with its other ligands, CR2, CR3 and CR4 (complement 
receptors type 2,3 and 4). 'llie number of proteins involved in IgE system or activated by 
its components extends further to two soluble receptor molecules called IgE binding 
protein (cBP) and IgE-binding factor(s) (IgE-BF). It is clear that although IgE is expressed 
at very low concentration in human serum (50-300 ng/ml, as compared by 10 mg/ml for 
IgG), its action is powerfully amplified by the activities of the receptors and other proteins 
to which it binds, and subsequently by the activities of the proteins activated by these 
interactions. This has led Sutton and Gould, (1993), to introduce the term "IgE network" 
comprising IgE and its receptors and CR2 as the second ligand for CD23. The schematic 
representation of the IgE network and its interaction with complement system through 
CD23 is given in Fig. 1-1. 
1.1.2. The structure of IgE 
From the structural point of view IgE assembles similarity to the other immunoglobulin 
classes, comprising two heavy and two light chains, but the IgE e heavy chain, like the 
p chain of IgM consists of five domains, as compared to the four domains in other 
immunoglobulins. The additional domain (W) is placed into the constant region of the 
heavy chain in place of the hinge region in IgG and IgA. Unlike IgG, IgE is heat labile 
and its half-life in the serum is two and a half days, as compared with 21 days for IgG. 
The restricted proteolysis of IgE generates an Fc fragment (CF, 2-Ce4) that still retains the 
capacity to bind both IgE receptors. 
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Fig. 1-1 The human IgE network and the interaction with complement system. 
This schematic representation indicates the major functional consequences of each 
particular interaction within the human IgE network and focuses on FcFRII/CD23 as the 
link molecule with complement system. CD23 reacts with three complement receptors (2,3 
and 4). 
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The binding site for FceRI on human IgE has been initially located to the sequence of 76 
an-dno acids at the Cc2/Cc3 junction (Helm et al., 1988) but it has been now further 
specified and it has been reported that the first 12 an-dno acid residues of the W domain 
are necessary for binding, with possible contribution of other residues in the domains Ce3 
and Cc4 (Beavil et al., 1993; Presta et al., 1993). The binding site for CD23 has been 
mapped to the same domain (W) but it is distinct from the FceRI site and it appears to 
include the amino acids in the region of the glycosylation site Asn 371 (Vercelli et al., 
1989b; Ghadery and Stanworth, 1993). Neither of the two IgE receptors requires the 
carbohydrate moiety of IgE for binding, but the IgE-binding protein (cBP) was shown to 
bind to IgE in an S-lectin type manner, with the monosaccharide N-acetyllactosamine 
exhibiting the highest potency in inhibiting the interaction (Hsu et al., 1992). 
1.1.3. FceRI, the high affinity receptor for IgE 
The high affinity receptor for IgE (FccRI) is expressed on the surface of mast and 
basophilic cells where it initiates allergic reactions (Metzger et al.. 1986), but it has been 
recently found on a number of other cell types including Langerhans cells, eosinophils, 
monocytes and platelets. Sensitation of mast cells or basophils upon binding of IgE 
secreted by B cells to FcFRI and crosslinking of the receptors by multivalent antigen 
induces immediate cellular events such as cellular degranulation and the release of 
histamine, and synthesis and secretion of a number of cytokines. 
FceRI consists of four transmembrane polypeptides with the composition apy2. The 
binding site for IgE is in the extracellular part of (x chain, while P andy chains play a role 
in the insertion of the cc chain into the membrane and in signal transduction mediated by 
FcCRI. The (% chain of FccRI contains two domains characteristic of the immunoglobulin 
superfamily and IgE binds to the a2 domain (Robertson, 1993). Both domains are 
glycosylated and the role of the carbohydrates is probably protection from the serum 
protease activity and receptor expression on the cell surface. These domains each contain 
a pair of cysteines which most likely form the conserved disulphide bridge. The 0 chain 
of FccRI crosses the plasma membrane four times and has amino and carboxy ten-nini 
protruding into the cytoplasm while the y chain has a single transmembrane domain. The 
19 
affinity of the assembled receptor for monomeric IgE is about 10" M" (Miller et al., 
1989) and the stoichiometry of one receptor molecule per one IgE molecule was 
determined by hydrodynan-dc studies of a complex between the Fc fragment of IgE and 
a soluble fragment of the FccRI a domain (Keown et al., 1995). 
The mechanism by which FceRI is activated upon binding the allergen-specific IgE and 
immobilisation of the allergen still remains somewhat obscure. The aggregation of the 
receptor molecules on the membrane of the effector cell has been long recognised as an 
important event in this process (Metzger et al., 1986), but it is unclear what the minimum 
size of the aggregate is and in particular, what adjacent molecules may be involved. 
Aggregation of the receptor induces the phosphorylation of non-receptor kinases and other 
enzymes and the recent studies of the crosslinked IgE/receptor complexes in rat basophilic 
leukaemia (RBL) cells have revealed that at least two known kinases are associated with 
FcF_RI: the src-like kinase p/53/56'y' and the 8 isoform of protein kinase C (Mao et al., 
1995). Apart from protein kinases this signal transduction pathway involves calcium 
mobilisation, GTP binding proteins and phospholipid hydrolysis, but there is still no clear 
evidence about how the aggregation of FceRI and the influx of the intracellular calcium 
relate to each other. Several possible pathways for the signal transduction mediated by 
FcF_RI leading to degranulation of the effector cell have been proposed (Ravetch and 
Kinet, 1991). 
1.1.4. CD23/FccRIT, the low affinity receptor for IgE: cell type expression 
The first demonstration of a cell type other than the mast cell or basophil having receptor 
for IgE was presented by Lawrence et al., 1975, when it was discovered that human 
peripheral blood lymphocytes bind myeloma IgE. Following this discovery the second 
receptor for IgE was found on a variety of haematopoietic cell types, at least in humans. 
These include macrophages (Capron et al., 1977), eosinophils (Capron et al., 1981), 
platelets (Joseph, et al., 1983), Langerhans cells (Bieber et al., 1989), T lymphocytes 
(Yodoi et al., 1979), peripheral monocytes (Melewicz and Spiegelberg, 1980) and also 
some epithelial cells (Billaud et al., 1989). The application of specific monoclonal 
antibodies for detection of CD23 has allowed a more detailed re-evaluation of the 
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expression of this receptor on B lymphocytes and Kikutani et al., 1986b, established that 
qD23 is expressed on more than 90 % of the human B lymphocytes. Although CD23 
expression is restricted to the later stages of B cell development, the CD23 gene is being 
actively transcribed during all stages, at least in rnice (Hagen et al., 1995). This recent 
finding suggested the existence of a regulatory mechanism for CD23 expression that has 
not been described yet. As for the T lymphocytes, the presence of CD23 remains 
somewhat controversial although the evidence for a low-level expression seems to be 
prevailing. Recent evidence for the expression of allergen-induced CD23 on CD4: * T 
lymphocytes in patients with allergic asthma may provide clue to resolve this question 
(Gagro and Rabatic, 1994). 
1.1.5. Structure of CD23 
In contrast to all other Fc receptors CD23 does not belong to the immunoglobulin 
superfamily. The C-terminus of the protein is exposed on the cell surface while the N- 
terminus remains in the cytoplasm, in further contrast to most other cell surface antigens 
(Kikutani et al., 1986a; Ikuta et al., 1987). The human CD23 molecule is a type 2 integral 
membrane glycoprotein of about 45 kDa, including one N-linked oligosaccharide at Asn 
64 and one or more O-linked carbohydrates (Peterson and Conrad, 1985; Letellier et 
al., 1988; Gould et al., 1991), while murine counterpart is a 49 kDa sialoglycoprotein with 
two potential N-glycosylation sites (Conrad and Peterson, 1984). Analysis of the genomic 
sequence of human and murine CD23 shows that the homology between the two proteins 
is 57 % with a further 17 % of conservative substitutions. Human and murine CD23 both 
have discrete structural domains, as shown on the model proposed by Gould et al., 1991, 
in Fig. 1-2. 
The human CD23 exists in two forms (termed a and b in Fig. 1-2) differing only in the 
N-terminal 6/7 amino acid residues (Yokota et al., 1988). The distinct domains of CD23 
are the C-terminal ligand binding domain (known as, and referred to in the following text, 
"lectin" domain), the "stalk" region which links the lectin domain with the membrane, the 
hydrophobic transmembrane region and the short cytoplasmic N-terminal sequence. C- 
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Fig. 1-2 The structure of human and murine CD23 (Gould et aL, 1991). 
The model shows the distinct structural dornains of CD23; the lectin homology domain 
is linked to the cell membrane by a sequence that is predicted to form triple (x-helical 
structure and is referred in the text as the stalk region; the (auto)proteolytic cleavage sites 
and the single N-glycosylation site in human CD23 or two sites in mouse protein are 
shown. The human CD23 exists in two fon-ns, a and b, the difference between the two 
being only in the short N-terminal sequence, as indicated on the model. The further 
difference in the structure between human and mouse CD23 is reflected in the 
extracellular C-ten-ninal sequence that flanks the lectin domain, in human CD23 this 
sequence contains a reverse integrin binding tripeptide (DGR) which is not present in 
mouse CD23. 
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that may act in cell adhesion. The homology of the lectin domain of CD23 to 
asialoglycoprotein receptor and also a number of adhesion proteins known as selectins 
places CD23 in the fan-dly of C-type (calcium dependent) lectins (Drickamer, 1988). The 
lectin domain is flanked on the N-ten-ninal side by a sequence containing heptad 
hydrophobic repeats which form the stalk region of CD23. These repeats are each 21 
amino acid residues in length, and they are arranged in the way that resembles the leucine 
zipper motif which provides the mechaniým for the formation of a-helical coiled coil 
structure (Beavil et al., 1992). And indeed, the experimental evidence for this type of 
oligomerisation of CD23 came from chemical crosslinking data of Beavil et al., 1995, 
who showed that both the membrane bound CD23 and its soluble fragments can form 
protein dimers and trimers. Similar work on the murine CD23 has shown that it is also 
oligomeric and at least a trimer (Dierks, et al., 1993). 
CD23 undergoes natural proteolytic cleavage to yield fragments of 37,33,29,25 and 16 
kDa all of which retain the lectin domain (Letellier et al., 1989). There is considerable 
controversy about the nature of the protease(s) that cleave(s) CD23. There are suggestions 
that CD23 itself may possess the autoproteolytic activity or at least require the 37 kDa 
fragment for cleavage (Delespesse et al., 1992). However, there is no homology in the 
an-dno acid sequence of CD23 with any of known proteases. Two reports have appeared 
recently pointing at the major allergen of the house dust mite (Der pl) as the proteolytic 
source that cleaves CD23 and disrupts the IgE network (Schulz et al., 1994; Hewitt et al., 
1995). Two protease inhibitors of proteolytic cleavage, TLCK and iodoacetamide, can 
inhibit proteolytic degradation of CD23 (Cairns and Gordon, 1990). 
1.1.6. Biological function of CD23 
CD23 participates in several cellular events and its functions can be generally divided into 
two categories: IgE-dependent and IgE-independent. 
a) IgE dependent activities of CD23 
The involvement of CD23 in IgE biology was first demonstrated by Capron et al., 1975, 
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who showed that CD23 participates in IgE-dependent cytotoxic activities of inflammatory 
cells such as phagocytosis of antigen complexes by macrophages. Subsequently, the 
similar role for CD23 was described in eosinophils (Capron et at., 1981), platelets 
(Joseph et al., 1983) and monocytes (Kikutani and Kishimoto, 1990). In each of these 
cells CD23 binds IgE/antigen complexes and facilitates their phagocytosis. 
The role of CD23 in IgE-mediated antigen presentation has become the focus of a number 
of recent studies, in vitro and in vivo, as well. Analogous to Fcy receptors, CD23 acts 
synergistically with other proteins, namely with the complement receptors CD11b and 
CD 11 c, the a chains of the P. integrin adhesion molecule complexes CD 11 b-CD 18 and 
CD 11 c-CD 18 (Capron et al., 1987; Lecoanet-Henchoz et al., 1995). Biochemically, once 
bound to CD23 the IgE/antigen complex can be internalized by receptor mediated 
endocytosis, followed by proteolysis of the receptor, IgE and the antigen, and the re- 
expression of the antigen fragments on the cell surface, making them accessible for the 
interaction with T cells (Chen, 1991). Using hapten specific IgE, Kehry and Yamashita, 
1989, showed in mice that anfigen presentation by B cells to an antigen-specific T cell 
line could be enhanced up to 100-fold as compared to the antigen alone or with targeting 
through FcyRII receptor (the low affinity receptor for IgG) using IgGl. These data have 
been recently extended in the human system by demonstration that human EBV- 
transformed B cells can internalize and present IgE/antigen complexes via CD23, thus 
confirming the general nature of the phenomenon (Pirron et al., 1990). In 1994, Fujiwara 
et al. published the data on CD23-deficient mice demonstrating that although the other 
known functions of CD23 may exist in vivo, the IgE-mediated antigen presentation was 
the only one unique for C1323, at least in mice. The possible consequence of the 
CD23/IgE-mediated antigen presentation in allergy is a continuous activation of the 
immune system by very low concentrations of allergen, which could lead from sensitivity 
to a single group of allergens into sensitivity to multiple groups of allergens (Mudde et 
al., 1995). 
In addition to IgE-mediated. antigen presentation and cytotoxic clearance of the antigen, 
CD23 is reported to participate in the control of IgE synthesis, a role which has been 
suggested on the basis of several lines of evidence. In general, the regulation of IgE 
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synthesis by membrane CD23 and its soluble fragments is dependent on the stage of B 
cell development and can be either positive or negative (Sarfati et al., 1988,1992a, 
1992b; Sutton and Gould, 1993). ne stimulative role of soluble CD23 (sCD23) in 
modulating IgE synthesis is IL-4 dependent and characteristic of IgE committed B cells 
(Saxon et al., 1990). Ibis is supported by the observation that some anti-CD23 
monoclonal antibodies inhibit the 11-4 stimulated IgE production in human peripheral 
blood or by tonsillar lymphocytes (Pene et al., 1988; Bonnefoy et al., 1994), presumably 
by neutralizing the IgE-potentiating activity of sCD23 or preventing the proteolytic 
cleavage of membrane CD23. The negative regulation of IgE synthesis by membrane 
CD23 requires the binding of IgE itself to the membrane CD23 and possibly also 
crosslinking of the membrane CD23 and IgE. Anti-IgE monoclonal antibodies can inhibit 
binding of IgE to the membrane CD23 and thus stimulate IgE synthesis in vitro (Sherr et 
al., 1989). The negative regulatory role of membrane CD23 in the production of IgE was 
confirmed in vivo by the demonstration that CD23 deficient mice showed an increased 
and sustained specific IgE antibody titre (Yu et al., 1994), Therefore, the IgE suppressive 
activity of CD23 through interaction with IgE may be viewed as a negative feedback loop 
in the IgE synthesis (Sutton and Gould, 1993). 
b) IgE-independent functions of CD23 
The first indication that FcP_R1I is the same molecule as the B cell differentiation antigen 
CD23 came in 1987 (Bonnefoy et at.; Yukawa et al. ) suggesting that this protein may be 
involved in the biology of the B cell independent of its role as the IgE receptor. MHM6, 
an antibody to CD23, provides a progression signal to human B cells primed to enter the 
G1 phase of the cell cycle by phorbol ester and also stimulates IL-4 promoted DNA 
synthesis (Gordon, 1994). In contrast to that, some other anti-CD23 antibodies and 
IgElanfigen complexes have been found to down-regulate 11-4-dependent stimulation of 
B cells (Delespesse et al., 1992). The signal transduction pathway activated by CD23 
involves a rapid increase in intracellular calcium as the consequence of generation of 
inositol-triphosphate, following the phospholipase C catalyzed hydrolysis of 
phosphatidylinositol-biphosphate (Kolb et al., 1991; Kolb and Abadie, 1992). At present 
it is not clear what initiates this cascade of events but a tyrosine kinase seems to be 
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involved, the evidence for which was provided by a study demonstrating an association 
between CD23 (isoform a) and the src related protein kinase p59"' (Sugie et al., 1991). 
The activation of phospholipase C by phosphorylation triggers adenyl-cyclase activation 
and leads to accumulation of cAMP, although the generation of cAMP can be triggered 
independently from mobilisation of CP ions (Kolb et al., 1993). It is interesting that the 
two isoforms of CD23 (a and b) appear to facilitate different signal transduction pathways, 
and this fact must be attributed to the difference in the first 6/7 amino acids of their 
cytoplasmic N-termini (Gordon, 1994). Both isoforms trigger accumulation of cAMP, but 
only the isoform a is coupled to phospholipase C hydrolysis of pbospatidylinositol- 
biphosphate. 
The structure of CD23 may have important implications for the signal transduction 
mediated by this protein. Gould et al., (199 1) have suggested that a conformational change 
in the structure of CD23 upon binding IgE or anti-CD23 monoclonal antibodies may play 
an important role; IgE binding stabilizes the a-helical coiled coil structure of the stalk 
region and thus prevents proteolytic cleavage of CD23; the binding of a monoclonal 
antibody produces an opposite effect and results in the cleavage of the protein. 
Several studies have focused on the potential function of sCD23 as an autocrine B cell 
growth factor (Mossalayi et al., 1991; Gordon et al., 1985) but this appears to be the most 
controversial function of CD23 of all. Some of the controversy can be attributed to the 
wide heterogeneity of soluble CD23 fragments. Delespesse et al., 1989, showed that a 12 
kDa CD23 fragment promotes the proliferation of B cells whereas Gordon et al., 1989, 
reported that 37 kDa fragment is responsible for this function. Further to that, Armitage 
and Goff, 1988, reported that stimulation of cell growth by sCD23 is conditional and 
requires the interaction between cells. The availability of recombinant soluble forms of 
CD23 should provide the necessary means to study the possible role of CD23 in 
stimulating B cell growth. And finally, it has been proposed that sCD23 in synergy with 
IL-1 is involved in the rescue of the centrocytes from programmed cell death by apoptosis 
(Liu et al., 1991). This finding is supported by the evidence of expression of CD23 on 
follicular dendritic cells (FDQ located at the same place as the centrocytes. Bonnefoy et 
al., 1993, presented the evidence that the involvement of CD23 in the rescue of germinal 
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center cells from apoptosis is exerted through its interaction with CR2. The interaction of 
CD23 and CR2 and its possible functional implications will be dealt with in more detaill 
later on in this thesis. A summary of biological functions of CD23 is given in Table 1-1. 
1.1.7. Lectin properties of CD23 
As mentioned before, CD23 belongs to the fan-dly of C-type animal lectins which also 
includes asialoglycoprotein receptor, chicken hepatic lectin, mannose binding protein, 
tetranectin, Lyb-2 B cell antigen and other proteins. All of these proteins share a common 
sequence consisting of 14 amino acid residues, which acts as the carbohydrate binding 
domain (Drickamer and Taylor, 1993). The highly conserved residues include 4 cysteines 
that form two disulphide bonds and also glutamic acid, aspartic acid and asparagine, while 
several glycine and proline residues are found at the critical turn positions in the structure. 
There also appears to be a subfamily of structurally related C-type lectins comprising CC- 
helical coiled coil stalks of different lengths, of which CD23 is a member (Beavil et al., 
1992). 
Although IgE binds to the lectin domain of CD23 and requires Ca? ' for binding, the 
interaction is not mediated by the carbohydrate chains of IgE, as shown by the 
demonstration of the ability of IgE e-chain fragments synthesized in E. coli to bind CD23 
(Vercelli et al., 1989b). The first demonstration of lectin function of CD23 came in 1992 
when Pochon et al. reported that CD23 binds to a ligand different from IgE and this 
second ligand was found to be CR2 (CD21), the complement receptor for C3dg fragment 
of the complement (Aubry et al., 1992). The binding was found to be Ce" dependent and 
the tunicamycin treatment of the CR2 expressing cells significantly decreased binding of 
CD23. Also, the authors reported that the monosaccharide fucose-1 -phosphate inhibited 
the binding of CD23 to its ligand suggesting the involvement of a glycan structure 
containing, or related to, fucose- I -phosphate type. This was further reinforced by the 
finding that the glycosylation mutants of CR2 failed to bind CD23 and that 2 N-linked 
oligosaccharides are involved in interaction (Aubry et al., 1994). However, another line 
of evidence implicated the monosaccharide galactose as the principal carbohydrate 
component of glycoproteins involved in interaction with CD23 (Kijimoto-Ochiai et al., 
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Table 1-1: Summary of biological functions of CD23 (Some of the representative references 
for each function are given). 
IgE dependence Biological function Reference 
Cytotoxic clearance of Capron et al., 1975,1981; Joseph et al., 1983; 
antigen 
IgE-dependent 
Antigen presentation Capron et al., 1987; Kehry and Ywnashita, 1989; Pirron et al., 1990; Chen, 1991; 
Fujiwara et al., 1994, Gordon et al., 1991 
Control of IgE synthesis Pcne et al., 1988; Saxon et al., 1990; Sarfati 
et al., 1992, Sutton and Gould, 1993; 
Bonnefoy et al., 1994; Yu et al., 1994 
B cell activation Gordon, 1983,1989; Delespesse et al., 
1992 
Autocrine growth factor Gordon et al., 1985,1991; Delespesse et IgE-independent al., 1989; Mossalayi et al., 1991 
Rescue of germinal center Liu et al., 199 1; B onnefoy et al., 1993 
B cells from apoptosis 
Adhesion protein Bjorck et al., 1993; Lecoanet-Henchoz et 
al., 1995 
Other functions: Mossalayi et al., 1990b, 1990a; Flores- 
prothymocyte maturation, Romo et al., 1989 
myeloid precursor 
proliferation, inhibition of 
macrophage migration 
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1994). The report further indicated that CD23 binds with higher affinity the structure Gal- 
GaINAc (0-type sugar) than Gal-GlcNAc (N-type sugar). The same authors (Kijimoto- 
Ochiai and Uede, 1995) then showed that CD23 acts as a galactose-binding lectin in the 
cell aggregation of EBV-transformed human B cells. They showed that naturally 
aggregated CI)23ý EBV-transformed cells disaggregated after removal of galactose by P- 
galactosidase treatment or by addition of anti-CD23 monoclonal antibodies, as well as 
soluble CD23. Interestingly, anti-CR2 antibodies failed to exhibit the same effect and the 
authors suggested that CD23 may react with a ligand other than CR2. 
Overall, these reports showed that CD23, apart from binding IgE does indeed function as 
a lectin protein but the evidence for its carbohydrate specificity is still insufficient and 
apparently controversial. Clearly, more work is required to establish the carbohydrate 
binding specificity of CD23. 
1.1.8. IgE-binding protein (FBP) 
The existence of eBP was revealed when Liu et al., 1989, sequenced a cDNA clone 
encoding for a 31 kDa protein which was regularly copurified with the high affinity 
receptor for IgE from the rat basophilic leukaemia (RBL) cells, and was actually thought 
to be one of the subunits of FcFRI. The biological function of the protein was not known 
for some time until it was established that the carbohydrate-binding protein (CBP35) was 
the mouse counterpart of FBP, which has led to the classification of CBP as an 
endogenous S-type lectin. Soon after, it was also discovered that this protein had been 
long known in humans as Mac-2 (a macrophage differentiation marker) and L-29 (a lectin 
initially identified in human lungs). 
The tissue distribution of cBP is widespread and the specificity for P-galactoside 
containing oligosaccharides is not uncommon, thus making it unlikely that EBP is specific 
only for IgE. Multiple functions have been proposed for this protein but to this day no 
clear evidence about its role in either IgE biology or in general, have been presented. The 
lack of clarity could be explained by the mentioned broad specificity and tissue 
distribution, in addition to the fact that different researchers still use different names for 
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this protein which inevitably adds to the difficulty in searching for a function unique to 
F, BP. Nevertheless, several suggestions about the function of cBP have been made, based 
on both, experimental and hypothetical evidence. IgE binding activity of cBP points to a 
possible role in IgE mediated allergic reactions (Robertson et al., 1990); CBP35 has been 
implicated in regulation of cell growth (Laing and Wang, 1988); the studies with Mac-2 
suggested that this protein may be a differentiation marker of macrophages (Cherayl et 
al., 1989); the finding that the laminin binding protein L-29 is identical to CBP35/Mac- 
2/eBP suggests a possible role in cell adhesion to the extracellular matrix (Woo et al., 
1990). 
Like many other lectins, F-BP is bivalent and the studies with the recombinant protein 
expressed in E. coli showed that FBP possesses the ability to self-associate (Hsu et al., 
1992). Massa et al., 1993, have shown that L-29 binds to glycoconjugate ligands such as 
Ian-dnin with a positive cooperativity between the protein subunits. Together with the 
discovery that FBP binds not only IgE but also FcERI (Frigeri et al., 1993), this finding 
reinforces a possible role for cBP in allergic reactions. A model has been suggested in 
which eBP activates mast cell by crosslinking the IgE receptors, receptor-bound IgE or 
IgE and the receptor, and thus provides the mechanism for receptor aggregation leading 
to mast cell activation (Liu, 1993). The function of FBP as a modifier of cellular response 
may then be extended to other cell types expressing glycoprotein ligands for this lectin. 
1.1.9. IgE binding factors 
The term IgE binding factors" (IgE-BFs) was originally used for the low molecular 
weight soluble proteins that were able to bind IgE and potentiate IgE synthesis (Sarfati 
et al., 1984; Metzger, 1988). With the studies of molecular structure of CD23 it became 
clear that IgE-BFs are in fact proteolytic cleavage products of CD23, namely 25 and 16 
kDa fragments. However, in rats there appear to exist two IgE-BFs not related to CD23. 
Both factors bind IgE but have contrasting effects on IgE synthesis: IgE-PF potentiates 
while IgE-SF suppresses IgE synthesis (Ishizaka, 1988). Cloning of cDNA for these 
proteins revealed that they are encoded by a single gene (Martens et al., 1987) and the 
only difference between them was the presence of N-glycans on IgE-PF (Ishizaka, 1988). 
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Other studies showed that a single T cell can produce either IgE-PF or IgE-SF, depending 
upon the presence of a regulatory protein GIF (glycosylation inhibitory factor) which can 
down-regulate the production of IgE-PF (Uede et al., 1983). The IgE-PF is 60 kDa 
glycoprotein which can be cleaved to produce aII kDa fragment that still retains the 
ability to potentiate IgE synthesis (Martens et al., 1985). 
Most of these studies have been performed with rat T lymphocytes and very little is 
known about human IgE-BFs. The critical issue with these molecules is establishing better 
their role in the synthesis of IgE and examining the possible clinical implications in 
suppressing IgE mediated allergic reactions. 
1.2. Introduction to CR2 (CD21) 
1.2.1. Complement system 
The complement system has evolved as one of the major effector pathways in the process 
of inflammation. It is composed of a number of distinct plasma proteins which are termed 
C1, C2,... C9 but the actual sequence of reactions is: Cl-C4-C2-C3-C5-C6-C7-C8-C9. The 
activation of the complement occurs when one of the complement proteins binds antibody 
and triggers a cascade of reactions activating all other components. The activation of the 
complement system by an antibody binding to antigen is part of the adaptive humoral 
immune response but there is also an alternative pathway by which the complement 
system takes part in the early induced (innate) response to the pathogen. 
Once the complement system is activated it leads to proteolytic cleavage of the 
complement components and one of the major events in the first phase of complement 
activation is the cleavage of C3 to produce C3b which binds covalently to the surface of 
the pathogen. 7he marking of the pathogen with C3b exposes it to the phagocytic cells 
that can bind Ob through complement receptors (CRs) expressed on these cells. Ob also 
activates the alternative pathway, which deposits more C3b on the surface of the pathogen 
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leading to opsonization of the pathogen. The terminal components of the complement (C5- 
C9) polymerize to form a membrane attack complex which can inflict pores in the 
membrane of the pathogen and in that way destroy it. 
The formation of C3b fragment is catalyzed by the enzyme called C3/C5 convertase which 
is activated by the cascade of the following reactions (Janeway and Travers, 1994): The 
first component of complement (Cl) is composed of 3 proteins, Clq, C. Ir and Cls, in 
such a way that each C1q molecule has attached to it two molecules of Clr and Cls. 
Binding of the antibody attached to the surface of pathogen occurs through Clq, which 
requires at least two antibody molecules for activation. Soluble antibodies free of antigen 
cannot bind to Clq because of inaccessibility of the binding site. The activation of Clq 
is followed by the enzymatic activity of C1r which cleaves Cls to generate an active 
serine protease, which in turn cleaves C4 to produce C4b, and also cleaves C2 to produce 
C2b, which is itself a serine protease. C2b is generally called C3/C5 convertase and its 
generation from the C2 component takes place on the surface of the pathogen, to which 
it is bound via C4b. The main product of C3/C5 convertase activity is Ob which, as 
mentioned before, binds in large numbers to the surface of the pathogen, but also 
important is the C3a fragment which initiates a local inflammatory response. Finally, Ob 
binds C5 leading to the generation of C5b that associates with the pathogen membrane 
and triggers the polymerisation of the terminal components of the complement and 
formation of the membrane-attack complex capable of damaging the membrane of the 
pathogen. The alternative pathway of complement activation can amplify the effect of this 
classical pathway by depositing more molecules of Ob which are generated by a positive 
loop comprising factor B which binds to Ob and becomes cleaved by factor D, resulting 
in the formation of the C3b-Bb complex that possesses C3/C5 convertase activity. Thus, 
new Ob is generated and at this point the two pathways converge. A list of the 
complement components, their active fragments and related functions in the order of 
activation is shown in Table 1-2. 
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C1q Binds to antibody/antigen complex on pathogen. Activates 
CIr. 
Cl, 
CIr Cleaves CIr to generate protease CIS. 
CIS Cleaves C4 and C2. 
C4a, Mediator of inflammation. 
C4 C4b Covalently binds to pathogen and opsonizes it. Binds C2 
for cleavage with CIS. 
C2a, Unknown 
C2 
C2b, C3/C5 convertase (cleaves C3 and C5). 
C3a, Mediator of inflammation. 
C3 Ob Binds to pathogen in large numbers and opsonizes it. 
Initiates positive loop of alternative pathway. Binds C5 for 
cleavage with C2b. 
C5a, Mediator of inflammation. 
C5 C5b Initiates fon-nation of membrane-attack complex. 
C6 C6 Binds C5b and accepts C7. 
C7 C7 Binds C5b, C6. Complex insertion into membrane. 
C8 C8 Binds complex C5b/C6/C7. Initiates C9 polymerisation. 
C9 C9 Polymerises to C5b/C6/C7/C8 to form a channel in the 
membrane. 
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1.2.2. Complement receptors 
The actual destruction of pathogen is facilitated by phagocytic cells which are abundant 
in complement receptors and therefore can bind the complement marked pathogen. There 
are five known complement receptors: CRI( CD35), CR2 (CD21), CR3 (CDllb-CD18), 
CR4 (CDllc-CD18) and Clq receptor. CR1 is the best known complement receptor and 
is expressed on both macrophages and polymorphonuclear leucocytes. CRI. binds Ob 
component of C3 (Gigli and Nelson, 1968) but it is not sufficient alone to trigger 
phagocytosis in a macrophage. It also serves as a cofactor for the serine esterase Factor 
I which cleaves Ob to iC3b and CH, and subsequently iC3b to Oc and C3dg (Abeam 
and Fearon, 1989). All of the cleavage products of Ob are inactive and therefore, CR1 
has an important regulatory function. In addition to that, CRI may serve in conjunction 
with CR2 as a receptor for mediating lymphocyte activation. 
The role of CR2, CR3 and CR4 is the binding of inactivated forms of Ob that remain 
attached to the pathogen surface. CR2 is capable of binding of all three degradation 
fragments of Ob (iC3b, C3dg, C3d) (Ross and Cambris, 1982). C3 and C4 belong to a 
superfamily of structurally related cell surface receptors and adhesion molecules which 
includes the fibronectin receptor and other integrins. These receptors bind to their ligands 
in a calcium dependent manner and have a common binding specificity for the tripeptide 
RGD (Arg-Gly-Asp). The receptor for the Clq component of complement is the least 
characterised of the complement receptors. Table 1-3 shows the binding specificities of 
the complement receptors and cell types expressing them. 
1.2.3. Expression, structure and function of CR2 (CD21) 
The co-expression of CR2 and EBV receptor on multiple B cell lines had been known for 
some time but it is the studies of Fingeroth et al., 1984, that presented the evidence that 
CR2 and EBV receptor are the same protein. They showed that modulation of CR2 from 
the surface of B cells with the specific anti-CR2 antibody HB5 blocked EBV binding. 
This was later confirmed more directly by showing that CR2 incorporated into liposomes 
can bind EBV, as well as Od (Mold et al., 1986). 
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Table 1-3: The complement receptors (CRs) and their binding specificities 
Receptor CD name 
I Binding Cell type expression 
specificity 
CRI CD35 C3b, C4b Macrophages, erythrocytes, 
monocytes, polymorphonuclear 
leucocytes, B cells 
CR2 CD21 C3d, C3dg, B cells 
iC3b 
CR3 CD11b-CD18 iC3b Macrophages, monocytes, 
polymorphonuclear leucocytes 
CR4 CD1lc-CDl8 iC3b Macrophages, monocytes, 
polymorphonuclear leucocytes 
qR none Clq B cells, macrophages, monocytes, 
I platelets, endothelial cells 
35 
The expression of CR2 is -. a - characteristic of 
IgM'/IgD' mature B cells and it is rapidly 
lost following cellular maturation. Follicular dendritic cells (FDQ in germinal centers are 
also CR2 positive but the function of CR2 on these cells Is: not well known. Later, the 
distribution of CR2 was expanded to include epithelial cells (Sixbey et al., 1983) and T 
lymphocytes (Fingeroth et al., 1988; Watry et al., 1991). 
CR2 is heavily glycosylated 140 kDa protein containing 11 potential glycosylation sites 
occupied by N-linked but not O-linked oligosaccharides (Weis and Fearon, 1985). The 
carbohydrate content of CR2 is not required for binding to its complement ligand C3d, 
as shown by the capacity of unglycosylated or underglycosylated CR2 protein precursor 
to bind to C3 immobilised to Sepharose (Weis and Fearon, 1985). Several antibodies to 
CR2 have been generated and the studies using these antibodies as potential blockers in 
binding to Od or EBV have indicated that CR2 possesses discrete structural domains with 
distinct functional properties (Cooper et al., 1988). The entire extracellular domain of CR2 
is composed of 60-75 amino acid tandem repeats or short consensus sequences (SCRs) 
and there are 15 or 16 of these in the structure of CR2, depending on the (non)splicing 
of the SCR 11 (Fujisaku et al., 1989). The 60-75 amino acids SCR structure of CR2 
places it into the group of 20 or more related cell membrane or plasma proteins, some of 
which are complement related molecules (CR I, C4 binding protein, C2, Factor B, Factor 
H) and the others non-complement related molecules such as 02-glycoprotein I, P chain 
of IL-2 receptor, blood clothing factor III, etc. (Cooper et al., 1988). Each SCR has four 
cysteine residues that are probably disulphide bonded in a cysl-cys3, cys2-cys4 pattern 
forming a triple loop structure (Janatava et al., 1989). The binding sites for Od and EBV 
are contained within the SCRs 1 and 2. 
The hydrophobic transmembrane domain of CR2 is composed of 28 amino acid residues 
and this is followed by a 34 amino acids cytoplasmic sequence that among the other 
residues comprises 3 serines, 2 threonines and 4 tyrosines, including a protein kinase C 
motif TSPK. Although the cytoplasmic domain of CR2 is too small to encode a tyrosine 
kinase '- -, 
it could serve as a substrate for phosphorylation, as can be suggested from the 
presence of sequence EAREVY, a common motif for tyrosine kinase substrates (Ahearn 
and Fearon, 1989). The schematic representation of CR2 molecule with indicated binding 
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sites for different ligands or monoclonal antibodies is shown in Fig. 1-3. 
Apart from binding Od and the gp350/220 of EBV, CR2 is also an interferon-(X receptor 
(Delcayre et al., 1991) and also interacts by its intracytoplasmic carboxy-terminal domain 
and two distinct binding sites with p53 anti-oncoprotein and the p68 calcium-binding 
protein (Frade et al., 1992), both of which are intracellular regulatory proteins. Carter et 
al., 1988, have shown that crosslinking of CR2 and IgM on the B cell surface with 
monoclonal antibodies to each protein produces a synergistic increase in intracellular 
calcium. CR2 also associates with CD 19, CD81 (TAPA- 1) and Leu- 13 to generate a signal 
transduction complex that is independent of the antigen receptor (Fearon and Carter, 
1995), the role of which is closely associated with B cell activation and development 
regulation (Tedder et al., 1994). The recent discovery that CR2 binds to the low affinity 
receptor for IgE, CD23 (Aubry et al., 1992) further strengthens the role of CR2 in B cell 
development and provides both proteins with the role of an adhesion pair in B-B or B-T 
cell interactions. 
1.3. Interaction of CD23 and CR2 
1.3.1. Discovery 
The demonstration that CD23 has a second ligand apart from IgE came in 1992 when 
Pochon et al., showed that CD23 incorporated in liposomes binds to a number of cell 
types in a specific manner and, of these, the two myeloma B cell lines RPMI 8226 and 
U266 B1 were shown to be the most positive, while Daudi and Burkitt lymphoma cells, 
as well as T cells and non-lymphoid cells were negative. The binding of CD23-liposomes 
to the cells was shown to be calcium dependent with a maximum binding at 2 mM Caý' 
and inhibited by the monosaccharide fucose- I -phosphate. Also, tunicamycin (an inhibitor 
of N-glycosylation of proteins) treatment of the cells greatly reduced binding of CD23- 
liposomes, suggesting a possible carbohydrate involvement. The binding could be inhibited 











Human CR2 (CD21) 
Fig. 1-3 The structure of human CR2/CD21. 
This model of hurnan CR2 depicts its "beads on a string" like structure and indicates the 
binding sites of its seven known ligands: Odg, EBV, CD23, interferon-cc (IFN-cc), 
fibonucleoprotein p120, calcium binding protein p68 and anti-oncoprotein p53; it also 
indicates the binding sites of several, more often used monoclonal antibodies to this 
protein. The number of SCRs (short consensus repeats) in CR2 can be either 16 or 15, 
depending on the (non)splicing of SCR II in the mRNA transcript; each SCR is thought 
to contain two S-S bonds fliat are fon-ned between cysteine residues 1-3 and 2-4; the insert 
represents a simplified model of one SCR (number 10) by analogy to the structure of 
SCRs in C4b binding protein (Janatava et al., 1989). Shown in red are the residues that 
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this report, Aubry et al., 1992, then showed that a number of anti-B cell antibodies 
inhibited the interaction of CD23 and its new ligand and all of them were antibodies to 
CR2 (CD21). It was, therefore, established that CR2 is the new figand for CD23 and that 
the interaction is of the lectin type, requiring the carbohydrate content of CR2. 
1.3.2. The nature of CD23-CR2 interaction 
Aubry et al., 1992, reported that of all the tested anti-CR2 antibodies those with the 
epitopes within the sequence SCR 5- SCR 8 on CR2 had exhibited the most potent 
inhibitory effect on the interaction of CD23 and CR2. The analysis of CD23 binding to 
CR2 deletion and glycosylation mutants expressing cells confirmed the site of interaction 
on CR2 to SCR 5 -SCR 8. Three asparagine residues (at positions 295,370 and 492) 
comprising the potential glycosylation sites in this sequence have been mutated, together 
or individually, and it was found that asparagines 370 and 295 but not 492 are critically 
involved in binding to CD23, through the N-linked oligosaccharides. However, the 
deletion mutant of CR2 which expresses only the SCRs 1 and 2 also showed significant 
binding of CD23-liposomes (approximately 50 %, as compared with the wild type) and 
tunicamycin treatment did not affect the binding. Thus, it was concluded that the SCRs 
I and 2 contribute to the binding through the peptide backbone rather than carbohydrate 
moiety. 
There is, however, some uncertainty about the exact nature of the interaction of CD23 and 
CR2. Although the involvement of carbohydrate structures on CR2 seems to be reasonably 
well documented, there is some inconsistency in evidence for actual contribution of the 
carbohydrates to the binding. For example, Aubry et al., 1994, reported that tunicamycin 
treatment of CR2 expressing cells can greatly reduce the binding of CD23-liposomes (to 
less than 20 % of the positive control), while the deletion mutant comprising only SCRs 
I and 2, which contributes to the binding by its peptide bone, alone retains already 50 % 
binding. Also, some of the CR2 positive cell types did not bind CD23-liposomes and this 
was explained by the fact that the glycosylation of CR2 in these cells is not appropriate 
for binding to CD23 (Aubry et al., 1992,1994; Pochon et al., 1992); yet, if the peptide 
sequence of SCRs I and 2 contributes to the binding by half, some binding should be 
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observed in all CR2 positive cell types. And finally, fucose-I phosphate was shown 
capable of inhibiting the interaction of CD23 and CR2 (Pochon et al., 1992), while other 
studies on lectin properties of CD23 indicated galactose as the principal component of the 
glycoproteins involved in binding to CD23 (Kijimoto-Ochiai et al., 1994; Kijimoto-Ochiai 
and Uede, 1995). Obviously, more studies are necessary to establish the exact nature of 
the interaction between CD23 and CR2. 
1.3.3. Functional implications 
Aubry et al., 1992, showed that interaction of CD23 and CR2 is not merely physical but 
has a regulatory function in IgE synthesis. They showed that engagement of CR2 by anti- 
CR2 antibody BU-33 or soluble CD23 increases IgE production. A possible explanation 
of this effect could be that the interaction of CD23 and CR2 provides an enhancement of 
the T cell-B cell contact which is required for IgE production (Vercelli et al., 1989a), and 
the particular characteristic of the CD23-CR2 interaction is that this pairing controls IgE 
synthesis in an isotype specific manner (Bonnefoy et al., 1995). Molecular analysis 
showed that triggering of CR2 by CD23 or anti-CR2 antibodies increased the IL-4 induced 
germline e transcription levels and produces a synergistic increase in the expression of C 
transcript induced by T cells (Henchoz et al., 1994). Further to that, Bonnefoy et al. 
(1993) demonstrated that a subset of anti-CR2 antibodies and soluble CD23 can promote 
the rescue of germinal center B cells from apoptosis, extending the previous observation 
of Liu et al. (1991) that soluble CD23 in synergy with IL-1 can rescue the B cell 
centrocytes in germinal centers from programmed cell death and suggesting that the 
CD23-CR2 interaction is responsible for this effect of soluble CD23. 
Bacon et al., 1993, showed that CR2 expressed on basophilic cells is involved in 
histamine release triggered by CD23 and anti-CR2 antibodies, suggesting that CD23/CR2 
pair acts at another stage of the allergic reaction by regulating the effector cell. The 
interaction of CD23 and CR2 was also reported to play other functions such as mediating 
the homotypic aggregation of D lymphocytes (Djorck et al., 1993). The role of CD23-CR2 
interaction in B cell aggregation or in binding of B cell to FDC, rather than B cell to T 
cell, is signified by the fact that both, B and Fl) cells express CD23 and CR2, whereas 
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T cells are negative or express low amount of these molecules. 'nis is somewhat 
contrasted by the recent finding that CD4* T lymphocytes in patients with allergic asthma 
were CD23 positive and that the expression of CD23 in these cells was induced with 
either an allergen or recombinant IL-4 (Gagro and Rabatic, 1994). Sutton and Gould 
(1993) have proposed a model for the cell-cell interaction mediated by CD23 and CR2 
in which the two major signal transduction pathways mediated by the membrane IgM and 
CD19 are synergistically related to each other (Fig. 1-4). Taken together, the presented 
evidence suggests an important biological role for CD23-CR2 interaction. The clarification 
of this will require still further studies, some of which are presented in this thesis. 
1.4. FcyRII/CD32: The low afrinity receptor for IgG 
1.4.1. Diversity of Fcy receptors 
The Fcy receptors (FcyRs) are a distinct subclass within the Ig superfamily defined for 
their capacity to bind the Fc fragment of IgG. The FcyR gene family consists of 8 
members transcribed into at least 12 different mRNAs, and although not all the 
corresponding proteins have yet been identified, the diversity of the FcyR fan-lily is quite 
remarkable: there are 3 classes of FcyR genes (IJ1,11I), each class is represented by 2 or 
3 different transcripts (a, b, c) encoding for 1-3 isoforms (1,2,3) and finally, some of these 
isoforms are composed of heterogeneous protein subunits or require the association 
of additional subunits Q. The molecular analysis of the encoding genes and the translated 
products has indicated that these molecules have evolved from a common precursor 
through gene duplication. The homology between the extracellular parts of different Fc7R 
isoforms is very high but the transmembrane and cytoplasmic parts, in contrast, display 
very little homology, the consequence of which is the diversity of intracellular signalling 
pathways mediated by FqRs- 
These receptors play several important roles in the immune defence system and some of 
the effector functions triggered by FcyRs are phagocytosis, endocytosis, antibody- 
dependent cellular cytotoxicity (ADCC) and release of inflammatory mediators (Unkeless 
et al., 1988). They are expressed on variety of white blood cells, usually in cell-specific 





Fig. 1-4 CD23-CR2 adhesion pair in the context of FDC-B cell interactions (Sutton and Gould, 1993). 
Antigen presenting cells such as FDC (follicular dendritic cells ) express the Fc receptors diat can t)ijid and 
immobilise antigen within in immune complex and present it to the B cell via the antigen receptor (IgM for, 
example). CD23 and CR2 may participate hi the interaction between the two cells and if die complement is 
activated may enliance die response of B cell by crosslinking witigen receptor and CR2 (as indicated in die 
figure). CR2 is closely associated with anodier membrane protein, CD19 that iiLs great signal transducing 
capacity and both, CR2 and CD19 are known to synergise widi antigen receptor, the consequence of which is 
lowering the threshold concentration of the witigen required for cell activafiori md enhancement ofthe response. 
42 
receptor mediates which effector function. The overall knowledge about these receptors 
has greatly advanced with the isolation of corresponding cDNAs and genollic clones, and 
in particular with the development of transgenic mice techniques, allowing the generation 
of strains that express only one particular FcyR isoform. 
FcyRI (CD64) is normally found on monocytes and macrophages (Huber and Fudenberg, 
1970) but its expression can be induced on other cell types by interferon y and IL-10. The 
unique property of FcyRI is binding of monomeric IgG with high affinity while FcýRII 
and III are both low affinity receptors. The expression of FcTIUI on B lymphocytes and 
Fc-yRIII on natural killer (NK) cells seems to be exclusive but other haematopoietic cells 
express both low affinity receptors. Crosslinking of the receptors on these cells results in 
the transduction of signals leading to the activation of tyrosine kinases, accumulation of 
intracellular calcium, release of inflammatory mediators such as leucotrienes, 
prostaglandins and hydrolases, and induction of expression of several cytokines (Ravetch, 
1994). FcyRII and III interact with the same IgG immune complexes, presumably acting 
synergistically under conditions of high concentrations of these molecules. 
Table 4 summarises the evidence for polymorphism and IgG binding specificities of Fey 
receptors. 
1.4.2. FcyRIVCD32: Polymorphism and function 
Fc-yRII is the most abundant of the three JgG receptors and it is found virtually on every 
Fc, yR bearing cell except NK cell. Unlike FqRL the affinity of FcyRII for IgG is rather 
low (Ka: 5 W M-) so that binding of monomeric ligand practically cannot be detected. 
However, FcyRII binds efficiently to immune complexes, a property it shares with the 
other low affinity receptor for IgG, Fc7RIII. The molecular studies of FcyRII have been 
carried out with the use of several, well characterised monoclonal antibodies to this 
protein, in addition to the heterologous expression of cDNA clones in several cell lines 
(Ravetch and Kinet, 1991). 
In human system, FcyRII is encoded by a minimum of 3 genes giving rise to 6 distinct 
transcripts (Qin et al., 1990). The Fc*IIB gene gives rise to 3 transcripts (bl, b2, W) as 
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Table 1-4: Diversity of human Fcy receptors; nomenclature and IgG binding characteristics. 
Nomenclature Other names Gene Affinity for Specificity for 
transcripts IgG (Ka) IgG isotypes 
huFcyRI Fc*I, CD64 4 (a, bl, b2, c) 1011- 109 IgGl=IgG3> 
IgG4>>IgG2 
huFc, yRIIA Fc-yRlIa, CD32 2 (al, a2) 107 IgGl=IgG3 
>>IgG2, IgG4 
huFcyRIIB FcyRIIb, CD32 3 (bl, b2, b3) < 107 IgGl=IgG3 
>>IgG2, IgG4 
huFayRIIC FcyRIla, CD32 1 (c) < 107 IgGI=IgG3 
>>IgG2, IgG4 
huFc, yRIHAcc 111-2, CD16 1 (a) < 107 IgGI=IgG3 
I I >>IgG2, IgG4 
huFcyRIUB III-1, CD16 1 (b) < 107 IgGI=IgG3 
>>IgG2, IgG4 
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a result of alternative splicing, while FcyRHA gene encodes for two proteins (al, a2) and 
FcyRIIC for one. The further diversity among this receptor isoforms is provided by a 
single point mutation in Fc7Rbl (tyrosine at the position 12 is replaced by aspartic acid), 
giving rise to a variant which is in the already complex nomenclature of FcyRs given the 
distinction by an "*" (Fc7RIlbl*). The homology between the extracellular parts of 
different FcYRH isoforms is very high (> 95 %) so that no monoclonal antibody that 
would distinguish between them has yet been generated. The FcyRIIB isoforms are 
preferentially expressed in lymphocytes, whereas IIA and IIC isoforms are expressed in 
neutrophils; monocytes express all three classes. The affinity of the Fc-yRH isoforms for 
different IgG isotypes is largely common and IgG3 and IgG1 are bound with much higher 
affinity than IgG2 and IgG4 (Warmerdarn et al., 1993; Parren et al., 1992). 
FcyRII is a 40 kDa membrane protein which can be cleaved close to the cell surface to 
generate soluble forms which circulate in biological fluids. However, Delasalle et al., 
1992, presented the evidence for the presence of two different mRNAs for FcyRII, one 
of which encoded the membrane bound receptor and the other, --, - - 
the soluble form of 
the protein. The ratio between the two forms was 1: 1.5 in the favour of the mRNA 
encoding. ' .- the membrane expressed receptor. The addition of TNF (x (tumour necrosis 
factor) to the culture of human Langerhans cells modified this ratio to 1: 0.6 in favour 
of the soluble receptor encoding mRNA, thus suggesting a role for TNF cc in modifying 
the expression of FCýRH (or, at least class A) at the mRNA level. The soluble forms of 
FcyRII, as well as the other two classes of Fcy receptors (I and III) display the capacity 
to bind IgG in the similar manner as the membrane bound fon-ns of the receptor (Teillaud 
et al., 1994). 
The ability of FcYRII to trigger phagocytosis, endocytosis, influx of Ca", capping and 
cytokine release after crosslinking has been confirmed in both, human and murine system. 
The FcyRH signalling pathway is linked to G proteins and may take different patterns 
resulting in different cellular responses (Unkeless, 1989). Neutrophil degranulation and 
superoxide production can be triggered by anti-FcyRII antibodies, while monocyte FcyRII 
activation results in an internal increase of C2' ions. The human Fc7RII may also serve 
as a bridge between NK cells and target cells, as shown by the evidence that anti-FcyRII 
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antibody mAb IV. 3 and its Fab fragment partially block NK cytotoxic activity against the 
target cells (Perl et al., 1986). 
FcyRII is generally used as the model receptor for antibody/antigen complexes on antigen 
presenting cells for various studies. In these studies, FcyRII positive cell line is often used 
as the antigen presenting cells, to study the effects of ligation of different B cell antigens, 
alone or in combination with the antigen rqCeptor ligation. Although the name "FcyRII" 
was used in this section of the Thesis, for the purpose of correct nomenclature of Fcy 
receptor isoforms, this receptor also has a CD name, CD32 (initially CDw32). This name 
will be used in the rest of this thesis, to emphasise the distinction from the alternative 
name for CD23, FcCRIL 
1.5 Objective of the study 
This study aimed to further asses the interaction of CD23 with CR2 by applying different 
recombinant and native forms of both proteins and look at the functional consequences 
of this interaction in the process of B cell activation. One of the major objectives in this 
framework was to find out whether soluble CD23 can bind CR2. Soluble CD23 has been 
shown capable of promoting the survival and differentiation of germinal center B cells and 
it has been suggested that this is achieved through its interaction with CR2 on these cells. 
However, no published evidence has yet been presented that would confirm this 
hypothesis and, in fact, two reports indicated that recombinant soluble CD23 failed to bind 
CR2. The role of soluble CD23 as an autocrine growth factor for activated B lymphocytes 
has been also questioned following a report that recombinant form of the protein did not 
display the activity that has been ascribed to the native soluble fragments. 
The laboratory in which the current work was conducted has developed an experimental 
approach to the study of CD23 that -- ý-- emphasises 
the significance of the relationship 
structure-function of this protein. The structural requirements and the stoichiometry of the 
interaction of CD23 with IgE could be quoted in justification of such an approach. Thus, 
it was intended in this study to generate a recombinant fon-n of CD23 that could 
structurally resemble the native soluble protein and to test its capacity to bind CR2. Also, 
it was intended to generate a recombinant form of CR2 and asses its ability to bind CD23; 
/ 
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this was of the particularly great interest in this work with respect to the published reports 
that had suggested that only certain glycosylation subtypes of CR2 could bind CD23. 
The functional implications for CD23-CR2 interaction, notably, the regulation of IgE 
synthesis, cell-cell adhesion and the rescue of germinal center B cells from apoptosis, 
have been suggested. This study aimed to further explore the functional aspect of this 
interaction, in particular in the context of FDC mediated B cell activation. The 
experimental approach to study this was to create a fibroblast cell line that could mimic 
FDC with respect to expression of CD23 and an IgG receptor (CD32) and to look at the 
effect of CD23 on antigen receptor induced stimulation of B cells. Ultimately, the 
interaction of CD23 with CR2 has been focused on as the molecular basis for stimulatory 
activity of both proteins; in addition, a possible synergistic interaction of CD23 with the 
low affinity receptor for IgG (CD32) on antigen presenting cells has been studied. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Reagents and enzymes 
All restriction and DNA modification enzymes were from New England Biolabs (Hitchin, 
UK); DNA sequencing kit was from Promega (Southampton, UK); the reagents IPTG 
(isopropyl-p-D-thiogalactopyranoside), guanidine chloride, glutathione, OGP (octyl-o-D- 
glucopyranoside), and TLCK (L- I -chloro-3-[; osylamido] -7-amino-2-heptanone). were all 
from Sigma (Poole, UK); EDC (1-ethyl-3-(dimethylaminopropyl)-carbodiimide-HCI) was 
from Pierce (Chester, UK); POPC (1-palmitoyl-2-deoyl-sn-glycero-3-phosphocholine) was 
from Avanti Polar Lipids (Alabaster, USA); DiOC18 (3,3'-dioctadecyloxacarbocyanine 
perchlorate) was from Molecular Probes (Eugene, USA); protein A and Protein G affinity 
gels, and Affigel-10 were from BioRad (Hemel Hempstead, UK); ECL reagents for 
Western blotting, ['251]-NaI and [3 H]-thymidine were from Amersham (Little Chalfont, 
UK); GlycoTrack reagent was from Oxford Glycosystems (Abingdon, UK) and the 
DOTAP cell transfection reagent was from Boehringer (Mannheim, Gen-nany). The tissue 
culture media and reagents were purchased as follows: Dulbecco's Modified Eagle's 
Medium, Iscove's Modified Eagle medium, Minimal Essential Medium a-modification, 
RPMI 1640, Foetal Bovine Serum, Phosphate Buffered Saline (PBS), Trypsin-EDTA 
solution, 100 mM glutamine solution, Penicillin-Streptomycin solution, HAT and HT 
supplements, Percoll and mitomycin C were from Sigma; Hybridoma SFM medium, SF 
900-11, geneticin-sulphate (G418), interleukin 4 (IL-4), and versene solution were from 
Gibco (Paisley, UK); sheep red blood cells (SRBC) were purchased from , TCS 
(Buckingham, UK), lymphoprep was obtained from NYCOMED Pharma (Oslo, Norway). 




The plasmid pET-5a was purchased from Novagen (Madison, USA); pUC18-CD23 was 
obtained from Dr. J. Yodoi (Kyoto University, Kyoto, Japan); plasn-dd BlueScript was 
from Stratagene (Cambridge, UK); pEE12 was obtained from Dr. R. J. Owens (Celltech, 
Slough, UK) and pRTK3 was obtained from Dr. A. Reith (Ludwig Institute, Middlesex, 
UK). 
2.1.3. Antibodies 
Anti CD23 antibodies: MHM6 was initially obtained from Dr. J. Gordon (University of 
Birmingham, Birmingham, UK) and was later purified from hybridoma culture; mAb25 
was obtained from Dr. J. Y. Bonnefoy (Glaxo Institute, Geneva, Switzerland) and BU38 
was purchased from Binding Site (Birmingham, UK). 
Anti CR2 antibodies: OKB-7 was from Orthodiagnostics (High Wycombe, UK); HB5 was 
purified from hybridoma culture; BU32 and BU36 were from Binding Site (Birmingham, 
UK). 
Other antibodies: mAb IV. 3 (anti-CD32) was from Medarex, (Annandale, USA), DAAA 
(anti-IgM) was obtained from Dr. D. T. Fearon (Cambridge), HD37 (anti-CD19), negative 
controls IgGI and IgG2a/b and all secondary antibodies were from Dako (Glostrup, 
Denmark). 
2.1.4. Cells and cell lines 
B cells: RPMI 8866, RPMI 8226 and Raji cells were purchased from ATCC (American 
Type Cell Culture, Rockville, USA); tonsils for isolation of B cells were obtained from 
Royal National Hospital, London, UK. 
Other cells: Insect cells Sf9 were obtained from ECACC (European Collection of Animal 
Cell Cultures, Salisbury, UK); LTK7 fibroblast cell line transformed with human FcyRII 
cDNA was obtained from Dr. D. T. Fearon (Cambridge). 
Hybridomas: MHM6 producing hybridoma cell line was obtained from Dr. J. Gordon 
(Birmingham) and HB5 producing hybridoma cell line was purchased from ATCC. 
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2.1.5. Common buffers and solutions used in this work 
PBS: Phosphate-buffered saline, 11.9 mM with respect to phosphate and 140 mM with 
respect to chloride; 11 of solution is prepared by dissolving in distilled water 8.0 g NaCl, 
0.2 g KCI, 1.44 g Na2HP04 and 0.24g KH2pO4and adjusting pH to 7.4. 
TBS: Tris-buffered saline, 25 mM with respect to Tris and 140 mM with respect to 
phosphate; 11 of solution is prepared by dissolving in distilled water 8.0 g NaCl, 0.2 g 
KCI and 3.0 g Tris-base, and adjusting the pH to 7.5. 
HBS: HEPES-buffered saline, 20 mM with respect to HEPES and 140 mM with respect 
to NaCl; II of solution is prepared by dissolving in distilled water 4.77 g HEPES free 
acid and 8.19 g NaCl, and adjusting the pH to 7.2. 
TE: Tris-EDTA; 10 mM Tris pH 8.0,1 mM EDTA. 
TAE: Tris-acetate-EDTA DNA electrophoresis buffer; 40 mm Tris, I mm EDTA, pH 
adjusted to 8.0 with glacial acetic acid. The solution is prepared as a 50X stock. 
SDS-PAGE buffer: 25 mM Tris, 250 mM glycine, 0.1 % SDS (pH should be about 8.3); 
II of 5X stock buffer solution is prepared by dissolving in distilled water 30.25 g Tris 
base, 187.5 g glycine and 10 g SDS. 
Native PAGE buffer. 25 mM Tris, 25 mM boric acid (pH should be about 8.7); the 
solution is prepared as a 5X concentrated stock. 
Western blotting buffers: anode buffer contains 0.3 M Tris pH 10.4 and 20 % methanol; 
cathode buffer contains 25 mM Tris pH 9.4,40 mM e-aminocaproic acid and 20 % 
methanol. 
Blocking bufferfor Western blotting: 5% nonfat dried milk in PBS, with 0.02 % sodium 
azide. 
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Cell lysis buffer: 1.4 % OGP in PBS, with protease inhibitors added. For isolation of 
CD23 the inhibitors were: 2 mM PMSF, 0.2 mM TLCK, 20 mM iodoacetamide, 10 mM 
benzamidine hydrochloride, 50 niM e-aminocaproic acid. 
Bufferfor coupling antibodies to Affigel-10: 0.1 M MOPS, 0.3 M NaCI. 
Affinity column elution buffer: for elution of antibodies from protein A or protein G 
columns 0.1 M glycine pH 2.5 was used; for elution of native CD23 from anti-CD23 
affinity columns 0.2 M glycine with 0.2 % OGP and 0.2 mM TLCK was used. 
Binding buffer for FACs analysis: for antibody binding to cell antigens PBS containing 
2% BSA and 0.1 % sodium azide was used; for CD23/CR2 binding the buffer used was 
HBS with I% BSA, 2 mM CaCl2 and 0.1 % sodium azide. 
Coomassie staining and destaining solutions: 0.25 % Coomassie Brilliant Blue stain in 
60 % methanol, 10 % acetic acid; destaining solution was 60 % methanol, 10 % acetic 
acid. 
Silver staining and reducing solutions: 100 ml of silver staining solution is prepared by 
dissolving 0.8 g AgNO3 in 2 mM NaOH solution to which 1.4 ml of 35 % ammonia 
solution is added; the reducing solution is prepared from 0.5 ml of I% citric acid and 52 
pi of formaldehyde added to 100 ml of distilled water. 
RE buffers: all restriction enzyme buffers used in this work were those supplied with the 
enzymes by the manufacturer. 
Ligation buffer: 50 mM Tris, 5MM MgC12,5 mM DTr and 0.5 mM AT?; the blunt ends 
ligation buffer is described in the text. 
Sodium azide solution: 20 % sodium azide solution was prepared and used as a IOOOX 
stock (where the purpose was preventing bacterial contamination of solutions) or 20OX 
stock (where the purpose was preventing the endocytosis of cell surface antigens). 
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2.2. Recombinant DNA techniques 
2.2.1 Transformation of E. coh and large scale bacterial culture 
The competent E. coll cells (strains HB101 or TGI for general purpose plasn-dd isolation 
or otherwise as stated in the text) were transformed in the total volume of 200 PI by 
addition of 1-10 pl of plasmid DNA in TE buffer (the amount of DNA used was typically 
0.1 pg) and incubation on ice for 30 min. After that the cells were exposed to the 
temperature shock (42 *C/2 min) and returned to ice for 5 min, followed by addition of 
0.8 ml of LB medium (I % bactotryptone, 0.5 % bacto-yeast extract, I% sodium 
chloride, pH adjusted to 7.0 with 1M NaOH) and incubation at 30 T for 45 min. An 
aliquot of 100 pl was spread over agar plates (L-agar/ LB medium) containing 50-100 pg 
ampicillin and the plates were incubated for up to 24 h, by which time the bacterial 
colonies become visible. Several colonies were expanded onto new agar plates and after 
overnight incubation these cultures were used for inoculation of fresh LB medium 
(containing ampicillin). This was usually done in 21 sterile laboratory flasks 
accommodating 500 ml of culture, which was incubated for 12-18 h at 30 T with 
constant shaking. 
2.2.2. Large scale isolation and purification of plasmid DNA 
For the large scale isolation and purification of plasmid DNA the method of lysis of 
bacterial cells by alkali was used followed by two rounds of centrifugation in CsCI 
gradient. The bacterial pellet from 500 n-d culture was resuspended in 10 ml of solution 
1 (50 mM glucose, 25 mM Tris-Cl pH 8.0,10 mM EDTA) containing 5 mg/mI lysozyme 
and incubated at room temperature for 5 min. 20 ml of solution 2 (0.2 M NaOH, 2% 
SDS) was added and the tube gently inverted several times to mix the contents, followed 
by 10 min incubation on ice. 15 ml of solution 3 was added (5 M potassium acetate pH 
4.8), the tube inverted sharply several times until the white precipitate from denatured 
proteins forms and incubation on ice continued for another 10 min. Ile mixture was 
filtered through 2 layers of sterile muslin and centrifuged for 30 min at 10000 rpm in a 
Sorvall GSA rotor at 4 IC. The supernatant was warmed up to room temperature and 0.6 
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volumes of isopropanol was added, followed by 15 min incul5ation at room temperature. 
The DNA was recovered by centrifugation in a Sorvall S-34 rotor at 12000 rpm and 
washed with 70 % ethanol. Finally, the DNA pellet was dried on air and dissolved in TE 
buffer. 
The plasmid DNA was purified by centrifugation in, CsCl density gradient which was 
prepared by dissolving 1g of CsCI and 80 pI ethidium bromide solution (10 mg/ml) per 
each ml of DNA solution and brief centrifugation at 8000 rpm to remove the insoluble 
material. The solution was transferred into Beckman Quick-Seal tubes and centrifugation 
performed in Ti65 rotor at 60000 rpm for 24 h. The plasmid DNA band was located in 
the gradient under UV light and extracted from the tube with a needle and syringe. The 
centrifugation in CsCl gradient was repeated once more if the DNA was to be used for 
transfection of cells. After extraction of ethydium bromide by chloroform the sample was 
extensively dialysed to remove CsCl and DNA precipitated by ethanol. 
2.2.3. General DNA techniques 
The restriction enzymes and DNA modification enzyme, reactions were performed 
according to the manufacturer's instructions. Typically, the restriction digestion was 
carried out with 5-10 units of enzyme activity per I pg of plasmid DNA for 2-3 hours at 
37 'C; in the case of partial digestion lower concentration of the enzyme was used and 
the optimal incubation time determined by pilot experiments. The ligation of blunt DNA 
ends was performed at 16'C with 2-5 Weiss units of bacteriophage T4 DNA ligase (high 
concentration) in the buffer: 50 mM Tris, 5 MM MgC12,5 mM DTT, 10 mM 
hexaminocobalt chloride, 0.5 mM spermidine and 100 pM ATP, over a period of 12 h. 
Prior to ligation, the 5'- ends of the linearised plasmid DNA were dephosphorylated by 
alkaline phosphatase treatment (1 IV37 *Q following the completion of the digestion 
reaction. PCR was performed using the appropriate oligonucleotide primers and plasmid 
DNA as the template (for generation of given PCR fragment) or cell lysate as the source 
of template (for screening the transformants). In most cases the PCR conditions were: 
denaturation, I min / 94 T; annealing, 2 min / 55 OC; polymerisation, 2 min / 74 T; 25 
cycles were usually sufficient to generate the required amount of the desired DNA 
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fragment. Where necessary, the Me concentration was varied to achieve the maximum 
yield. The DNA was routinely concentrated by ethanol or iso-propanol precipitation. DNA 
sequencing was performed according to the protocol supplied with the Promega 
sequencing reagents. 
2.2.4. DNA electrophoresis 
DNA electrophoresis was performed on 0.8-1.2 % agarose gels with TAE electrophoresis 
buffer (Sambrook et al., 1989) containing 0.5 pg/mI ethidium bromide. Depending on 
purpose, small (analytical) or large (preparative) gels were used. The DNA size markers 
used were phage X DNA fragments obtained by digestion with Sty I and the corresponding 
sizes of fragments are: 19.3,7.74,6.22,4.25,3.47,2.69,1.88,1.49,0.92,0.42 and 0.014 
kb. Following electrophoresis, the DNA bands were located in the gel by illumination with 
UV light and the DNA fragment of interest was recovered and purified from the gel using 
the Geneclean kit (La Jolla, USA), according to the manufacturer's instructions. 
2.2.5. Construction of the expression vector pRR28 
A cDNA fragment coding for the entire extracellular sequence of CD23 was amplified by 
PCR using pUC-18 (CD23 cDNA storage plasmid) as the template and the primers 5'- 
CAGGATCCCATATGGACACCACACAGAGT-3' (forward) and 5'- 
C 
. 3CGGATCCTA'ITATCAAGAGTGGAGAGG-3' 
(reverse) with the both primers designed 
to generate a new cleavage site for the restriction enzyme BamHI and the forward primer 
carrying a new site for Ndel. The PCR fragment was blunt-ended using T4-DNA 
polymerase, purified by electrophoresis and ligated into SaII, SacIl cleaved and blunt- 
ended plasn-M Blue Script. The large BstEII-SacIl fragment of the PCR insert was then 
replaced within the Blue Script plasmid with the same insert of genomic DNA from the 
original CD23 plasmid and the remaining parts of the insert on both sides sequenced. The 
plasmid was then digested with NdeI and BamHI and the CD23 DNA carrying fragment 
subcloned into the E. coli expression vector pET-5a linearised with the same enzymes. 
Thus, the NdeI site containing ATG codon was restored and the following codon encodes 
for the first amino acid of the extracellular sequence of CD23. 
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2.2.6. Construction of the expression vector pML95 
The plasmid pML95 was constructed from the mammalian cell expression vector pEE12 
into which the entire CD23 coding sequence was inserted as described below. pUC-18 
containing the cDNA for CD23 was cleaved with restriction enzymes Sall and RsaI and 
the 1.25 Kb SaII-Rsal fragment isolated and purified. This fragment, which carries the 
CD23 cDNA, was then subcloned into the plasmid pBSM13- previously cleaved with the 
same enzymes, followed by isolation of a HindIII-EcoRI fragment (partial digestion with 
HIndIII was necessary to preserve the HindIII site within the CD23 cDNA). The HindIII- 
EcoRI fragment was finally subcloned into the expression vector pEE12 which had been 
previously cleaved with HindIII and EcoRL The transcription of the sub-cloned insert is 
driven by hCMV (humanmýgalovirus) promoter and the plasmid contains the glutamine 
synthetase gene for selection of stable transformants and the ampicillin resistance gene for 
amplification in bacteria. 
2.3. Analytical methods 
2.3.1. Polyacrylamide gel electrophoresis (PAGE) of proteins 
a) SDS-PAGE: electrophoresis of proteins under denaturing conditions 
The electrophoresis of proteins in the presence of SDS was performed essentially by the 
method of Laemmli, 1970. ne polyacrylamide gels (110 mm x 80 mm xI mm) were 
prepared from 10 ml of the mixture according to the Table 2-1, which was poured in to 
the pre-set cassette and left to polymerize for 20-30 n-dn. On the top of the resolving gel 
of given concentration 1.5 ml of the stacking gel mixture (5% acrylamide ) was poured 
and 12 teeth comb inserted, generating slots of the maximum loading capacity of 25 Pl. 
The protein samples (0.1-30 pg, depending on the detection method applied) were mixed 
with the sample-loading buffer (50 mM Tris pH 6.8,2 % SDS, 10 % glycerol, 0.1 % 
bromphenol blue) with or without 100 mM DTT (dithiothreitol) and boiled for 3 min to 
denature the proteins. Electrophoresis was performed in the electrophoresis apparatus 
model AE-6450 (ATTO Corporation, Japan) in the presence of running buffer (section 
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2.1.5), at 120 V for approximately 2 h, after which the gel was used for detection of 
proteins as described below or for transfer of proteins to nitrocellulose filter and immuno- 
detection of the specific protein. Parallel to the samples the standard molecular weight 
protein markers were applied (pre-stained protein markers from Amersham, 14.3-200 kDa 
and 2.35-46 kDa). 
Table 2-1: Solutions for preparing 10 ml of resolving SDS-polyacrylamide gels of the 
given concentration (the volumes are in mi) 
COMPONENT 6% 8 %- 10% 12% 15% 
Distilled water 2.6 4.6 4.0 3.3 2.3 
30 % acrylamide mix* 1.0 2.7 3.3 4.0 5.0 
1.5 M Tris (pH 8.8) 2.5 2.5 2.5 2.5 2.5 
10 % SDS 0.1 0.1 0.1 0.1 0.1 
10 % amm. persulphate 0.1 0.1 0.1 0.1 0.1 
TEMED 0.008 0.006 0.004 0.004 0.004 
* 30 % acrylan-dde solution contains 29 % acrylamide and 1%N, N- 
methylenebisacrylamide 
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Table 2-2: Solutions for preparing 2 ml of 5% 
stacking gel for SDS-PAGE 
COMPONENT VOLUME IN ML 
Distilled water 1.4 
30 % acrylan-dde mix 0.33 
1.0 M Tris (pH 6.8) 0.25 
10 % SDS 0.02 




b) Native PAGE: electrophoresis of proteins under native conditions 
This was perfon-ned as for the SDS-PAGE with the following exceptions. The gel 
preparing, sample loading and running buffers did not contain any SDS and the Tris- 
borate buffer was used instead of Tris-glycine. The protein sample was applied onto the 
gel directly, without boiling and the separation of proteins was usually performed on 
polyacrylamide gradient (5-20 %) instead of homogenous gels. The gradient gels were 
prepared using a gradient maker consisting of two chambers connected with a tap, and a 
peristaltic pump to transfer the mixture into the pre-set cassette into which a needle was 
inserted. Table 2-3 contains the details for preparation of polyacrylamide gradient gels. 
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Table 2-3: Solutions for preparing 10 ml of native PAGE gel 
with linear gradient of polyacrylan-dde 5-20 % (n-d): 
COMPONENT 5% gel 20 % gel 
Distilled water 2.87 0.4 
30 % acrylamide mix 0.83 3.3 
1.0 M Tris pH 8.7 1.25 1.25 
10 % anunonium persulphate 0.050 0.050 
TEMED 0.002 0.002 
2.3.2. Detection of proteins in gels 
Following the electrophoresis, the proteins were detected in gels either by staining in 
Coomassie Brilliant Blue solution for 2 or more hours and removing the excess of the dye 
by incubation in the destaining solution, or with staining by silver nitrate method. The 
silver staining method was performed by first incubating the gel in 20 % TCA 
(trichloroacetic acid) for 2 or more hours followed by 2 washes in 50 % methanol (30 min 
each) and 2 washes in distilled water (20 min). The gel was then submerged into the 
silver staining solution (paragraph 2.1.5) for 10-15 min on a shaking platform, followed 
by 2 washes in distilled water (5 min) and finally transferred to the reducing solution in 
which it was incubated until the appearance of protein bands. In the case of [1251]-labelled 
proteins the gel was dried on 3MM Whatman filter paper and exposed to X-ray film (Fuji) 
at -70 T for several hours to overnight. 
2.3.3. Western blotting 
Following electrophoresis the proteins were transferred to nitrocellulose filter in a semi- 
dry blotter apparatus (20 V/ 20 min) and the remaining free sites on the filter blocked 
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by incubation in 5% nonfat dry milk solution in PBS, for 2h at room temperature or 
overnight at 4 'C (sodium azide added), with constant agitation on a shaking platform. 
The filter was briefly washed in PBS and antibody solution added (most of the 
commercial antibodies were used at the dilution 1: 1000, or otherwise, at the concentration 
0.05-0.5 pg/i-nl, in PBS) and the filter incubated in the antibody solution for 2h at room 
temperature or overnight at 4 'C, followed by 3 washes in PBS containing 0.02 % Tween 
20 (10 min each). After that the filter was incubated with either secondary antibody - 
peroxidase conjugate or with streptavidin - peroxidase complex in the case where the 
primary antibody was biotinylated. In either case the nitrocellulose was incubated in the 
solution for 2h at room temperature, washed 3 times and the immunoreactive proteins 
detected by developing the peroxidase reaction. For this, the ECL Western blotting 
reagents from Amersham were used or the conventional method was applied, utilizing the 
chromogen diaminobenzidine tetrahydrochloride. 
2.3.4. ELISA Immunoassay 
The ELISA immunoassay was performed in 96-well Nunc-immuno plates by coating the 
plates with the first protein at the concentration 2 pg/ml in 100 mM sodium carbonate 
buffer pH 9.6, for 2h at room temperature or overnight at 4 *C, followed by blocking the 
unoccupied sites with, 2% nonfat dry milk solution in the same buffer. The wells were 
then briefly washed with PBS, 0.02 % Tween 20, and the second protein was added at 
serial dilution (2-fold or 10-fold). Again, the plates were incubated for 2 h, washed 3 
times and in the case where the second protein was primary antibody, the secondary 
antibody - peroxidase conjugate was added; where the second layer was another protein 
the primary antibody was added followed by incubation with secondary antibody - 
peroxidase conjugate. After the incubation and washing as above the peroxidase reaction 
was developed using the chromogen substrate tetra-methylbenzidine and the absorbance 
read at 630 nm, in a multi-channel absorbance reader Mtertek Multiscan Plus, from ICN 
Flow). In some cases, where higher sensitivity was required, -an equal volume of 3M 
sulphuric acid was added to the final reaction and the absorbance read at 450 nm. 
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2.3.5. Isolation and purification of recombinant CD23 from E. coU 
The bacterial cells from II of minimal medium M9 were harvested 6h following the 
induction with 0.4 mM IPTG and the inclusion bodies with accumulated recombinant 
CD23 extracted from the cell pellet by the modified procedure of Bohmann and Tjian, 
1989. The cell pellet was resuspended in 72 n-d of solution 1 (10 rnM Tris pH 7.9,25 % 
sucrose, 100 mM KCI, 2 mM DTT, 2 mM PMSF) and 1/4 vol. (18 ml) of the solution 2 
(300 mM Tris pH 7.9,100 mM EDTA, 4 mg/ml lysozyme) was added. Following 10 min 
incubation on ice, the equal volume (90 ml) of solution 3 (1 M LiCl, 20 mM EDTA, 0.5 
% Nonidet NP-40) was added and the suspension mixed and sonicated (Soniprep 150). 
The inclusion bodies were pelleted by centrifugation at 10000 rpm for 10 min, 
resuspended in 200 ml of solution 4 (10 mM Tris pH 7.9,0.1 mM EDTA, 0.5 mM LiCl, 
0.5 % Nonidet NP-40,1 mM DTr, I mM PMSF) and the sonication repeated. After 
centrifugation (as before) the pellet was resuspended in 200 ml of solution 5 (10 mM Tris 
pH 7.9,0.1 mM EDTA, 2% Nonidet NP-40,1 mM DTr, I mM PMSF), sonicated again, 
centrifuged and resuspended in 200 ml of solution 6 (10 mM Tris pH7.9,0.1 mM EDTA, 
0.5 % Nonidet NP-40, I rnM DTT, I mM PMSF). Finally, the sonication was repeated 
once more and the remaining pellet frozen at -70 T. For isolation of recombinant CD23 
from the inclusion bodies, the pellet was dissolved in 5 ml of 6M guanidine-HCI (GnCI), 
20 % sucrose, 10 mM DTT and incubated at room temperature for I h. CD23 was then 
purified by gel-filtration on a Sephacryl S-100 column (Pharmacia) with 6M GnCl as the 
running buffer. The fractions were analyzed for CD23 by electrophoresis and Western 
blotting, and the positive fractions pooled and concentrated by ultrafiltration (Amicon). 
2.3.6. Renaturation of recombinant CD23 
For the renaturation of insoluble, inactive CD23 isolated from the bacterial culture by 
GnCI extraction and purified by gel-filtration, several protocols were applied, based on 
different oxidation conditions. The optimal protocol for the refolding of CD23 was shown 
to be similar to that for the protease papain, as described by Taylor et al., 1992. The 
protein stock solution (I mg/ml, in 6M GnCl) was concentrated further 10-fold by 
ultrafiltration and DTT was added to the final concentration of 10 MM. Following 1h 
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incubation at 37 *C the sample was diluted 10-fold in 0.5 M Tris-acetate pH 8.6 
containing 6M GnCI and 0.1 M oxidised. glutathione, and stored at 4T for 24 h. The 
sample was diluted further 100-fold in 100 rnM Tris-acetate buffer pH 8.0,2 mm CaCl., 
3 mM cysteine and incubated for 36 h at 4 T. Finally, CD23 was concentrated 1000-fold 
by ultrafiltration, with a gradual change of the refolding buffer for TBS pH 7.5,2 mM 
CaCl2.0.2 mM TLCK (L-1-chloro-3-[4-tosylamidol-7-an-dno-2-heptanone). 
2.3.7. [12511-labelling of recombinant CD23 
100 pg of recombinant CD23 was labelled with ["'1]-Nal by mixing 100 pl of protein 
sample (1 mg/ml), 100 pl of 0.5 M sodium phosphate buffer pH 7.5,1 MCi Of ['2' I]-NaI 
(Amersham) and 200 pl of chloramine T solution (2 mg/ml, in 250 mM sodium phosphate 
buffer pH 7.5). Following 2 min incubation at '- room temperature, 400 pl of stop 
solution (2 mg/mI sodium-metabisulphite, in PBS) and 200 pl of PBS were added. The 
free label was removed by gel-filtration on a small Sephadex-50 column and the protein 
containing fractions (1 ml each) combined and frozen. An aliquot of this was used to 
measure the total radioactivity in a gamma radioactive counter, and the specific 
radioactivity was measured on the basis of protein measurement by spectrophotometry. 
2.3.8. Chemical crosslinking of recombinant CD23 
The chemical crosslinking of recombinant CD23 was performed as described by Beavil 
et al., 1995. The conditions for optimal cross-linking with respect to pH of the buffer, 
concentration of the protein and the crosslinker and the length of incubation, were tested 
separately. Typically, the ["'11-labelled CD23 was crosslinked at the protein concentration 
2 pg/mI in 20 pI of 25 mM sodium acetate buffer pH 5.0 with the crosslinker 1-ethyl-3- 
(dimethylaminopropyl)-carbodiimide-HCI (EDC). After 15-30 min incubation at the room 
temperature the sample was subjected to SDS-PAGE (12 % polyacrylamide gel) under 
reducing conditions and the dried gel exposed to X-ray film. For crosslinking of CD23 
at higher concentrations (50 pg/ml, 0.5 mg/ml) the same conditions were used except that 
unlabefled CD23 was used and the protein visualised in the gels after electrophoresis by 
silver or Coornassie staining methods. 
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2.3.9. HPLC analysis of proteins 
For additional purity of CD23 or for analytical purposes (molecular weight determination, 
Stokes radius measurement) some protein preparations were subjected to HPLC on 
Superdex-75 column (Pharmacia). The running buffer was TBS pH 7.5 containing 2 mM 
CaC12 and 0.2 mM TLCK. The column was equilibrated with the standard protein 
molecular weight markers, as indicated in the text. 
2.3.10. Sucrose gradient centrifugation 
The sucrose gradients (5-20 %) in TBS, 2 mM CaC12.0.2 mM TLCK were prepared in 
12 ml polypropylene tubes (Beckman) using a gradient maker comprising two equal 
chambers connected with a tap, to which 6 ml of 5% or 20 % sucrose solution were 
added and the tap opened (the chamber closer to the pump to which the 5% solution is 
added contained a small magnetic stirrer, for rapid mixing of the solution). The mixed 
solution was poured into the tube via a small glass capillary inserted to the bottom of the 
tube, so that the incoming sucrose solution of higher concentration was pushing the 5% 
solution upwards until reaching the top of the tube. 
The protein sample was loaded on the top of each gradient and the centrifugation 
performed with a Beckman SW 41 rotor at 35000 rpm, at 4 *C. The centrifugation time 
was calculated from the "K" value of the rotor (given in the catalogue supplied by the 
manufacturer) adjusted for the actual speed as compared to the maximum speed (Kadj. = 
Kx [rpm(max)/rpm(actuaI)1). The time of centrifugation was usually calculated with respect 
to the protein with highest Sw, 20 value (sedimentation coefficient) nearly reaching the 
bottom of the tube at the end of centrifugation; in the equation K=txS, t represents the 
time and S the sedimentation coefficient of the protein. For most of the experiments the 
centrifugation time was between 24 and 36 h. 
Following the end of centrifugation, the gradients were fractionated in 50-60 samples (0.2- 
0.25 ml) and the fractions analyzed for proteins by spectrophotometry (OD290. ). The 
sedimentation coefficient for CD23 was determined from a calibration curve obtained for 
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the internal standards and subsequently used to calculate the molecular weight of the 
protein from the classical Svedberg's equation (described later in the text). 
2.3.11. Surface plasmon resonance (SPR) 
This was performed in a BlAcore biosensor apparatus (Phan-nacia) as follows. The protein 
of interest was immobilised via primary an-dne groups to a carboxylated dextran-coated 
CM5 sensor chip at the concentration 50 pg1ml and the unoccupied sites on the chip 
blocked with IM ethanolamine-hydrochloride. The ligand was then injected at various 
concentrations and association phase was monitored for 6 min at a flow rate of buffer at 
5 pl/min, while the dissociation was monitored for 10-15 min. Between each run the 
remaining ligand was removed from the surface by repeated pulses of 0.1 M glycine pH 
2.5. As the negative control a sensor chip with no first protein immobilised but treated 
in the same way, was used. Since binding was measured in presence of the constant 
concentration of the first protein in the flow cell, the association rate constant (k. ) was 
calculated assuming pseudo first-order kinetics. If R is the signal (in resonance units, RU) 
dR/dt was plotted against R for each concentration (over the time period in which the 
binding is not limited by mass transfer). The gradients of these lines were then plotted 
against the concentration of ligand and k, 1 obtained from the gradient of this plot 
(Karisson et al., 1991). The dissociation rate constant (k_1) was obtained from the gradient 
of a plot of ln(F, /R, ) against time, where & and Rt are the signals at the start of, and 
during the dissociation phase. The affinity constant for binding was then calculated as 
k,,, /k-,. 
2.3.12. Purification of native CD23 from RPMI 8866 cells 
The membrane form of CD23 was isolated and purified from the detergent lysates of 101, 
RPMI 8866 cells similarly as described by Cairns and Gordon, 1990, with one 
modification. The detergent used was octylglucopyranoside (OGP) instead of Nonidet NP- 
40. The cells were lysed in the buffer PBS pH 7.4,1.4 % OGP, 10 mM benzamidine 
hydrochloride, 20 mM iodoacetamide, 50 mM e-aminocaproic acid, 0.2 mM TLCK and 
1 rnM PMSF, for 2h on ice, followed by 30 min centrifugation at 16000 x g. The 
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supernatant was applied onto MHM6 anti-CD23 antibody affinity column prepared by 
binding of 100 mg pure antibody to 20 ml of Affigel-10 (Bio-Rad) and the column 
washed with 20-30 volumes of lysis buffer before the protein was eluted in 0.2 M glycine, 
pH 2.3,0.2 mM TLCK, 0.2 % OGP. In some cases the CD23 preparation purified in this 
way was passed through a second affinity column prepared by binding of 20 mg anti- 
CD23 antibody mAb25 to 10 n-d of Affigel-10. In either case the CD23 positive fractions 
were pooled, concentrated and kept frozen. 
2.3.13. Preparation of fluorescent CD23-liposomes 
The native, detergent solubilized CD23 was incorporated into liposomes together with a 
fluorescent label by a method similar to that described by Pochon et al., 1992. The 
phospholipid POPC was dissolved in chloroform at 50 mM concentration (380 mg in 10 
ml) and aliquoted in 1 ml samples which were flashed with nitrogen (to remove oxygen) 
and frozen at -80 T. The 0.5mM solution of the fluorescent label DioCl8 was prepared 
by dissolving 4.4 mg in 10 ml of dymethy1formamide and kept at -20 T in 0.5 ml 
aliquots. 
For preparation of 1.0 n-d of CD23-liposomes 10 pmol (0.2 ml) of POPC and 50 nmol 
(0.1 ml) of DioC18 were mixed and the solvents evaporated under the flow of nitrogen 
for 2 h. The sample was further dried in. Speed-Vac concentrator and dissolved in 50 PI 
of 800 mM OGP in PBS, by intensive vortexing. 150 pI of PBS was added (OGP is now 
200 mM) followed by addition of 800 pI of 50 mM OGP solution in PBS containing 0.2 
nmol of CD23 (approx. 9 pg), to make a ratio protein/lipid 1: 50000. The mixture was 
briefly vortexed and incubated on ice for 1 h, followed by filtration through a 0.2 pm 
filter and dialysed in a Slide-A-lyzer cassette (Pierce) for 3 days, against 20 mM HEPES 
buffer pH 7.0. The fon-nation of liposomes can be observed by the rapid increase in 
turbidity of the solution. Sodium azide was added and the CD23-liposome solution was 
kept at 4 OC, in dark. 
CD23-liposomes could not be formed if the detergent for CD23 solubilization was 
Nonidet NP-40. Even -' , traces of this or other non-dialysable detergents will alter the 
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CMC (critical micelle concentration) value for OGP, preventing its dialysis and thus, the 
formation of liposomes. 
2.3.14. Purification of native and soluble CR2 
The membrane fonnCR2 was isolated and purified from 1010 RPMI 8226 cells which 
were lysed in the buffer PBS pH 7.4 containing 1% Nonidet NP-40 and 1 mM PMSF, 
for 2h on ice. The lysates were centrifuged at 16000 xg for 30 min and the supernatant 
passed through anti-CR2 antibody HB5 affinity column'. - The column was washed with 30 
volumes of lysis buffer and the bound pro tein eluted with 0.1 M glycine, pH 2.5,0.1 % 
Nonidet NP-40. 
The recombinant CR2 expressed in insect cells was partially purified from the cell culture 
supernatants as follows. The insect cell culture supernatants from infected cells were 
collected usually on day 5 following the infection, centrifuged at 8000 rpm/20 min to 
remove the cells and cell debris and filtered through 0.4 prn filter. The supernatant was 
concentrated up to 5 times by Amicon ultra-filtration and extensively dialysed against 10 
mM potassium phosphate buffer pH 7.8 (the iso-electric point of CR2 is 7.36). In the 
meantime a small amount of the ion-exchanger DEAE Sephadex A50 was reconstituted 
in the same buffer and allowed to equilibrate with the buffer for several hours. The 
capacity of this ion-exchanger is exceptionally high (> 10 mg/ml), but for the convenience 
of using a packed column approximately 5 ml wet volume of the matrix was used. The 
supernatant was applied to the column and the column washed with the running buffer. 
The elution of the bound proteins was performed with gradient of sodium chloride 0-300 
mM, in 10 mM phosphate buffer pH 7.8 and the fractions analyzed for protein content. 
The protein containing fractions were further analyzed for presence of CR2 by Western 
blotting. 
2.3.15. Production and purification of antibodies 
The hybridoma cell cultures were gown in hybridonia-SFM low protein content medium 
(Gibco) until approximately 21 of culture was collected. The cells were removed by 
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centrifugation (5000 rpm/10 min) and the supernatant filtered through 0.2 pm filter. The 
supernatant was concentrated by ultrafiltration (Amicon) 100-fold and the antibody 
purified by affinity chromatography on either protein A (IgG2 type antibodies) or protein 
G (IgG1 type antibodies) column. 7be chromatography was repeated several times until 
there was no significant amount of antibody left in the supernatant. 'Me eluted antibody 
was concentrated to 2-4 mg/mI and stored frozen. 
2.3.16. Detection of carbohydrates in glycoproteins 
This was performed using GlycoTrack carbohydrate detection kit from Oxford 
Glycosystems, according to the manufacturer's instructions. The protein sample (0.1 -1 pg) 
was labelled in solution (20 pl) followed by electrophoresis and transfer of the proteins 
to nitrocellulose filter. Also, a modified protocol for preferential labelling of sialic acid 
was performed. 
2.4. Cell culture techniques 
2.4.1. General conditions for growth of cells and cell lines 
RPMI 8866: This mature B cell line was used as the source of native CD23. The cells 
were grown in RPMI 1640 medium supplemented with 10 % FBS (foetal bovine serum), 
2 mM glutan-dne and the antibiotics penicillin (100 U/ml) and streptomycin (100 Pg1ml). 
Once confluent, the cells were divided at the ratio 1: 10 and culture continued. 
RPMI 8226: These plasma B cells were used as the CR2 positive cells in flow cytometry 
(FACs) assays and also for isolation and purification of native CR2. The growth 
conditions and maintenance of the cells were same as for RPMI 8866 cells except that the 
cells were divided at the ratio 1: 5 at the passage time. 
Tonsillar B cells: The cells were used to study differentiation upon stimulation by 
crosslinking CD23 and CD32. Once isolated and purified from human tonsils, the cells 
were kept in complete RPMI 1640 medium supplemented with 10 % FBS and gentamycin 
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in the incubator (5 clo C02,37 T), at the concentration 10' cells/n-d, for up to 3 days. 
LTIC fibroblast cells: This cell line has been previously transformed with , human 
FcyRII and was used in this work for expression of CD23. The cells were grown in 
minimal essential medium ((x-modification) supplemented with 10 % FBS, 2 mM 
glutan-flne, penicillin (100 U/n-d), streptomycin (100 pg/ml) and geneticin/G418 (I mg/mI). 
The CD23 transformed cells were TK (thymidine kinase) positive, and were grown in 
HAT supplemented medium (100 pM hypoxhantine, 0.4 pM an-dnopterin, 16 pM 
thymidine). The stable transfon-nants were maintained in HT medium, after selection was 
complete. The cells were divided every 5-6 days at the ratio 1: 10. 
Hybridomas: Hybridoma cell lines were used for antibody production. The cells were 
grown in Hybridoma-SFM low protein content medium from Gibco supplemented with 
penicillin and streptomycin. The cells were allowed to expand rapidly by dilution with 
fresh medium (1: 3) until sufficient amount of culture supernatant was collected. 
Insect cells SO: These cells were used for production of soluble CR2 by the baculovirus 
expression system. The cells were grown in SF 900-11 medium supplemented with 
penicillin and streptomycin, on a shaker. After the infection with recombinant virus the 
cells were kept in the culture until the cell number fell to 50 % as compared to the initial 
culture. 
2.4.2. Maintenance of cell cultures 
All cells were incubated at 37 *C, in the atmosphere of 5 clo C02, except the insect cells 
which were grown at the room temperature in the absence of C02. The cells were 
generally grown in tissue culture flasks (T-type) and in some cases in roller bottles on a 
rolling wheel, while the large scale isolation of membrane CD23 required fen-nenter 
production of RPMI 8866 cells (this was done at Pfizer, Kent, UK). The adherent cells 
were detached from plastics either by trypsin (for maintenance) or by versene (for cell 
binding assays), or were scraped for preparation of cell lysates. The cells were regularly 
counted and tested for viability by Trypan Blue staining. 
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2.4.3. Transfection of cells and selection of stable transformants 
The cells were transfected with plasn-dd DNA double purified by CsCI gradient 
centrifugation, by the method of liPofection using the transfection reagent DOTAP from 
Boehringer. The cells were grown in the appropriate cell culture medium until nearly 
confluent and 5x 1W cells transferred to a new 25 cm' tissue culture flask and left to 
reach 80 % confluence (usually 24 h later). 30 pl of the transfection reagent DOTAP was 
diluted to 100 pl with HBS, pH 7.2, and 5 pg of plasn-ýd DNA (4 pg of plasrnid carrying 
the gene of interest and I pg of selection marker gene carrying plasmid, in the case of co- 
transfection) was separately also diluted to 100 pl with HBS. The two solutions were 
mixed and incubated for 10 min at room temperature, after which the mixture was added 
to 5 ml of culture medium and the cells were incubated with this medium for 12 h. The 
medium was removed, cells washed with fresh medium and incubated for 24 h in the 
fresh medium. The cells were left in the incubator for 3 days before they were used in the 
case of transient expression, or divided in ratio 1: 10 and placed in the selective medium 
in the case of stable expression. The selection took about 2-3 weeks to complete, after 
which period the single clones were isolated by the method of limited dilution and 
gradually expanded. 
2.4.4. Infection of insect cells with recombinant baculovirus DNA 
5x IW insect cells (Sf9)/mI were infected with the concentrated pure viral stock (3.7 x 
101 viral particles per I ml of the stock) and monitored for viability over a period 1-8 
days. After 50 % of the cells were dead (usually 5 days post-infection) the culture was 
terminated and used as a new viral stock in following infections (approximately 10' viral 
units per 1 n-d of the stock). I'his new stock was routinely used to infect the insect cells 
in such a way that to the given volume of cell suspension (5 x 105 _Ix 10' cells/ml), 
1/10 vol/vol of the viral stock was added and the cells incubated until the cell number 
falls to 50 %. 
68 
2.4.5. Cell binding assays and flow cytometry 
For binding of CD23-liposomes to CR2 positive cells , 106 cells were washed with PBS 
and resuspended in 200 pl of liposome preparation diluted 5-fold in HBS containing 2% 
BSA, 2 mM CaCl2and 0.1 % sodium azide, and incubated for 2h on ice. The cells were 
washed two times in the binding buffer and analyzed for fluorescence in a FACscan 
apparatus (Becton-Dickinson) against the negative control (liposomes with no CD23). 
For analyzing the expression of cell surface antigens, 106cells were resuspended in PBS 
containing 2% BSA, 0.1 % sodium azide, and the appropriate antibody was added (1: 20). 
Following 1h incubation on ice the cells were washed twice and incubated with the 
secondary antibody-FITC conjugate for Ih on ice. In some cases this was not necessary 
as the primary antibody was FITC labelled. After washing twice the cells were analyzed 
by FACs. 
2.4.6. AET treatment of sheep red blood cells (SRBQ 
The AET (2-an-dnoeyhylisothiouronium bromide) was prepared as 140 mM solution (1.97 
g in 50 n-d of distilled water) and pH adjusted to 8.8 with sodium hydroxide (5 M). 7he 
solution was filter sterilised before use. The SRBC was aliquoted into two 12.5 ml 
samples in 50 tril Falcon tubes and to each tube PBS was added to 50 ml. The cells were 
collected by centrifugation at 12000 rpm/5 min and resuspended in 25 ml of AET 
solution. 7be incubation was done at 37 *C for 20 min, after which the cells were 
collected as previously and repeatedly washed 3-4 times with cold PBS. Finally the cells 
in each tube were resuspended in 50 ml of complete RPM1 1640 medium with 10 % FBS. 
This protocol is designed to yield a sufficient amount of AET treated SRBC cells for 
isolation of B cells from I pair of tonsils. 
2.4.7. Isolation of human tonsillar B cells 
This procedure is an adaptation of the protocol obtained from Dr. J. Murphy (King's 
College London). The tonsils were first washed in sterile PBS and then cut and minced 
using scissors and a sterile Petri dish. To release cells two different protocols were 
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successfully applied. In the first protocol the minced tissue was pressed and squeezed in 
the Petri dish using a 20 ml syringe plunger and a tea strainer and the released cells 
collected in 10 ml of RPMI medium. This was repeated 4-5 times until 50 ml of the 
medium containing cells was collected. In the second protocol the n-dnced tonsillar tissue 
was placed in a 25 ml glass tissue homogeniser to which 10 ml of RPMI medium was 
added and the cells released by gently squeezing the tissue. This was repeated several 
times until the tissue no longer contained mononuclear cells. In either case, the medium 
with cells was left in the conical 50 ml tube for 5 min and then transferred to a new tube 
carefully, so that remaining small pieces of the tissue were left behind. 25 ml of 
Lymphoprep solution (Nycomed) was added per 50 n-d Falcon tube and 12.5 ml of the 
tonsil extract was carefully layered on top of it. The samples were spun at 16000 rpm for 
25 min, at the room temperature. The interface between the two media contains the 
mononuclear cells and was collected in 5-7 ml medium which was then placed in new 
tube. To wash the cells 50 ml of RPMI medium was added and the cells collected by 
centrifugation (12000 rpm 15 n-dn), and this was repeated once more. The cell pellet was 
resuspended in 25 ml of complete RPMI medium and the same volume of freshly 
prepared AET treated SRBC was added. The contents of the tubes were mixed by gently 
inverting the tubes and incubated at 4 'C for 30 min. After that the cells were collected 
by centrifugation at 12000 rpnV5 min and resuspended in 25 n-d of complete RPMI 
medium. This was carefully layered over 25 ml of Lymphoprep solution and 
centrifugation repeated as above (16000 rpnV25 min, at room temperature. The interface 
containing B cells was collected in 5-7 ml and the cells washed once with RPMI medium. 
The rossetting of T lymphocytes with AET-treated SRBC was repeated once more in the 
exactly same way. If the cell pellet appeared red as a consequence of contamination with 
SRB cells 2 ml of the red cell lysis buffer was added (10 mM potassium bicarbonate, 155 
mM ammonium chloride, 100 mM EDTA) and the cells incubated at 4 'C for 5 min. 50 
ml of RPMI medium was added to wash the cells and after centrifugation at 12000 rpm 
for 5 min the cells were resuspended in 10 ml of the complete RPMI 1640 medium 
containing 10 % FBS and the antibiotics streptomycin, penicillin and gentamycin. The 
cells were counted and accordingly diluted to the final concentration of Ix 10" cells/ml. 
For cell proliferation assay the cells were left in the medium for 24 h at 37 *C, in the 
atmosphere of 5% C02. 
70 
In some experiments, following the two rounds of SRBC treatment the cells were applied 
on the top of discontinuous Percoll gradient which -, consisted of 30,40,45,50,55, 
60 and 80 % Percoll in Hanks' balanced saline solution (HBSS) pH 7.2 and centrifuged 
at 28000 rpm /25 min, at 4 T. The high density cells were collected at the interface 
between 55 and 60 % percoll, washed with RPMI 1640 medium and left overnight in the 
complete medium as described above. 
2.4.8. Mitomycin treatment of cells 
To elin-dnate the interference from non-B cells in the proliferation assays, the transformed 
fibroblast cells which were used as supplier of CD32 and CD23 were treated with 
n-dtomycin C, the inhibitor of DNA synthesis. This was usually done with 15-20 Pg of 
mitomycin C per ml of medium for 12-14 h (overnight) or with 50 Pg/mI for 2 h. 'Tile 
cells were then washed 3 times with PBS and incubated in the mitomycin free medium. 
The cells treated in this way can survive up to 3 days, which is sufficient time for the B 
cell proliferation assay. 
2.4.9. B cell proliferation assay 
The tonsillar B cells were used 24 h after the isolation and purification. The cells were 
seeded at the concentration of 2.5 x 105 cells/ml in complete RPMI medium with 10 % 
FBS and the appropriate stimuli of cell activation were added. The typical experiment 
was performed in 96-well plates in such a way that the resting B cells (5 x 10' cells/well 
in 0.2 ml medium) were co-incubated with the fibroblast cells (2 x 1W cells/well) 
expressing the low affinity receptor for IgG (CD32) in the presence of anti-IgM antibody 
DA4.4 and 200 units/ml of IL-4. Following 48 h incubation, I pCi of [methyl-'H]- 
Thymidine was added to each well and the incubation continued for 12-16 h. The cells 
were harvested onto glass fib er paper and washed to remove free radioactivity prior 
measuring the counts. The amount of incorporated radioactive thymidine is proportional 
to the increase in DNA synthesis as the result of cell proliferation. 
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CHAPTER 3: EXPRESSION OF HUMAN SOLUBLE CD23 IN ESCHERcHiA 
COLI: BIOCHEMICAL AND BIOPHYSICAL PROPERTIES 
OF THE RECOMBINANT PROTEIN 
3.1. Introduction 
Naturally occurring human soluble CD23 has been reported to play several important 
biological roles, but, although some of these roles have been firmly established there is 
still no consensus about which soluble fragments display which biological activities and, 
in particular, little is known about the molecular structure and organization of soluble 
CD23. The later has become a very important aspect of studying the role of CD23, as 
there seems to exist a general agreement that knowledge of the relation between the 
structure and function of CD23 can be used to interpret a number of activities of this 
protein. Use of cell culture supernatants to study the function and the structure of soluble 
CD23 has proven to be not only difficult but can actually lead to controversial findings, 
with the main reasons being indeterminate composition of different fragments, insufficient 
amount of the protein and its instability. Therefore, a better approach to study the role and 
the structure of soluble CD23 is heterologous expression and purification of workable 
amounts of the protein. Several efforts in that direction have already been made. Sarfati 
et al., 1992b, have reported the generation of a 16 kDa CD23 fragment in CHO cell line 
that was capable of suppressing IgE synthesis. Kalsner et al., 1992, expressed soluble 
CD23 in both the yeast Saccharomyces cerevisiae and CHO cell line and found that the 
two products had different glycosylation. Gmber et al., 1992, reported expression and 
partial characterization of soluble CD23 in insect cells using baculovirus expression 
system. The authors showed that the recombinant protein was biologically active in at 
least two aspects: binding to IgE and promoting the survival of germinal centre B cells 
in synergy with interleukin 1. The insect cell expressed soluble CD23 was shown to be 
a monomer but the subsequent studies on this protein (Beavil et al., 1995) showed that 
it forms dimers and trimers which can be chemically cross-linked. 
It was one of the objectives of this study to generate a reliable source of soluble CD23 
and study its structural and functional properties. The expression of proteins in E. coli has 
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several advantages over the other expression systems, in particular with respect to the 
amount of material obtained. No previous attempt of expression of CD23 in E. coli has 
been reported. Therefore, it was intended in this work to generate large amount of E. coli 
expressed CD23 and design optimal conditions for the recovery of its biological activity. 
Several considerations were taken into the account in making this choice of expression 
system. First, for the structural studies anticipated in this work sufficiently large amount 
of readily available material was required. Second, it was assumed that the bacterial 
product might be more stable than mammalian cell expressed protein, since the protease(s) 
that cleave(s) it is (are) unlikely to be present in the bacterial culture, as opposed to the 
animal cell cultures. And finally, another consideration taken into account was the fact 
that the bacterial cells are unable to glycosylate proteins and CD23, having one N- 
glycosylation and several potential 0-glycosylation sites, produced in E. coli may 
represent a good model to study the role of glycosylation in animal type lectins. A parallel 
study (not part of this work) was undertaken with the aim of generating another 
recombinant form of soluble CD23 using a mammalian cell line, providing the possibility 
of comparison of the two recombinant forms of the protein from different sources and the 
study of the role of glycosylation, in particular. 
However, it is well known from the literature that most of the proteins expressed in E. 
coli accumulate within the cell in the form of insoluble inclusion bodies (reviewed by 
Fischer et al., 1992). To recover the protein, the insoluble protein pellets must be 
separated from the other cellular components and then solubilized in denaturants such as 
guanidine chloride or urea, followed by the chemical reduction of cysteines. The refolding 
of the protein in vitro is not always easy, but several different protocols are available and 
numerous proteins have been successfully refolded (Fischer et al., 1992). 
Of particular interest in this work was deten-nination of the molecular weight and the 
oligornerisation state of soluble CD23 as well as the study of the biological activities of 
the recombinant protein with respect to binding of IgE and CR2. The experimental 
approach to these objectives was to design the optimal protocol for renaturation of the 
expressed protein and to test its binding properties. Several molecular weight 
determination methods including HPLC, native gel electrophoresis, sucrose gradient 
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centrifugation, dynamic light scattering and chen-dcal crosslinking were used to distinguish 
between different oligomerisation forms of the protein. 
3.2. Construction of the expression vector pRR28 and expression of CD23 in E. coli 
The expression vector pRR28 was constructed by inserting the cDNA for the extracellular 
sequence of human CD23 into the plasmid pET-5a. The cDNA fragment was amplified 
by PCR and ligated into the plasn-dd Blue Script from which the NdeI-BamHI fragment 
was isolated and subcloned into the expression vector pET-5a. The plasmid contains the 
ampicillin resistance gene for amplification in bacteria and transcription of the inserted 
gene is driven by the bacteriophage 77 promoter which is controlled by IPTG inducible 
lac promoter/operator. The T7 RNA polymerase is supplied by the host strain BL21/DE3 
and the induction is achieved with 0.4 mM IPTG in minimal medium M9. The expressed 
CD23 polypeptide starts with the aspartic acid residue at position 48 and includes the 
whole stalk region of the protein, the lectin domain and the C-terminal sequence. A 
schematic representation of the domains of CD23 together with the expression vector 
pRR28 is shown in Fig. 3-1. ne expression of CD23 by the transformed strain BL21 was 
tested in a small scale culture of 5 ml. The rapidly growing cells were divided in ratio 
1: 20 and incubated long enough to reach the OD 0.6-1.0, after which 0.4 mM IPTG was 
added and the cells incubated a further 6-10 h. To confirm the expression of CD23 and 
also to screen the transfon-nants for the level of expression, the cells from 5 ml culture 
of different clones were harvested and lysed directly in 100 pl of SDS-PAGE sample 
buffer and a 20 pl aliquot was applied on a 15 % gel together with the negative control 
(non-induced cells). The Coomassie staining of the gel showed the presence of a dominant 
protein band with the apparent molecular weight of 35 kDa which was not present in the 
negative control (Fig. 3-2). No significant difference in the level of expression among the 
tested transformants could be observed. This protein band was subsequently shown to be 
immuno-reactive with a polyclonal antibody to CD23 (Rb55) while no immuno-reactive 



















Fig. 3-1 Expression vector pRR28 for expression of human CD23 extracellular 
sequence in E. coli. 
Above is shown the linear map of himlan CD23 cDNA and tile discrete protein donlains 
of CD23 protein are marked (a); NT, N-terminal seqtience, TM, transmernbrane rcgion, 
S, stalk, H, head domain, CT, C-ternimal seqiience. b) The expression vector pRR28 
contains the extracellular CD23 cDNA fragment as indicated oil the linear 111ap; tile 
















Fig. 3-2 Expression of CD23 in E. coli. 
The bacterial culture (strain BI-21) was grown until OD,. reached 0.6-1.0 and 0.4 InM 
JvTG was added. Following 10 h incubation the cells were harvested, lysed in SDS-PAGE 
sample reducing buffer and analyzed by electrophoresis and Coomassie staining. Lanes 
1-9 represent different clones of transformed cells; lane 10 is the negative control (cell 
lYsate from non-transfon-ned cells). CD23 is represented by the massive protein band 
(indicated by the arrow) of an apparent molecular weight of 35000. No significant 









Fig. 3-3 Western blot of recombinant CD23. 
A sample of cell lysate frorn transfon-ned (lane 1) or nontransformed cells (lane 2) was 
treated with 10 mM UIT and applied on SDS-PAGE followed by transfer of separated 
proteins to nitrocellulose filter. The polyclonal anti-CD23 antibody Rb55 was used to 
detect CD23 in the cell lysate. The result confirms that the 35 kDa protein from the 
previous figure is indeed CD23. 
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3.3. Extraction and purification of recombinant CD23 from bacterial pellet 
The recombinant CD23 generated by E. coli is expressed in insoluble and biologically 
inactive form, as ' inclusion bodies. To obtain the soluble protein the insoluble inclusion 
bo& material was separated from other cell components by cell disruption, 
homogenisation by several rounds of sonication and washing in buffers containing non- 
ionic detergent Nonidet NP-40, and finally solubilised in 6M GnCl. DTT was added to 
complete the reduction of the present sulphydryl groups and CD23 purified by gel 
filtration on a Sephacryl S-100 column with 6M GnCI as the running buffer (Fig. 3-4). 
The fractions were analyzed for CD23 by electrophoresis and Western blotting, and the 
positive fractions were pooled together. This was concentrated to 1 mg/mI by 
ultrafiltration (Amicon) and kept at 4 *C as the guanidine stock of CD23. The typical yield 
of the purified protein from II bacterial culture was 50 mg which compares favourably 
with other expression systems. 
3.4. Refolding of recombinant CD23 
3.4.1. Partial refolding of CD23 by the method or dilution 
In order to test preliminarily the ability of the recombinant CD23 to fold correctly, an 
experiment was designed in which the concentration of the denaturant (GnCl) was reduced 
stepwise to 2,1,0.6 and 0.2 M, respectively, by dilution in 0.1 M Tris buffer pH 7.8. 
Each sample was then analyzed by measuring CD (circular dichroism) spectrum. Fig. 3-5 
shows the increase of a-helical structure in the partially refolded protein with the decrease 
of concentration of GnCl. 
3.4.2. Refolding of CD23 by the method of dilution and dialysis 
A protein refolding protocol was applied in which guanidine stock of CD23 was diluted 
to 50 pg/ml in 0.1 M Tris buffer, pH 7.8 (guanidine concentration was 0.3 M), and 
incubated for 12 h at 4 IC, followed by the further dilution of the protein to 10 pgImj in 













Fig. 34 Gel filtration of denatured recombinant CD23 on Sephacryl S-100 column. 
The GnCI solubilised CD23 preparation following the extraction from bacterial pellets was 
incubated with 10 mM DTT and applied on a Sephacryl S-100 column pre-equilibrated 
with 6M GnCl and gel filtration performed as described in Chapter 2. The fractions were 
analyzed for protein content (OD2go nm) and for CD23 by SDS-PAGE and Coomassie 
staining. Above is the gel filtration profile obtained by spectrophotometric analysis of 
fractions. The large peak represents CD23 the purity of which was subsequently estimated 
at 95 %. 
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Fig. 3-5 Circular dichroism (CD) spectra of partially refolded CD23 by dilution in 
renaturation buffer. 
The shown CD23 CD spectra were obtained in the presence of different concentrations 
of GnCI covering the range 6.0-0.2 M (baseline subtracted). The renaturation buffer used 
was 0.1 M Tris, pH 7.8. The increase in size of the minimum peaks at 205 and 220 nm 
is characteristic of (x-helical secondary structure fon-nation. The minimal concentration of 
GnCl that still allows significant structure formation was 1.0 M. 
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oxidized glutathione, 0.01 mM reduced glutathione and 0.6 M GnCl. The sample was 
dialysed against 20 volumes of the same buffer for 24 h and against 20 volumes of 100 
mM Tris, pH 7.8,2 mM CaCl2 for the same time period. The protein was concentrated 
to I mg/ml by ultrafiltration and kept frozen in aliquots at -20 T. This refolding protocol 
was designed to favour an early oxidation of the sulphydryl groups followed by a more 
limited degree of freedom formation of secondary structure in partially refolded protein. 
A good indicator of folding efficiency, in particular with respect to correct intramolecular 
pairing of sulphydryl groups, is the percentage of the aggregated protein in the preparation 
after the completion of the refolding protocol. This can be checked by SDS-PAGE, by 
running parallel non-reduced as well as the reduced sample of the protein. As can be seen 
in Fig. 3-6 this refolding protocol resulted in fon-nation of nonspecific protein aggregates 
while only a minor proportion of the protein remained in soluble form. The recovery of 
the protein cannot be considered satisfactory and, therefore, other refolding protocols were 
tested. 
3.4.3. Refolding of CD23 by the method of mixed disulphides 
This protein refolding protocol was previously successfully applied for renaturation of the 
protease papain by Taylor et al., 1992, and after testing a number of other refolding 
protocols (including the one described above) was found in this work to be the optimal 
protocol for refolding of recombinant CD23. The protocol, as described in details in 
"Materials and methods" utilizes blocking of the 8 sulphydryl groups of CD23 by 
conversion to mixed disulphides with high concentration of oxidized glutathione. The 
initiation of correct pairing of cysteine residues is achieved by addition of free cysteine 
to displace glutathione from the protein-S-S-glutathione mix and further dilution of the 
sample to prevent intermolecular interactions. ne oligomerisation of the protein was then 
induced by concentrating the sample to a final concentration 1 mg/ml. The SDS-PAGE 
showed that the CD23 preparation had low percentage of the aggregated form and that 
most of the protein remained intact (Fig. 3-7, lanes 3 and 4). However, it is worth noticing 
that the presence of protease inhibitor TLCK is crucial for the stability of CD23, as 
indicated by significant decomposition of the protein in the absence of the inhibitor (lanes 
1 and 2 in Fig. 3-7). 
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Fig. 3-6 Refolding of CD23 by method of dilution and dialysis. 
The figure shows an unsuccessful attempt to refold CD23 by direct dilution in renaturation 
buffer and dialysis against the same to remove the denaturant. Coornassie stained gel 
shown above is SDS-PAGE analysis of the refolded material (20 pg) in the absence (lane 
1) and presence (lane 2) of reducing reagent (10 rnM DTT). Most of the protein is in the 
aggregated form indicating that this refolding protocol is not appropriate for renaturation 
of CD23. 
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Fig. 3-7 Refolding of CD23 by method of mixed disulphides. 
In contrast to the previous protocol (Fig. 3-6) the protein obtained by this refolding 
technique was mainly in soluble fon-n as can be seen from tile SDS-PAGE analysis of the 
protein sample (20 pg) in nonreducing or reducing conditions (lanes 3 and 4). The lanes 
1 and 2 is the same except that the protease inhibitor TLCK was not added at the end of 
refolding protocol; most of the protein was degraded, thus demonstrating the requirement 
of this inhibitor for preservation of intact CD23 structure frorn (auto)proteolytic cleavage. 
Lane 5 is high molecular weight protein markers from Arnersham. 
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3.4.4. CD spectrum of refolded recombinant CD23 
The CD spectrum of refolded recombinant CD23 was measured in Tris buffer pH 8.0 at 
the protein concentration of 400 pg/nil. The spectrum obtained (Fig. 3-8) indicates a 
minimum at 205 nm typical of a-helical structure but the calculated ratios of each 
particular structure (15 % cc-helix, 56 % P-sheet, 29 % random) fall short of the 
theoretical estimates for a-helical structure (50 %) on the basis of molecular modelling 
(Beavil et al., 1992). One possible explanation for this could be a significant 
underestimate of cc-helical structure by the employed programme but it is likelier that the 
soluble form of the protein may have less cc-helical structure than the membrane form due 
to the lack of hydrophobic transmembrane domain which could stabilize the cc-helix. 
3.5. Binding of recombinant CD23 to IgE 
The capacity of the recombinant CD23 to bind IgE was tested by ELISA immunoassay 
and plasmon surface resonance (SPR) assay. In the ELISA assay, CD23 was coupled to 
the plate and IgE added as the second layer. After incubation and washing, the plates were 
incubated with anti-IgE antibody followed by incubation with the secondary antibody- 
peroxidase complex and detection with chromogenic peroxidase substrate. The result is 
shown in Fig. 3-9. As can be seen on the graph, the recombinant CD23 binds to IgE in a 
concentration dependent manner. This result was confirmed by SPR, a similar but rather 
more direct binding assay. In this case CD23 was coupled to the surface of a sensor chip 
and IgE-Fc was added at 4 different concentrations: 2,1,0.5 and 0.25 pM. The 
association (kj) and dissociation (k., ) rates were measured and the affinity constant (Ka) 
was calculated as kj/k. j. The calculated Ka constant was 2.1 x 106 M-1. The obtained 
sensograms for binding of recombinant CD23 to IgE-Fc are shown in Figure 3-10 and the 
calculated values for the kinetic parameters and Ka constant are shown in Table 3-1. 
84 











190.00 200.00 210.00 220.00 230.00 240.00 256.00 
Wavelength [nm] 
Fig. 3-8 CD spectrum of refolded recombinant CD23. 
The spectrum was taken from the final preparation of the refolded CD23 at 0.4 mg/Ml; 
the baseline is subtracted. The estimated amount of (x-helical structure was 15 %; 56 % 
was P-sheet and 29 % random coil. The molecular elipticity (ordinate) is expressed in 
mdeg x cn*dmol. 
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Fig. 3-9 Binding of recombinant CD23 to IgE in ELISA assay. 
The capacity of recombinant CD23 to bind IgE was tested by ELISA assay in which 
CD23 was coupled to the plate and IgE added in solution, followed by addition of anti- 
IgE and secondary antibody peroxidase conjugate. The intensity of the developed yellow 
colour in the peroxidase reaction was measured at 450 nm; the negative control (no IgE 
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Fig. 3-10 Binding of recombinant CD23 to IgE analyzed by SPR assay. 
CD23 was immobilised on BIAcore sensor chip and IgE-Fc: was allowed to bind for 5 min 
after which period the dissociation was induced by the free flow of the binding buffer 
(TB S pH 7.5,2 mM CaCl2); the different curves represent the sensograms obtained with 
the following concentrations of IgE-Fc (in pM): 2 (1), 1 (11), 0.5 (111) and 0.25 (IV), 
respectively. 
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Table 3-1: Measurement of the affinity constant for recombinant CD23 binding to IgE. 
Conc. of IgE-Fc 
(M) 
kl x 10' (M-ls-1) kj X 10-3 (g-1) Ka x 106 (M-1) 
2x 10-6 5.7 4.5 1.3 
IX 10-6 5.4 4.8 1.1 
5x 10-7 10.6 4.5 2.4 
2.5 x 10-7 17.4 4.8 3.6 
The ave age affinity constant for CD23 interaction with IgE-Fc: 2.1 x 
106 M-1 
3.6. Determination of oligomerisation state and molecular weight of recombinant 
CD23 
3.6.1. Native PAGE 
In order to measure the molecular weight of recombinant CD23 under native conditions, 
a sample of the protein was run on a gradient gel (5-20 %) in the absence of SDS and 
DTT- Since the migration of proteins in native electrophoresis gels is dependent on both 
the size of the protein and the total charge of free residues it is impossible to measure the 
exact molecular weights of proteins as in the case of SDS-PAGE. Nevertheless, this can 
be compensated to some extent by overrunning the gel and getting the proteins to decrease 
the migration rate in the part of gradient where the concentration of polyacrylamide is 
sufficiently high to prevent further n-dgration. The consequence of this is that the 
contribution of the charge of the protein to the migration rate and resolution becomes 
smaller while contribution of the size of protein increases; in this way one can estimate 
the molecular weight of the protein within reasonable limits of the experiment. In the case 
of CD23, the molecular weight estimate is 70000-100000, based on the comparison with 
BSA monomer (66000) and BSA dimer (132000). Fig. 3-11 shows a native 5-20 % 




Fig. 3-11 Native PAGE of recombinant CD23. 
The sample of CD23 (20 pg) was applied on native gel with linear gradient of 
polyacrylamide concentration 5-20 % and the electrophoresis performed as described in 
Chapter 2. Lanes I and 2 represent denatured samples (either by 8.0 M urea, lane 1, or 
by 8.0 M urea plus 5 min boiling, lane 2); this was aimed to be internal marker control 
for CD23 monomer, but was obviously not sufficient to keep the protein denatured (1) or 
denatured and in solution (2). Lanes 3 and 4 are identical samples of CD23 in the absence 
of any denaturing reagents. The molecular weight of the two internal molecular weight 
protein markers (BSA monomer and dimer) are 66000 and 132000; under the experimental 
conditions applied CD23 migrates as a protein of the molecular weight between 66000 and 
132000 (see also Fig. 6-1, Chapter 6). 
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is represented by a diffuse protein band of the indicated molecular weight. 
3.61. Chemical crosslinking of CD23 with EDC 
For the determination of the oligomeric state of recombinant CD23 one of the 
experimental approaches in this work was chemical cross-linking of the protein subunits 
with the crosslinker EDC. Ibis particular crosslinker was chosen because of its property 
to crosslink only the amino and carboxyl groups which are sufficiently close to each other 
or ideally part of the ionic bridges that can be formed between lysine and glutamic or 
aspartic acid residues, for example. The ionic bridges participate in stabilization of the a- 
helical stalks of CD23 through which the oligomerisation of the protein is thought to 
occur (Beavil et. al., 1992). Several parameters which influence the efficiency of 
crosslinking were tested, including the ratio EDC/protein, pH of the buffer and the time 
required for the completion of the reaction. A typical reaction was carried out in 20 pl 
reaction volume which contained the appropriate volume of protein preparation, 2 PI of 
250 mM (IOX) sodium acetate buffer, 2 pl EDC 1OX solution and the rest was distilled 
water. The influence of pH of the buffer on the crosslinking efficiency was tested over 
the pH range 3.0 - 6.0 and it was found that the optimal pH of the reaction was 5.0-5.5 
(Fig. 3-12). All the subsequent reactions were carried out at the pH 5.0 and at room 
temperature. The final concentration of the crosslinker in the reaction was typically 25 
mM unless stated otherwise. 
The crosslinking of recombinant CD23 was carried out at three different concentrations 
of the protein: 2,50 and 
500 pg/ml, using three different detection methods: 
autoradiography, silver and 
Coomassie staining. For the lowest concentration of CD23, 
an iodinated sample was useý 
detected by autoradiography. Fig. 3-13. shows an increase 
in the yield of the dimeric form with the increasing concentration of the crosslinker and 
the appearance of trimer at the highest concentration of EDC. Further 
increase of the 
concentration of EDC 
did not change the ratio of dimer to trimer, neither did die 
prolonged incubation time 
(2 h, not shown). in order to find out if the ratio dimer/trimer 
is concentration dependent, that 
is, if the trimer is more easily formed at higher protein 
concentrations, an experiment was 
designed in wbich constant concentration of labelled 
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Fig. 3-12 Optimal pH for crosslinking of CD23 with EDC. 
The effect of pH of the buffer on efficiency of crosslinking was studied; the buffer 
solutions (sodium acetate, final concentration 25 mM) in the pH range 3.0-6.5 were 
prepared and added to the reaction mixture together with a constant concentration of the 
crosslinker and [12511 -labelled protein. Following SDS-PAGE in reducing conditions the 
gel was dried and autoradiography was performed. The optimal pH of the buffer for 
crosslinking of CD23 with EDC was found to be 5.0. The letters T, D and M in tile above 














Fig. 3-13 The effect of the ratio protein/crosslinker on the crosslinking of CD23. 
The concentration of the [12511 -labelled protein in the reaction mixture was 2 pg/ml and 
the concentration of EDC was in the range 0.01-100 mM (from lane 8 to 1: 0.01,0.1,1, 
5,10,25,50 and 100 mM; lane 9 is negative control (no crosslinker added)). Under the 
experimental conditions no further increase of efficiency of crosslinking could be achieved 
with concentrations of EDC above 100 mM (not shown). The letters T, D, and M mark 
the positions of CD23 trimer, dimer and monorner, respectively. 
12345678 
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CD23 was used and increasing amounts of the unlabelled protein added. The consequence 
of this should be that the yield of the formed trimer should increase with the increasing 
concentration of the unlabelled protein for as long as the concentration of EDC is not the 
limiting factor. Indeed, as can be seen in Fig. 3-14 the increase of concentration of added 
unlabelled CD23 results in the increase of the yield of trimer as compared with the 
labelled protein alone, but after the unlabelled protein exceeded a critical concentration 
at which it actually competes for binding of the crosslinker with labelled CD23, the yield 
of trimer began to decrease. To confirm that this was true, CD23 was crosslinked at the 
concentration of 50 and 500 pg/n-d, respectively. In both cases (Fig. 3-15 and 3-16) the 
dominant form of the crosslinked CD23 was the trimer. As expected, with the increase 
of the concentration of the crosslinker some of the protein was intermolecularly 
crosslinked, resulting in the formation of nonspecific aggregates. 
3.6.3. HPLC analysis of recombinant CD23 
The fact that recombinant soluble CD23 can form trimers that can be detected by 
chemical crosslinking may not be definitive proof that this is the actual oligomerisation 
state of CD23 or the predominant form of the protein because of the possibility that there 
may exist an equilibrium between the protein monomer and trimer, with the dimer as an 
intermediate form. Other experiments were therefore carried out to investigate the 
oligomerisation state of recombinant CD23. On a Superdex-75 HPLC column (Pharmacia, 
optimal separation range 5000-70000) CD23 gives the profile shown in Fig. 3-17. The 
larger of the two major peaks corresponds to a 65 kDa protein while the smaller peak 
corresponds to a 33 kDa protein. These molecular weights which were calculated from the 
standard curve obtained with the proteins of knýwn molecular weights clearly correspond 
to the dimer and monomer of CD23. Although it is possible to notice the presence of the 
third small peak which might represent the trimer, it is impossible from this HPLC 
column,, which has the size exclusion limit 75000, to conclude whether this might indeed 
be true; in addition to that, the proportion of this protein fraction in the total preparation 
is rather low (approximately 20 %). The ratio dimer/monomer does, however, increase 
with the increase of the concentration of the protein applied on the column (Fig. 3-17c and 
d). The native CD23 showed a profile with one major peak which comes in the void 
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Fig. 3-14 Protein concentration effect on crosslinking of CD23. 
The concentration of 11211 ]-labelled CD23 in the reaction mixture was kept constant (2 
pg1ml) while the concentration of the added unlabelled protein was increased by 
increments of 2 pg/ml; lane 1, no crosslinker added, lane 2, no unlabelled CD23 added, 
lane 3-9, incremental increase of unlabelled protein added: 2,4,6,8,10,12 and 14 Pg/ml, 
respectively. The concentration of EDC was kept constant at 100 rnM; the positions of 
different molecular forms of CD23 and the standard molecular weight protein markers in 










Fig. 3-15 Crosslinking of CD23 at the protein concentration of 50 Pg/mI. 
Above is a picture of a silver stained gel of CD23 crosslinked with EDC at the protein 
concentration of 50 pg/rnl (lane 1) and the negative control of crosslinking (no EDC 
added, lane 2). The experimental conditions were the same as in the previous experiments 
except that the optimal concentration of EDC for this concentration of the protein was 50 
Mm. The positions of CD23 trimer (T), dirner (D) and monomer (M) are marked. 
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Fig. 3-16 Crosslinking of CD23 at high protein concentration (I mg/mI). 
The Coomassie stained gel shown above is an attempt to dernonstrate the concentration 
dependent oligornerisation of CD23 by chemical crosslinking at high concentration of the 
protein; unfortunately, most of the protein was converted into non-specific aggregates. The 
concentration of EDC in the experiment had been increased by 5 mM increment, from 0 
(lane 1) to 20 rnM (lane 5); the positions of CD23 trimer (T), dimer (D) and monomer 
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Fig. 3.17 HPLC analysis of CD23 on Superdex S-75 column (Pharmacia). 
A) The column was calibrated with standard molecular weight proteins (alcohol 
dehydrogenase, Mr 150000; BSA, Mr 66000; carbonic anhydrase, Mr 29000; cytochrome 
c, Mr 12400); the first marker (alcohol dehydrogenase) was used to indicate the exclusion 
limit of the column which is about 100000 (effective separation range is 3000-75000); B) 
native full length CD23 isolated from RPMI 8866 cells, at the concentration 0.033 mg/ml; 
C, D) recombinant CD23 at the concentration 0.33 and 1.33 mg/ml, respectively; the 
figures above the protein peaks indicate the calculated molecular weights according to the 
standard curve obtained from the profile shown in section A of the figure. 
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volume of the column and therefore is of the minimum molecular weight of 75000 but 
it is impossible to say whether this represents dimer or trimer of the protein. 7le second, 
smaller peak, however, has got the molecular weight of 40000 which corresponds to the 
size of native protein monomer. 
On the basis of these HPLC profiles it is possible to measure the Stokes radius of CD23. 
Fig. 3-18 shows the calibration curve for measurement of the Stokes radius of CD23 using 
Superdex 75 column, which was found to be 3.6 nm for the larger and 2.6 nm for the 
smaller protein fraction. 
3.6.4. Calculation of the diffusion coefficient for CD23 
The diffusion coefficient for the two protein fon-ns observed on Superdex 75 profile were 
calculated from the equation: 
D= KT / 6"Rs 
where K is Boltzman constant (1.380622 x 10-23 kern2S2 ), T is temperature (293 K), q 
is viscosity of the buffer used for gel filtration; this was practically same as the viscosity 
of water at room temperature, 1.00 g/ms), and Rs is the Stokes radius of the protein. The 
calculated values for D were 
8.2 x 10-7 cO/s (smaller protein form) and 6.0 x 10-7 CM2/S 
(larger form). 
3.6.5. Measurement of the sedimentation coefficient of recombinant CD23 
The sedimentation coefficient of CD23 was measured by centrifugation in the gradient of 
sucrose 5-20 % using the Beckman rotor SW 41. The protein sample was applied on top 
of the gradient (12 ml) and the centrifugation performed at 4 *C, at the speed of the rotor 
of 35000 rpm. The centrifugation time was 24-48 hours. After fractionation of gradients 
each fraction was analyzed for protein content and the typical profile obtained for CD23 
is shown on Fig. 3-19. Parallel to the CD23 sample, internal protein standards were run 












Fig. 3-18 Measurement of the Stokes radius (Rs) for CD23. 
The standard curve for measurement of Stokes radius of CD23 was constructed from the 
profile shown in Fig. 3-17A; the values obtained were 3.6 nm (for the protein form of the 
apparent molecular weight of 65000 and 2.6 nm (for the protein form of the apparent 
molecular weight of 39000). 





























]Fig. 3-19 Centrifugation of recombinant CD23 in the gradient of sucrose 
concentration 5-20 %. CD23 sample (I mg/ml, 0.1 ml) was applied on top of the 
sucrose gradient (5-20 %, 12 ml total volume) and the centrifugation performed at 35000 
rpm in a Beckman rotor type SW 41, at 4 T. Following 36 h centrifugation, the gradient 
was fractionated into 60 samples (0.2 ml) and the fractions were analyzed by 
spectrophotometry. Two major protein peaks were detected; the gradient of sucrose 
concentration is indicated by the diagonal line. 
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the standard curves used for determination of sedimentation coefficient (S20, ") of CD23. 
A representative of these curves from 5 independent experiments is shown on Fig. 3-20. 
The corresponding mean values for S20, w of the two protein forms of CD23 observed on 
the profile in Fig. 3-19 were 3.5; SD: 0.17321; N=5 (for the larger protein form) and 
2.0 ; SD: 0.0923 1; N=5 (for the smaller protein form). Neither of the two protein forms 
contains degradation products as confirmed by SDS-PAGE (not shown). 
3.6.6. Calculation of the molecular weight of recombinant CD23 
On the basis of measured diffusion and sedimentation coefficients for CD23 the molecular 
weight was calculated from the Svedberg's equation: 
Mr = RTS /D(I-10p) 
where R is gas constant (8.314 J/K mol), S is sedimentation coefficient, T) is partial 
specific volume of CD23 (0.7196 g/ml) and p is the density of CD23 containing fraction 
from the sucrose gradient (1.0299 g/ml). Tie calculated mean values for Mr were 55000; 
SD: 3000; N= 5) for the larger protein form and 32000; SD: 2400; N=5 (for the smaller 
protein form). 
3.6.7. Dynamic light scattering analysis of recombinant CD23 
The experiment was performed in a DynaPro-801 instrument (Protein Solutions, High 
Wycombe, UK). CD23 solution at the protein concentration of 2 mg/mi was prepared, 
injected into the sample cell and illuminated by laser. The obtained data include several 
parameters such as radius of the protein (nm), polydispersity of the solution (nm), 
estimated molecular weight, baseline (corresponds to the quality of the obtained fit for the 
applied model) and sum of squares, SOS (refinement of the fit). From these parameters 
it is possible to distinguish between single protein form and mixture of two or more 
forms, and in the case where the polydispersity is negligible it is possible to measure the 













Fig. 3-20 Standard curve for measurement of sedimentation coefficient (S20,. ) of CD23. 
The standard curve for deten-nination of SAW of CD23 was constructed from the 
sedimentation profiles obtained for proteins of known molecular weights and S20. w 
coefficients: BSA (Mr 66000, S20, w 
4.73), ovalburnin (Mr 45000, S20,,,, 3.66), carbonic 
anhydrase (Mr 29000, S20, w 
2.8), cytochrome c (Mr 12400, S20, w 
1.71). 7be S20, w values 
for 
the two CD23 forms shown in Fig. 3-19 were 3.5 (larger) and 2.0 (smaller). 
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Table 3-2: Dynamic light scattering analysis of recombinant CD23. 
Reading 
number 




Baseline Sum of 
squares 
1 4.8 negligible 136000 1.003 4.672 
2 4.7 negligible 129000 1.005 4.192 
3 5-7 3.1 200000 1.018 8.119 
4 4.9 negligible 138000 0.999 2.988 
5 4.3 negligible 101000 1.005 7.613 
* This reading was exempted from the calculations. 
As can be seen in Table 3-2 one of the readings gave unacceptable polydispersity factor 
and was excluded from the calculation of the average molecular weight which was found 
to be 126000. This is close to the theoretical molecular weight of CD23 tetramer 
(120000). The Baseline parameter is interpreted as follows: 0.997-1.001, distribution is 
monomodal; 1.002-1.005, distribution is primarily monomodal but there may be a small 
amount of larger size molecules; >1.005, size distribution is polydisperse. Thus, although 
CD23 at the concentration of 2 mg/mI behaves as a primarily monodisperse system the 
parameters for baseline are close to the transition range for polydisperse system. The SOS 
parameter can be interpreted in similar manner. These data are discussed in detail in 
Chapter 6. 
3.7. Summary and conclusions 
In this chapter, the expression of human soluble CD23 in E. coli is described. The 
extracellular sequence of CD23 was subcloned into a bacterial expression vector and large 
quantities of the recombinant protein were obtained (50 mg/ I of cell culture). An optimal 
protocol for renaturation of the bacterial product was designed, based on the method of 
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mixed disulphide formation between the cysteine residues of protein and oxidised 
glutathione. CD23 possesses 8 cysteine residues capable of forming 4 disulphide bridges, 
all of which are located in the lectin domain of the protein. This is a certain difficulty in 
any attempt to refold the denatured protein, as the probability of incorrect cysteine pairing 
is high in addition to the nonspecific intermolecular pairing. Several different protocols 
were applied with variable success. In most cases the amount of the aggregated material 
at the end of refolding procedure was unacceptably high as compared to the amount of 
soluble protein (> 80 %). However, the protocol described in this work has been proved 
to work reasonably well with at least 50 % recovery of the soluble protein. 
It has been further shown that the refolded protein binds to IgE (Ka = 2.1 x 106 M) and 
moreover, it can greatly enhance the internalization of IgE-CD23 complexes on B cells 
presumably through a noncovalent association with membrane CD23 (S. Karagianis, Ph. D 
thesis). In the following chapter the evidence will be presented showing that it also binds 
to the second ligand, CR2. Therefore, the E. coli expressed CD23 displays the two most 
important activities and could be used for relevant biophysical studies carried out in this 
work. It has been demonstrated by HPLC and sucrose gradient centrifugation method that 
the recombinant CD23 preparation consists of at least two distinct molecular forms of the 
Corresponding molecular weights of 55000 and 32000, respectively, as calculated from the 
Svedberg's equation. These two forms correspond well with the expected molecular 
weights of the protein dimer (60000) and monomer (30000). In addition to these two 
protein forms, a larger protein form with the minimal calculated molecular weight of 
70000 was detected onHPLC column and this may represent protein trimer of CD23. 
However, no trimer or any other form apart from dimer and monomer were detected by 
sucrose gradient centrifugation. 
The previously published results of Beavil et al., 1995, showed that soluble CD23 is 
capable of forming protein trimers which can be detected by chemical crosslinking. In this 
work, it has been shown that the recombinant CD23 from E. coli does indeed form 
protein trimers, according to the results obtained by crosslinking of the protein. 
Nevertheless, it was not possible to accurately demonstrate the presence of this protein 
form by any of the size exclusion limit methods applied in this work. Instead, the gathered 
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experimental evidence indicates the possibility of an equilibrium between the three forms 
of the protein (monomer/dimer/trimer) and a possible higher level association of CD23; 
this is discussed in more details in Chapter 6 (sections 6.3-6.5). 
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CHAPTER 4: INTERACTION OF CD23 AND CR2 
4.1. Introduction 
The interaction of CD23 and CR2 was first described by Aubry et al., 1992 by using the 
technique of fluorescent CD23-liposomes which were able to bind to some but not all 
CR2 positive cells. The same group of researchers and others then proposed several 
functional implications for this interaction described in Chapter 1, section 1.3.3. The 
published literature on this subject reveals that no other form of CD23, natural or 
recombinant, apart from the native intact protein was directly shown to interact with CR2. 
As for the nature of interaction between CD23 and CR2, it has been proposed that the 
carbohydrates on CR2 may be involved, although the peptide structure of SCRs I and 2 
contribute to the binding as well (Aubry et al., 1994). One of the aims of this study was, 
therefore, to test the ability of recombinant soluble CD23 to bind to both native and 
recombinant CR2 and to measure the affinity constant for the interaction. 
The experimental approach to resolve this question was to isolate and purify the native 
forms as well as to generate and characterize the recombinant soluble forms of both 
proteins and to compare the affinity constants for the interaction between different forms 
of CD23 and CR2. In Chapter 3, the production and characterization of recombinant 
soluble CD23 from E. coll has been described. This Chapter describes the production of 
recombinant soluble CR2 in insect cells using the baculovirus expression system. The 
recombinant CR2 baculovirus expression vector was readily available and was kindly. - 
provided by G. Nemerow (The Scripps Research Institute, La Jolla, CA). The expressed 
protein was previously reported to be capable of binding C3dg and inhibiting Epstein-Barr 
virus infection (Nemerow et al., 1990), and the protein appeared to be glycosylated 
according to the increase in the molecular weight as compared with the expected 
molecular weight of non-glycosylated polypeptide precursor. The glycosylation of 
recombinant CR2 was an important consideration for studying the interaction with CD23 
since it was reported that the carbohydrate structures on CR2, as well as the peptide 
backbone of SCRs I and 2, mediate the binding (Aubry et al, 1992; Aubry et al., 1994). 
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It is, however, as yet unclear why CR2 from only some types of cells, or just one 
particular isoform of the protein from the same type of cell bind, to CD23 (Aubry et al, 
1992). If the contribution of the peptide structures of the SCRs I and 2 to the total 
binding may be as high as 50 % (Aubry et al., 1994), one might expect that all CR2 
populations- would be able to bind CD23 with at least 50 % capacity, as compared to the 
isoforms with the most appropriate carbohydrate structures. Therefore, an attempt has been 
made to find out whether CR2 expressed in insect cells, which significantly differ in their 
glycosylation potential from the animal cells, is capable of binding CD23. In this Chapter, 
the presented results suggest that there is a detectable interaction between the recombinant 
soluble CR2 and CD23. In addition to that, this Chapter presents the evidence of 
simultaneous binding of CR2 and IgE to the dimeric CD23. 
4.2. Binding of native and recombinant CD23 to CR2 on cell surface 
4.2.1. Isolation and purification of intact, 45-kDa form of CD23 
The membrane-associated form of CD23 (45-kDa) was isolated from RPMI 8866 cells by 
detergent extraction in the presence of a cocktail of protease inhibitors as described by 
Cairns and Gordon, 1990. Initially, the cells were prepared on a small scale in cell culture 
flasks but for the larger quantities of CD23 the cells were grown in a 20 1 cell culture 
fermenter (Pfizer). In this way Ix 10" cells were prepared and used for isolation of 
CD23. Two detergents were tested for lysing the cells: Nonidet NP-40 and octyl- 
glucopyranoside (OGP). Although Nonidet-NP-40 seems to produce higher yield of the 
extracted protein it was found that this detergent is not appropriate because of the 
difficulty of removing it prior to the liposome preparation. The OGP-extracts of cells were 
run over anti-CD23 antibody columns (MHM6 or mAb-25) and the bound material eluted 
with 0.2 M glycine, pH 2.3,0.2 % OGP, 0.2 mM TLCK. CD23 prepared in this way is 
mostly intact (Fig. 4-1) but in some cases detectable degradation still occured (not shown). 
4.2.2. Preparation of fluorescent, CD23-liposotnes 








Fig. 4-1 Isolation and purification of intact 45 kDa CD23 from RPMI 8866 cells. 
The native intact CD23 was purified frorn the lysates of RPM1 8866 cellsby affinity 
chromatography on MHM6 column, in the presence of 0.2 rnM TLCK. The isolated 
material was probed with anti-CD23 antibody BU-38 by Western blotting (a) and the 
purity was verified by autoradiography of an iodinated sample of CD23 (b). No detectable 
degradation of the protein could be observed in either case. 
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1992 with a few modifications described in Chapter 2. To ensure that no free CD23 or 
fluorescent label has remained in the preparation the liposomes were pelleted by 
centrifugation at 40000 xg for 2 h, at 4 T. Some of the liposome pellet was used for 
electron microscopy analysis to show the actual incorporation of the protein into the lipid 
structure (Fig. 4-2) and the rest of the preparation was resuspended in the HBS-Caý' 
binding buffer and used for FACs, analysis. I'lie negative control in all subsequent 
experiments with CD23-liposomes was a fluorescent liposome- preparation with no CD23 
incorporated. 
4.2.3. Binding of CD23-liposomes to CR2 on RPMI 8226 cells 
The fluorescent CD23-liposomes were able to bind to RPMI 8226 cells which are CR2 
positive and were previously shown to be the most appropriate cell type tested for binding 
of CD23-liposomes (Pochon et al., 1992). After 2h incubation of Ix1 06 cells in the 5- 
fold diluted CD23-liposomes preparation most of the cells stained positively as compared 
to the negative control. The FACs profile of binding of CD23-liposomes to RPMI 8226 
cells is shown in Figure 4-3A. 
4.2.4. Inhibition of CD23-liposomes binding to RPMI 8226 cells by native CR2 
A small amount of native CR2 was isolated from Ix WO RPMI 8226 cells and purified 
by affinity chromatography on anti-CR2 antibody HB5 columnand used as the competitor 
in the CD23-liposomes binding assay. As a direct demonstration that CR2 is indeed the 
new ligand for CD23, the capacity of native CR2 prepared in this way to inhibit the 
binding of CD23-liposomes to RPMI 8226 cells is shown in Fig. 4-3B. The reason that this 
inhibition is not complete is probably the low concentration of CR2 in the preparation 
(higher concentration of protein could not be used because of extensive cell lysis caused 




Fig. 4-2 CD23-liposomes. 
CD23 liposomes were pelleted, frozen and the horizontal scolons examined by electron 
l-nicroscope; under the magnification 1: 9800 the liposomes appear as tightly packed 
spherical structures rather hornogerIOLis in size (A); under the magnification 1: 130000 it 
is possible to detect the protein spots oil tile lipid surface of' liposonics (13); oil tile shown 
photograph the white bar represent 100 ilm and the liposome just above the bar is 
approximately 200 nrn in size-, CD23 is represented by the small light spots that can be 




Fig. 4-3 CD23 liposomes bind to RPM1 8226 cells and the binding can be inhibited 
by native CR2 isolated from the same cells. 
Five-fold diluted fluorescent CD23-liposomes were added to the suspension of RPMI 8226 
cells 0x 106) and the incubation carried out on ice for 2 h; after that the cells were 
washed twice with the binding buffer (HBS, 2 mM Ca2', 0.1 % Na-azide) and examined 
for fluorescence by FACs (a); the open peak represents binding of negative liposomes that 
were prepared in the exactly same way as the CD23-liposomes except that no CD23 was 
added, and the red peak represents the binding of CD23-liposomes to RPMI 8226 cells. 
In a parallel assay the detergent solubilised native CR2 isolated from the same cells by 
affinity chromatography on HB5 column, was diluted to reduce the concentration of the 
detergent to below 0.1 % and added together with CD23-liposomes to the suspension of 
cells; the green peak represents the binding of CD23-tiposomes to RPMI 8226 cells in the 
presence of purified CR2. In this and all following FACs assays 10000 cells were counted. 
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4.2.5. Inhibition of CD23-liposome binding to RPMI 8226 cells by recombinant 
CD23 
In order to find out whether CD23 fragments can bind to CR2, the capacity of 
recombinant CD23 expressed in E. coli to inhibit the binding of CD23-liposomes to RPMI 
8226 cells was tested. The recombinant CD23 was added at various concentrations to the 
cell suspension in the presence of fluorescent liposomes or the cells were pre-incubated 
for 2h with recombinant CD23 before incubation with CD23-liposomes followed by 
FACs analysis. In either case complete inhibition of CD23-liposome binding could be 
obtained with 10 pg/ml of recombinant CD23 after 2h incubation on ice (Fig. 4-4). The 
observed inhibitory effect of recombinant CD23 is concentration dependent and can be 
seen at the concentration of CD23 of 5 pg1ml and higher (Fig. 4-5A-C). This shows that 
recombinant soluble CD23 can compete with the native 45-kDa protein incorporated into 
liposomes for binding to CR2 although from this experiment one cannot obtain 
quantitative measure of the relative affinities. The recombinant CD23 was not able to 
inhibit binding of CD23-liposomes to the cells once they were already incubated with 
CD23-liposomes (Fig. 4-5D-F). It was found that 30 min incubation of the cells with 
CD23-liposomes was sufficient to eliminate almost completely the inhibitory effect of 
recombinant CD23 while longer incubation (1.5 h) completely diminished this effect. 
Although the recombinant CD23 is able to compete with the native protein for binding 
to CR2 the affinity seems to be lower than that of the native CD23. The final 
concentration of the native CD23 in the assay was I pg/ml or less (depending on the 
amount of the protein that was not incorporated into the liposomes and was subsequently 
removed by centrifugation of the liposomes) and the addition of the recombinant CD23 
at the same concentration does not cause 50 % 
inhibition, as would be expected in the 
case of the same affinity. To achieve 50 % 
inhibition the required concentration of CD23 
was 5 pglml while for the complete inhibition it was necessary to add 10 pg/ml of CD23. 
4.2.6. Inhibition of CD23-liposome, binding to RPMI 8226 cells by IgE 







Fig. 4-4 Recombinant CD23 inhibits the binding of CD23-liposomes to RPMI 8226 
cells. 
Recombinant CD23 at the concentration of 10 pg/ml was added to the suspension of 
RPMI 8226 cells 2h before addition of CD23-liposomes (A) or together with the 
liposomes (B) and the cells were incubated for further 2 h; after washing off the unbound 
iiposomes the cells were assayed by FACs; the open light-grey peak represents the binding 
of negative 11posomes, the filled red peak binding of CD23-liposomes and the green peak 
the binding of CD23-liposoines in the presence of recombinant CD23. T'he fluorescence 
intensity in this and all other FACs experiments is given in logarithmic scale. 
Fig. 4-5 Inhibition of CD23-liposome binding to RPMI 8226 cells by recombinant 
CD23: concentration dependence and relative affinity of binding. 
Different concentrations of recombinant CD23 were analyzed for the capacity to inhibit 
the binding of CD23-liposomes to RPMI 8226 cells (green peak); 1 pg1ml (approximately 
- equal to the concentration of native 
CD23 in the reaction mixture) caused no 
significant inhibition (A), 5 pg/ml caused approximately 50 % inhibition (B) and 10 Pg/m, 
completely inhibited binding of CD23-liposomes (Q. Pre-incubation of the cells with 
CD23-liposomes for 30 min reduced the inhibitory effect of recombinant CD23 (10 P9/ml) 
by 70 % (D); further prolongation of the pre-incubation time to I and 1.5 b, respectively, 








interaction by IgE (which would indicate that the binding sites for IgE and CR2 on CD23 
molecule partially or fully overlap) is incomplete. Pochon et al., 1992, showed that IgE 
at the concentration of 200 pg/ml could cause approximately 80 % inhibition in binding 
of CD23-liposomes after 2h incubation at 4 T. In this work a 10 times lower 
concentration of IgE (20 pg/ml) was used under the same conditions of the experiment 
and from the graph shown in Fig. 4-6 it can be seen that the inhibition was only partial 
rather than complete (about 30 %). It is obvious that IgE exhibits some inhibitory effect 
on binding of CR2 to CD23 but from this experiment or from the previously published 
data it is difficult to distinguish between the possibilities of overlapping binding sites for 
IgE and CR2 on CD23 molecule or simply sterical hindrance due to the close proximity 
of the binding sites. A recently published structure based model of CD23 lectin domain 
favours the latter possibility as it appears that the single calcium binding site which is the 
likely site of interaction with the carbohydrate ligands is spatially distinct from the large 
surface area that is thought to be involved in the interaction with IgE (Bajorath and 
Aruffo, 1996; Bettler et al., 1992). 
4.3. Binding of recombinant CR2 to recombinant CD23 
4.3.1. Expression of soluble CR2 in insect cells using baculovirus expression 
system 
The source of native CR2 used in this work was rather limited and the isolation and 
purification not very simple either. In order to provide a better source of CR2 as well as 
to test the ability of other forms of this protein apart from the intact membrane form from 
RPMI 8226 cells to bind CD23, the baculovirus expression system was employed for 
production of soluble CR2. Ile baculovirus expression vector pAc373-CR2 (Nemerow 
et al., 1990) was used to infect the insect cells Sf9 and the expression of CR2 was 
monitored over the period of 7 days. It was found that maximum expression of CR2 is 
reached after 5 days following infection (Fig. 4-7), at which point about 50 % cells are 
dead. Further incubation does not improve the yield of CR2 significantly while tile 





Fig. 4-6 Inhibition of CD23-liposome binding to RPMI 8226 cells by IgE. 
Human IgE at the concentration of 2 (A) and 20 (B) pg/n-a was added to the suspension 
of RPM1 8226 and CD23-liposomes and the incubation on ice carried out for 2 h; the cells 
were washed twice with the binding buffer and examined for fluorescence, no detectable 
inhibition was observed with 2 pg/ml of IgE and a partial inhibition (20-30 %) was 
detected with 20 pg/ml of IgE (green peak). 
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Fig. 4-7 Expression of soluble CR2 in insect cells: time course for expression following 
the infection with recombinant CR2 baculovirus. 
The above photograph is a Western blot of soluble CR2 containing insect cell supernatants 
(SO cells) that were taken at different tirnes following infection with the virus; lanes 1, 
2 and 3 correspond to the tirne points 3,4 and 5 days, respectively; after 5 days no further 
increase in the secreted CR2 was detected (not shown). Lane 4 is the negative control in 
the experiment (supernatant from non-infected cells); the antibody used for detection of 
CR2 was BU32. 
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4.3.2. Partial purification of recombinant CR2 
Following 5 days incubation the cells were removed from the culture by centrifugation 
(3000 rpm, Sorvall GSA rotor) for 20 min and the supernatant was dialysed against 10 
mM sodium-phosphate buffer pH 7.8. The dialysed supernatant was applied to DEAE- 
Sephadex A-50 ion exchange column and the bound material eluted in 0-300 MM sodium 
chloride gradient. The fractions were assayed for protein content and for CR2 by 
spectrophotometric measurement at 280 nm and 
' 
Western blotting (Fig. 4-8). The elution 
of CR2 was achieved at 120-150 mM sodium chloride. The CR2 containing fractions were 
pooled and concentrated and a small aliquot was subjected to SDS-PAGE on 8% gel 
followed by Coomassie staining of the proteins (Fig. 4-9). An approximate level of 
expression of CR2 by insect cells ranges from 200 to 400 pg/l of cell culture. 
4.3.3. Glycosylation of the insect cell expressed CR2 
CR2 is heavily glycosylated protein with 11 potential glycosylation sites. The 
carbohydrate structures on CR2 have been implicated necessary for interaction with CD23 
(Pochon et al., 1992; Aubry et al., 1994) and therefore the ability of CR2 to bind CD23 
will depend on the type of glycosylation of the host cell. The insect cells are capable of 
protein glycosylation but the type of carbohydrate structures may be significantly different 
from the animal cells. In order to confirm the glycosylation of soluble CR2 expressed in 
insect cells by baculovirus expression system the partially purified protein was subjected 
to SDS-PAGE and subsequently transferred to nitrocellulose membrane. The glycoproteins 
were detected by GlycoTrack reagent kit and as can be seen in Fig. 4-10, CR2 is indeed 
glycosylated. The contribution of carbohydrates to the total molecular weight is at least 
about 10 kDa, as calculated from the apparent molecular weight of the protein in SDS- 
PAGE (120 kDa) and the expected molecular weight of the nonglycosylated peptide 
precursor (110 kDa). 
4.3.4. Binding of recombinant CR2 to recombinant CD23 by ELISA 



























Fig. 4-8 Purification of recombinant CR2 from insect cell supernatant by ion 
exchange on DEAE-Sephadex A-50 (Pharmacia). 
The concentrated insect cell supernatant was dialysed against 10 rnM sodiurn phosphate 
buffer pH 7.8 and applied on the DEAE-Sephadex A-50 colurnn equilibrated with the 
same buffer. The bound protein was eluted in the continuous gradient of sodiurn chloride, 
0-300 nIM (prepared in the running buffer), and the fractions analyzed for protein content 
by spectrophotometry (graph) and for CR2 content by Western blotting (inserted 
photograph). CR2 was eluted over the range of 100- 180 mM sodium chloride; the gradient 
of sodium chloride is indicated by the diagonal line. 
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Fig. 4-9 SDS-PAGE molecular weight determination of recombinant soluble CR2. 
The partially purified CR2 from insect cell supernatants was run on 8% SDS- 
polyacrylamide gel (lane 1) together with the standard molecular weight proteins (lane 2), 
followed by Coomassie staining of the gel. A parallel sample in the same gel was blotted 
onto nitrocellulose filter and probed with anti-CR2 antibody BU-32, to establish the 
position of CR2 in the gel (not shown). CR2 (CD21) migrates as a 120 kDa protein band 
(indicated by an arrow on the picture). 
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Fig. 4-10 Glycosylation of recombinant CR2. 
CR2 expressed in insect cells was analyzed for the presence of carbohydrates on the 
protein; a sample of CR2 together with the internal positive and negative controls for 
glycosylation of proteins (glycosylated CD23 expressed in NSO mammalian cell line and 
unglycosylated CD23 from E. coli, respectively) was probed with an antibody (BU32 for 
CR2, BU38 for CD23), (lanes 1,3 and 5) or with the GlycoTrack cornmercial reagent for 
detection of carbohydrates (lanes 2,4 and 6); the arrow indicates position of CR2; since 
in this segment of the gel there are no detectable contarninating proteins (Fig. 4-9), the 
obtained signal can be ascribed to CR2, therefore confirming the glycosylated state of the 
insect cell expressed protein. 
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recombinant CD23 expressed in E. coli the other recombinant form was mammalian cell 
expressed soluble CD23 Q. Shi, PhD thesis), which differs from the bacterial protein for 
being glycosylated. CD23 was coupled to the ELISA plate at the increasing concentration 
0-10 pg1mI and CR2 was added at the constant concentration of approximately 0.2 PgIml. 
Following the incubation with CR2 an antibody to CR2 (BU-32) was added and, finally, 
secondary antibody peroxidase conjugate was added. All the incubation steps were carried 
out at room temperature for 1 h, followed by extensive washing of the unbound material. 
The negative control in the experiment was prepared in'the exactly same way except that 
no CR2 was added. The result is shown in Fig. 4-1 1. Both the E. coli and the mammalian 
cell expressed CD23 were able to bind the soluble CR2 from insect cells, with the 
bacterial protein binding somewhat better. 
4.3.5. Binding of recombinant CD23 by the insect cell expressed CR2 
immobilised on BlAcore sengor chip 
In addition to confirming the interaction between the recombinant CD23 and CR2 one of 
the aims of this study was to measure the affinity constant of the interaction. The method 
of choice for this and other kinetic, -elated studies was surface plasmon resonance (SPR). 
CR2 was immobilised on a BlAcore sensor chip and the recombinant CD23 was allowed 
to bind at different concentrations to the point of (near)satumdon. After that the bound 
protein was allowed to dissociate from the immobilised receptor over a 15 min time 
period. In this way it was possible to measure the "on" (k,., ) and "off" (kl) rates of the 
interaction in real time and to calculate the affinity constant of the interaction. Fig. 4-12 
shows the sensograms obtained for recombinant CD23 from E. coli binding to 
immobilised CR2. A similar result with respect to the amount of bound protein was 
obtained for recombinant CD23 expressed in animal cells but a certain difference in the 
shape of the curve is notable. This refers to the alteration in the dissociation part of the 
curve as a consequence of a faster dissociation rate (Fig. 4-13). 
4.3.6. The affinity constant of CD23-CR2 interaction measured by SPR 
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Fig. 4-11 Binding of recombinant CR2 to recombinant CD23 by ELISA. 
Recombinant CD23 from E. coli (squares), as well as the same CD23 fragment expressed 
in NSO mammalian cell line (circles) was coupled. to the plastic plate and the recombinant 
soluble CR2 was added and the plates incubated for 1h at the room temperature; after the 
removal of the unbound protein the bound CR2 was detected by an anti-CR2 antibody 
(BU32) and the secondary antibody peroxidase conjugate. The negative control in the 














Fig. 4-12 Binding of recombinant CD23 from E. coli to recombinant CR2 immobilised 
on BlAcore sensor chip. 
CR2 was immobilised on the BlAcore chip and the recombinant CD23 from E. coU 
allowed to bind over 5 min; after that, the running buffer (HBS pH 7.2,2 mM CaC12) was 
allowed to flow over the chip for approximately 15 min, followed by the removal of non- 
dissociated CD23 by two injections of 0.1 M glycine buffer pH 2.5. The curves represent 
sensograms obtained with the following concentrations of CD23: 300 (1), 200 (11) and 100 
(III) pM, respectively. The response (ordinate axis) in this and all other SPR experiments 
is given in arbitrary resonance units. 
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Fig. 4-13 Binding of recombinant CD23 from NSO cell line to recombinant CR2 
immobilised on BlAcore sensor chip. 
The binding of mammalian cell expressed CD23 to recombinant CR2 from insect cells 
was performed in the exactly same way as for the CD23 from E. coli except that the 
injections of glycine buffer were not required, as the dissociation of the protein was 
complete after 15 min. The curves represent sensograms obtained with the following 
concentrations of CD23: 600 (1), 400 (11), 300 (111), 200 (IV) and 100 (V) pgtml. 
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recombinant CR2 from insect cells was determined by SPR. The obtained values for 
association (k. 1) and dissociation (k-, ) rates were: k,., = 1.2 x 103 M-IS-1 (SD = 0.07 x 103; 
N= 3) and k, = 2.6 x 10-3 g-1 (SD = 0.52 x 10-', N= 3). The ratio k"10 gives the 
affinity constant Ka of 4.6 x IW M" (SD = 0.88 x 105; N= 3). In the case of recombinant 
CD23 from animal cells the obtained figures were: kj = 3.19 x 103 M-s-1 (SD = 1.10 x 
103 ;N= 4), k., = 3.12 x 10-2 S-1 (SD =6x 10-3 ,N= 4) and Ka = 1.0 x 105 W (SD = 
0.36 x 10% N= 4). These results indicate approximately 5-fold higher affinity of the 
recombinant CD23 from . co i compared to mammalian cell expressed protein, 
presumably differing only in carbohydrate moiety. Summary of the SPR data for CD23- 
CR2 interaction is shown in Table 4-1. 
Table 4-1: Summary of the kinetic data obtained for the 
interaction of recombinant CD23 and CR2 by SPR. 
Kinetic parameter CD23 from E. coli CD23 from NSo 
k-11 (M-IS-1) 1.2 x 103 3.2 x 
103 
k., (§') 2.6 x 10-3 3.1 x 10-3 
Ka (M-1) 4.6 x 10' 1.0 x 10' 
4.4. Simultaneous binding of IgE and CR2 to oligomeric CD23 
The hypothesis that oligomeric CD23 could crosslink IgE and CR2 on the cell membrane 
(Sutton and Gould, 1993) was tested in an experiment utilising recombinant CR2 from 
insect cells, a recombinant Fc fragment of IgE and recombinant CD23 from E. coli, which 
was shown in the previous Chapter to be at least a dimer with the possibility of a dynamic 
balance between the dimer and trimer. The dimeric structure of CD23 should enable it to 
bind both ligands simultaneously. The recombinant CD23 was bound to the immobilised. 
CR2 on the biosensor chip and subsequently, at the point of near-saturation, a mixture of 
CD23 and IgE-Fc (in the molar ratio 1: 4) was injected. It was necessary to add a mixture 
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of CD23 and IgE rather then IgE alone to prevent the dissociation of the CR2-bound 
CD23. The further increase in binding was observed (Fig. 4-14) and this binding could be 
attributed either to additional binding of CD23 to CR2 (as the saturation appears to be 
incomplete) or binding of IgE to the bound CD23. After subtracting the curve obtained 
for additional binding of CD23 alone in the second injection (parallel experiment), the 
observed increase in binding during the second injection was largely unchanged and can 
be therefore ascribed to the binding of IgE. Similar result was obtained by ELISA assay 
in which IgE was coupled to the plate and the recombinant CD23 from E. coll or animal 
cell line NSO added, followed by the addition of recombinant CR2. 'Me bound CR2 was 
detected by an antibody to CR2 (BU-32) as previously described. The obtained results are 
shown in Fig. 4-15- 
4.5. Summary and conclusions 
The major aim of this work was to investigate the possibility that other forms of CD23 
apart from the intact molecule could bind the newly discovered ligand, CR2 (CD21). 
Aubry et al, (1992; 1994) and Pochon et al, (1992), demonstrated that native, full length 
CD23 incorporated in liposomes was able to bind CR2 on some B cells and suggested the 
involvement of carbohydrate structures on CR2 in the interaction. No soluble form of 
CD23, native or recombinant, was reported to exhibit the same binding capacity for CR2. 
On the other hand, all the soluble fragments of CD23 generated by proteolytic cleavage 
are able to bind to IgE although with different affinity. Provided that the interaction of 
CD23 and CR2 is indeed of the lectin type, all the soluble fragments of CD23 retaining 
the lectin domain might be expected to bind CR2. The reason that no CR2 binding 
activity with soluble CD23 has yet been reported is probably the inadequacy of the 
applied methods with regard to the sensitivity of assay and concentration requirements due 
to lower affinity of the interaction as compared to the native, full length CD23. The 
experimental approach undertaken in this work overcomes both of the mentioned 
difficulties by applying several different techniques for detecting the interaction, including 
the highly sensitive BlAcore assay while the expression of CD23 in E. coli provided an 
















Fig. 4-14 Two-step binding procedure for simultaneous binding of CR2 and IgE to 
CD23 by SPR. 
in the first binding step CD23 from E. coli was allowed to bind to CR2 immobilised on 
biosensor chip and in the second binding step either CD23 alone was added at the same 
concentration as in the first binding step or in a mixture with IgE in the molar ratio 1: 4. 
In a parallel experiment the same was done with a blank chip (negative control for 
binding in both cases). After appropriate substmction of negative curves the obtained 
resulting curves are shown above. 
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Fig. 4-15 Simultaneous binding of CR2 and IgE to recombinant CD23 from E. Coli in 
F, LISA assay. 
IgE was coupled to ELISA plate'at different concentrations and the recombinant CD23 
was added at saturating concentration (10 pg/ml). After that, recombinant CR2 was added 
followed by an anti-CR2 antibody (BU-32) and the secondary antibody peroxidase 
conjugate. The negative control in the experiment (no IgE) added was subtracted from the 
readings. 
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It was found that recombinant soluble CD23 does indeed bind the native CR2 on RPMI 
8226 cells according to its capacity to inhibit completely the binding of CD23-liposomes 
to these cells. It was also found that recombinant CR2 expressed in insect cells binds 
recombinant CD23 from E. coli and NSO cell line. However, the binding in the latter case 
appears to be rather weak because it could not be detected in a cell binding assay in 
which the soluble CR2 was added to the suspension of CD23 positive cells, followed by 
anti-CR2 antibody addition and FACs analysis (not shown), while the highly sensitive 
SPR method gave a reproducible result for binding although with what may be considered 
a relatively low affinity (the affinity constant was in the range 10-5-19' M*', which is 
approximately one order of magnitude less than Ka obtained for binding of the same 
CD23 preparations to IgE). If the carbohydrate structures on CR2 are indeed critically 
involved into the interaction with CD23 then the apparently low affinity constant may be 
explained. by possibly inappropriate or insufficient glycosylation of CR2 in insect cells; 
in that case, the observed binding would confirm the prediction that some basal binding 
does indeed take place, regardless of the cell type dependent glycosylation, as a 
consequence of the contribution of the peptide structures of SCRS 1 and 2 to the binding 
(Aubry et al., 1994). This interpretation, however, should be considered with a due 
allowance for the possibility of CD23 having wider carbohydrate binding specificity and 
thus being able to bind the altered (possibly only partially) carbohydrate structures on 
recombinant CR2 with a lower affinity. It is difficult to distinguish with certainty between 
the two possibilities. An attempt had been made in this work to measure the affinity 
constant of CD23 for native CR2 but the insufficient amount of the protein and the 
interference of the used detergent, posed great obstacles in completing this task. This work 
is still in progress, but the current work, however, does demonstrate that the requirements 
for the interaction between CD23 and CR2 may not be as strict as it was initially thought, 
regarding the structure and glycosylation of CR2. 
Further to that, the evidence that soluble CD23 can crosslink IgE and CR2 as proposed 
by Sutton and Gould, 1993, has been presented. The dimeric recombinant CD23 from E. 
coli bound to the immobilised CR2 on the BIAcore sensor chip was able to bind IgE (Fc 
fragment) which indicates that ofigomeric CD23 can indeed interact simultaneously with 
both ligands, at least in vitro. Further work is currently in progress to confirm this 
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observation in vivo conditions and the B cell line co-expressing CR2 and IgE has been 
already made. Therefore, it will be possible to look at the functional consequence of the 
crosslinking of IgE and CR2 on cell membrane by soluble CD23 fragments. 
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CHAPTER 5: CD23 IS A COSTIMULATOR OF B CELL ACTIVATION 
5.1. Introduction 
5.1.1. The B cells differentiation pathway 
The B lymphocytes are responsible for fighting infections by producing specific antibodies 
that recognise and bind to the target antigen. To achieve this function the B cells have to 
undergo a rather complex pathway including several distinct stages of development. B 
lymphocytes are generated from pluripotent stem cells in the bone marrow via a number 
of precursor B cell phenotypes leading to the rise of cells that express on their surface 
immunoglobulin M (IgM). If challenged by an antigen at this stage of maturation these 
cells undergo clonal deletion accomplished by programmed cell death (apoptosis), the 
biological significance of which is the removal of those B cells that express antigen 
receptors that bind self tissue components and may potentially lead to autoiMmune 
disease. The immature B cells develops further to express membrane IgD in addition to 
already present IgM and these "mature" B cells can now respond positively to the 
challenge of an antigen. The antigen-dependent differentiation of B cells is initiated by 
the ligation of the antigen receptor (membrane IgM, mIgM) and gives rise to either high 
rate IgM antibody secreting plasma cells or antigen specific memory B cells, .. 
which have undergone immunoglobulin isotype switching. In the latter case two cellular 
events are involved, follicular reaction and germinal centre forrnation (Liu et al., 1992). 
Follicles are found in secondary lymphoid tissues such as tonsils, spleen and lymph nodes 
and consist of a network of follicular dendritic cells (FDC) and large numbers of 
lymphocytes. The FDCs can immobilise antigen and present it to the memory B cells 
which in turn begin to proliferate. Once the network is filled with the newly formed cells, 
polarisation of cells within the follicle occurs giving rise to the typical histological 
appearance of germinal center! The further proliferation of the cells is accompanied by 
the loss of membrane Ig expression and migration towards the mantle zone of die follicle, 
finally, giving rise to non-dividing centrocytes which express membrane Ig other than 
IgM. The centrocytes normally undergo the programmed cell death pathway unless 
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challenged by antigen that had initiated their formation or rescued by certain cellular 
signals that are only beginning to be understood. One of the two ' --. known signals 
required for the rescue of centrocytes from apoptosis is the ligation of CD40 (Liu et al., 
1989) and the other is stimulation with soluble CD23 and interleukin- 1 oVlL- I cc (Liu et al., 
1991; 1992). 'Me antigen specific selection of the centrocytes leads to the final stage of 
B cell development, i. e. generation of IgG, IgA or IgE antibody secreting plasma cells. 
In the absence of an antigen the activation of mature B cells can be induced by anti-IgM 
antibodies, providing a good model for studying the cellular response in vitro. Numerous 
studies have shown that addition of monoclonal antibodies against IgM to the resting B 
cells stimulates them to proliferate, as observed by both calcium mobilization and DNA 
synthesis. IgM alone is not capable of transducing the signals but does so through 
association with several other membrane proteins, notably the tightly associated Ig-(x and 
Ig-P chains (Hombach et al. 1990), and the more loosely associated CD19/CR2/TAPA-1 
complex (Fearon and Carter, 1995). The association of IgM with the accessory molecules 
Ig-a and Ig-0 has led some researchers to introduce the term "antigen receptor complex" 
(Cushley and Harnett, 1993). Both the associated Ig chains and the CD19/CR2/TAPA- I 
complex provide the antigen receptor with the necessary signal-transducing elements and 
in addition to that, the latter amplifies the response of the B cell to the ligation of antigen 
receptor. Several reports have shown that crosslinking of CR2 or CD19 to CD32 (the low 
affinity receptor for IgG, FcyRII) with monoclonal antibodies results in the amplification 
of _B 
cell proliferation (Carteret al., 1988; Carter and Fearon, 1992; Sato et al., 1995). 
In addition to enhancing the IgM response upon ligation, CD19 also exhibits a unique 
capacity to decrease the threshold of anti-IgM antibody concentration that is required to 
initiate cell differentiation, once it is crosslinked to CD32 via monoclonal anti-CD19 
antibody (Carter and Fearon, 1992). Soluble antibodies to either CD19 or CR2 suppress 
rather than enhance IgM-mediated B cell proliferation. In contrast to CD19 and CR2, 
another B cell antigen, CD40, was shown capable of stimulating cell proliferation 
independently of IgM (Banchereau et al., 1990). Again, the activation was possible only 
when CD40 was crosslinked to CD32 on a fibroblast cell line via an anti-CD40 
monoclonal antibody. 
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5.1.2. CD23 and B cell activation 
The role of CD23 in B cell activation began to emerge with the discovery that this 
membrane protein is also B cell differentiation marker, in addition to being the low 
affinity receptor for IgE. As mentioned before, soluble CD23 displays autocrine growth 
factor activity (Gordon et al., 1991; Conrad, 1990; Delespesse et al., 1989) and is also 
reported to stimulate the differentiation of centrocytes from B cell germinal centers in 
vitro (Liu et al., 1991). Bonnefoy et al., (1993), demonstrated that a subset of anti-CR2 
antibodies, as well as soluble CD23 in conjunction with IL-loc, can promote the rescue 
of germinal center B cells from apoptosis, indicating that the interaction of soluble CD23 
with CR2, which is expressed on B centrocytes, is probably responsible for this effect. 
FDCs also express membrane associated CD23 at a high level and, in contrast to soluble 
CD23, no suggestion has been made yet as to its role in B cell activation. Sutton and 
Gould (1993) have proposed a model in which the membrane CD23 may interact 
synergistically with the low affinity receptor for IgG, FcyRII/CD32, on antigen presenting 
cells, the consequence of which would be either the enhancement of the IgM-mediated B 
cell response to antigen or lowering the threshold of the antigen concentration required 
for the activation of the cell. This hypothesis is based on the analogy to the synergistic 
interaction of IgM and CD19 after ligation of both receptors, in which case it was shown 
that in addition to the enhanced response of the cell a 100-fold lower concentration of 
anti-IgM antibody was sufficient to stimulate cell proliferation after crosslinking IgM and 
C1319, as compared to IgM alone. In order to subject this model to an experimental test, 
highly purified resting B cells from human tonsils were isolated and co-incubated with a 
fibroblast cell line which has been transfortned with both. CD23 and CD32 in the 
presence of anti-IgM antibody at a wide range of concentration (10-15_10-7 M). This 
Chapter presents the evidence on the effect of membrane associated CD23 on B cell 
activation and discusses the role of CD23-CR2 interaction in the context of FDC -B cell 
interactions. 
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5.2. Generation of fibroblast cell line expressing CD23 and CD32 
5.2.1. Construction of the expression vector pML95 
The expression vector pML95 (Fig. 5-1) was made from the plasmid pEE12 (R. J. Owens, 
Celltech Ltd., Slough, UK) to which the full length CD23 cDNA in the form of a Hind 
III-Ec, IYRI fragment was inserted, as described in .- section 2.2.3. This plasmid contains 
the hCMV (human cytomegalovirus) promoter and glutamine synthetase gene (GS) for 
selection of transformants in animal cells, in addition to allipicillin resistance gene for 
propagation in bacteria. 
5.2.2. Transfection of mouse fibroblast cells with pML95 vector 
The neomycin resistant -mouse fibroblast cell line expressing human FcyRII was 
transfected with the plasn-dd pML95 by the method of lipofection. Following transfection, 
the cells were incubated in "- low glutamine selection medium for 3 weeks in the 
presence of different concentrations of MSX (methionine sulphoximine), with no success 
in selecting the transformed cells. This was due to the high level expression of the 
endogenous glutaiTfine synthetase gene, which has made it difficult to kill non-transformed 
cells. Therefore, an alternative approach was undertaken in which the expression vector 
pML95 was co-transfected with another plasmid (pRTK3) carrying the gene for thymidine 
kinase and the cells selected for their ability to grow in HAT medium. Following the 
selection in HAT medium the transfortnants were routinely grown in HT tnedium 
containing I mg/mI G418. 
5.2.3. Expression of CD23 in fibroblast cells 
To confirm the expression of CD23 on the cell surface'the cells were immuno-stained 
with BU-38 antibody and analyzed for fluorescence by flow cytometry (FACs). As can 
be seen on Fig. 5-2 the fibroblast cells transformed with pML95 plasmid do express CD23 
on the cell surface. It is also clear from this figure that only about 50 % of cells selected 











( 8.4 kb ) 




Fig-5-1 pML95 vector for expression of full length human CD23 in mammalian cells. 
This vector is based on the plasn-ýd pEE12 (Celltech) to which the cDNA for human 
CD23 was inserted as a HindIII-EcoRI fragment (partial digestion with MOW of the 
CD23 cDNA donor plasmid pUC-18 was required to preserve the HindIII site within the 
insert). The plasmid contains the human cytomegalovirus promoter (hCMV), the poly-A 
signal for termination of the transcription, the ampicillin resistance gene for propagation 
in bacteria and the glutamine synthetase gene for selection in mammalian cells (GS). The 








Fig. 5-2 Expression of CD23 in fibroblast cells. 
The TK' fibroblast cells that already expressed CD32 were cotransfected with plasmids 
pML95 (havingthe CD23 cDNA insert) and pRTK3 (containing the thymidine kinase 
gene) by the lipofection method and the cells were selected for their ability to survive and 
grow in HAT medium. The FACs profile shown above is obtained by staining the 
fibroblast cells with the anti-CD23 antibody BU-38 and the negative control represents 
the cells staining by an isotype matched negative IgG. 
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homogenous cell population either positive or negative for CD23 expression)single clones 
from the initial population were isolated by the method of limited dilution and expanded. 
Among the several clones tested two were selected for all future studies. These were 
called F6 (CD23 positive) and C1 1 (CD23 negative). The staining of these cells with BU- 
38 anti-CD23 antibody gave FACs profiles shown in Fig. 5-3. 
5.2.4. Expression of CD32 by fibroblast cells 
The LdC fibroblast cell line expressing the low affinity receptor for IgG (FcyRII/CD32) 
was obtained from D. Fearon (University of Cambridge) and has been made by J. Ravetch 
(SCRIPPS Institute, La Jolla). This cell line was grown in cc-MEM medium supplemented 
with 10 % FBS and I mg/ml G418. The expression of CD32 by these cells was confirmed 
by immunostaining using the monoclonal antibody IV. 3 from Medarex (Fig. 5-4). 
5.3. Purification of mature B cells from human tonsils 
The human tonsils from children undergoing routine tonsillectomy were obtained 30 min - 
2h after the surgery and were used for isolation of B lymphocytes immediately. 
Following the dissection of the tissue the cells were released by gentle teasing against the 
surface of the container so that the release of dendritic cell was minimal. The total number 
of cells released from one single pair of human tonsils was typically about Ix 10' and 
the number of purified B cells at the end of the procedure was about 5x 10'. The results 
obtained for a representative experiment are summarised in Table 5-1. The cells were 
examined for phenotypic expression of the surface antigens to confirm the B lineage and 
purity, as well as to define stage of development. The FACS profiles obtained for staining 
of the cells with different antibodies are shown in Fig. 5-5. The staining of cells with anti- 
CD19 antibody HD37 shows that almost the entire cell population (> 95 %) consisted 
of B cells, while the cells did not stain with either the OKT3 antibody specific for CD3 
(T lymphocytes) or with an anti-CD16 antibody (NK cells and granulocytes). The cells 
were largely IgM positive and also showed partial staining for the CD21 and CD23 
antigens. The cell number did not increase over 24-48 h incubation period following the 









Fig. 5-3 Selection and isolation of single CD23' and CD23- clones from the 
transformed fibroblast cells. 
Staining of the cells with BU-38 anti-CD23 was performed following the HAT selection, 
isolation of single clones by the method of limited dilution and expansion of these clones 
in HT medium. Two clones, one of which was CD23 positive (ten-ned 176) and the other 







Fig. 5-4 Expression of CD32 in fibroblast cells. 
The fibroblast cells were stained with anti-CD32 antibody IV. 3 followed by the secondary 
antibody FITC conjugate and analyzed by FACs. The negative control for staining was 
an isorype matched negative antibody (represented by the open peak on the graph). 
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Table 5-1: Isolation and purification of resting B cells from human tonsils. 
Purification stage Total cells Purification factor Yield 
Release of cells 1.7 x 10 9 1 from tonsils 100 
Lymphoprep 
separation of 6x 108 2.8 35.3 
mononuclear cells 
T cell depletion 
by iroseftingwith 1.3 x 108 4.6 7.6 
SRB C (I st round) 
T cell depletion 
by: rosetting with 5x 107 2.6 2 9 SRBC (2nd round) . 
Overnight incubation 4x 107 1.2 2.4 




Fig-5-5 Phenotypic characterisation of tonsillar B cells. 
Following the isolation and purification of the B cells from human tonsils the cells were 
stained for several different surface antigens to confirm the B lineage and purity. More 
than 95 % cells were CD19 positive and 80 % were also 19M positive. No detectable 
staining was observed for CD3 (T cell marker) and CD16 (NK cells and granulocytes). 
The antibodies used were HD37 (CD19), BU-36 (CD21), BU-38 (CD23), DAAA (IgM), 
Dako-CD16 (CD16) and OKT3 (CD3)- 
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center cells. The remaining population was able to survive in the culture conditions for 
up to 5 days and no measurable DNA synthesis was detected according to the [3 H]- 
thymidine incorporation assay. These observations, taken together with the FACs data for 
antigenic expression suggest that the population of B cells used in this work largely 
consisted of inactive (resting) cells and a small fraction of non-proliferating cells that had 
been already activated but were consequently arrested at the stage prior entering the 
germinal centers. In some experiments, the resting B cells were further purified from the 
activated cells by Percoll gradient centrifugation. 
5.4. Activation of B cells by anti-IgM antibody 
In the absence of antigen the mature B cells can be stimulated to proliferate by antibodies 
to either IgM or IgD, the requirement being that the antibody is presented to the cell in 
the immobilised form. To achieve this a simple experimental model has been developed 
in which the B cells are mixed with some other, usually adherent, cells that express the 
low affinity receptor for IgG (FvyRII) and the antibody to IgM presented to B cells in this 
crosslinked fashion. Carter and Fearon (1992) have found that the minimal concentration 
of anti-IgM antibody DA4.4 required to stimulate the cell was 6.7 x 10" M but the 
optimal concentration for maximum stimulation of DNA synthesis was 10-8 _ 10-7 M. In this 
work a range of anti-IgM concentration from 10" - 10-7 M was applied in order to find 
out the minimal required concentration of the antibody that is still able to activate the cell, 
as well as to determine the maximal concentration at which the antibody can be presented 
to the B cells by FcýRII bearing fibroblast cells so that no free antibody which could 
inhibit stimulation remains in the solution. It was found that minimal required 
concentration of the antibody to activate the cells was similar to that one reported by 
Carter and Fearon (1992) and was in the range 10-"-19" M. The background 
incorporation was about 2000-3000 cpm. The concentration of antibody at which Ole 
maximum stimulation was achieved was 1078 M and further increase caused inhibition. 
This is shown throughout figures 5-5 to 5-9 which are detailed below. 
r 
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5.5. Co-ligation of CD23 and CD32 increases the responsiveness of B cell to IgM 
ligation by factor 10-100. 
Tonsillar B cells were incubated with mitomycin treated either CD32t/CD23- or 
CD32+/CD23+ fibroblasts in the presence of incremental concentrations of anti-IgM and 
200 Ulml of IL-4. Following 48 h incubation the cells were labelled with [3 HI-thymidine 
for 12-16 h, harvested on fibre glass paper and the incorporation of the label measured 
by scintillation counting. The minimal concentration of anti-IgM that stimulated the cells 
in the presence of CD32+/CD23- fibroblasts was 10-" M; in the presence of CD3r/CD23+ 
cells it was reduced by a factor 10-100. Two representative experiments are shown in 
Fig. 5-6 and 5-8. 
5.6. CD23 is mitogenic for pre-activated B cells 
Fig. 5-6 also shows that CD23"enhances the cellular response to antigen receptor ligation 
which is particularly obvious for the suboptimal concentrations of anti-IgM. The 
stimulatory activity of CD23 is even more noticeable in the absence of IL-4, although no 
change of the threshold concentration of anti-IgM required for the cell activation could 
be observed in this case (Fig. 5-7). It therefore appears that CD23 can simulate the 
cytokine activity of IL-4 but does not synergise with it. 
5.7. Recombinant CR2 inhibits the stimulatory activity of CD23 
In order to test if CR2 is the counterstructure for CD23 on B cells Ole recombinant CR2 
expressed in insect cells and partially purified by DEAE-Sephadex A50 ion exchange 
chromatography was added to the medium containing B cells and fibroblasts and die 
appropriate stimuli. The incubation conditions were exactly as above. As can be seen from 
Fig. 5-8 the B cell stimulatory activity of CD23 is completely inhibited in the presence of 
recombinant soluble CR2. Note that CR2 caused an additional slight inhibition of the IgM 
mediated B cell activation. 
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Fig. 5-6 CD23 is a costimulator of B cell activation. 
Triplicate samples of 5x IW tonsillar B cells were cultured together with 2x 10" 
n-litomycin treated CD32*/CD23- (0) or CD32/CD23* (0) cells in 96-well tissue culture 
plates, in the presence of 200 U/mI of IL-4 and the incremental concentrations of anti- 
IgM. Following 48 h incubation, the cells were labelled with IP Ci of [3 H]-Thymidine for 
16 h. The results in this and all following experiments in this Chapter are shown as the 
means of triplicates, +/- SE (standard error). The background incorporation of the label 
was about 2500 cpm. 
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Fig. 5-7 CD23 is mitogenic for pre-activated B cells. 
The experiment was carried out under exactly the same conditions as in Fig. 5-6 except 
that IL-4 was not added to the cells; CD3r/CD23" (0) or CD32"/CD23" (0) cells were 
added. The mitogenic effect of CD23 on the cells that had been pre-activated with anti- 
IgM is manifested through 2-3 fold enhancement of B cell response to suboptimal 
concentrations of anti-IgM. The background incorporation was 1000 cpm. 














Fig. 5-8 Recombinant soluble CR2 inhibits the stimulatory activity of CD23. 
B cells were co-cultured with CD3r/CD23- (0) or CD32/CD23' (40) cells, or with 
CD3r/CD23' cells in the presence of 2 pg/n-d of recombinant C112 (M). Anti-IgM was 
added at the incremental concentrations and IL-4 at the concentration of 200 U/ml; the 
conditions of the experiment were as described above in the text. 
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5.8. Synergistic interaction of CD19 and JgM lowers the threshold of anti-IgM 
concentration required for B cell activation 
The synergistic effect of crosslinking membrane Ig and CD19 via immobilised monoclonal 
antibodies to both proteins is manifested through both lowering the threshold of anti-IgM 
antibody concentration required for the activation of the cell by a, factor of 100 and the 
enhancement of the cell response to optimal antibody concentration by a, factor of 2-3 
(Carter and Fearon, 1992). In the present study, this was repeated with reasonable 
accuracy, in that the threshold concentration was indeed decreased from 10" to 10" M 
anti-IgM at least (perhaps even more, but as the increment of concentration increase was 
10 it is difficult to extrapolate the exact concentration at which the activation occurs). The 
enhancement of response in the presence of anti-CD19 antibody HD37 was 2-6 times at 
the sub-optimal concentration of anti-IgM but only slight at the optimal concentration of 
the antibody (Fig-5-9). 
5.9. CD23 modulates B cell response to CD19 ligation 
In order to find out whether the simultaneous co-ligation of CD32 and CD23 on antigen 
presenting cells such as the fibroblasts in the current assay or FDC in vivo, and CD19 and 
IgM on B cells leads to a further increase in sensitivity of the cell to a given antigen, so 
that the ligation of even fewer IgM molecules would be required to activate the cell than 
in the case of either of the two synergistic interactions alone, the tonsillar B cells were 
incubated with 5 pg/ml ((2.75 x 1OF" M) of anti-CD19 antibody and CD32*/CD23- or 
CD32'/CD23' fibroblasts. The result is shown in Fig. 5-9. In addition to a significant 
enhancement of proliferation, which cannot be achieved by coligation of either CD19 or 
CD23 with their respective counterparts for synergistic interaction, the cells also became 
activated in the effective absence of anti-IgM (concentrations of anti-IgM be] ow lor" M 
did not produce any effect on cell proliferation). The effect of coligation of CD19 and 
CD23 is dependent on the concentration of anti-CD19 antibody used and is detectable at 




co Cý' 25 If- 
c 
0 




5 k-- a 
. 15 10 -13 10 -11 10-9 
Anti-IgM (M) 
10-7 
Fig-5-9 CD23 modulates B cell response to CD19 ligation. 
B cells were cultured together with CD32+/CD23- fibroblast cells alone (0) or in the 
presence of 5 pg/ml of anti-CD19 antibody HD37 (E), together with anti-IgM at the 
incremental concentrations and IL-4 at the concentration of 200 U/ml. In the same 
experiment B cells were also incubated with CD32+/CD23+ fibroblasts in the presence of 
anti-CD19 antibody under the same conditions (0). The background incorporation of the 
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Fig. 5-10 Coligation effect of CD19 and CD23 is dependent on concentration of anti- 
CD19. 
The effect of coligation of CD19 and CD23 was tested for a range of anti-CD19 
concentration from 5.5 x 10"0 to 5.5 x 10'8 M; B cells were co-cultured with 
CD3Z'/CD23- (0) or CD32/CD23* (0) fibroblasts in die presence of anti-CD19 
(concentration is indicated on the graph) but not anti-IgM. The background incorporation 
of the label was 2000 cpm. 
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5.10 Summary and conclusions 
This chapter demonstrates the biological role for CD23-CR2 interaction in the 
development of B cells. CD23 on antigen presenting cells is able to bind CR2 on B cells, 
and the consequence of this interaction is a synergistic effect of CD23 and CD32 on IgM- 
mediated B cell activation and the enhancement of cellular response to the stimulation by 
an antigen. CD23 also modulates B cell response to CD19 ligation, when combined with 
IgM ligation, by enhancing the DNA synthesis 2-3 times; moreover, the simultaneous 
ligation of CD19 by an antibody and CR2 by CD23 was sufficient to activate the cell in 
the absence of antibody to IgM. The cell response to ligation of CD19 and CR2 is 
dependent on the concentration of antibody/ligand to CD19, therefore excluding the 
possibility of direct interaction between CD19 and CD23. 
These findings reinforce the role of CD23 in the process of B cell development and add 
further evidence for physiological importance of CD23-CR2 interaction in the human 
system. Further studies will be required to clarify the molecular mechanism for the up- 
regulation of IgE synthesis by CD23-CR2 interaction and the experimental model 
described in this work could be used to answer that question. Also, the interaction of 
CD23 and CR2 appears to have different biological outputs with respect to engagement 
of membrane associated or soluble CD23. The fibroblast cell lines generated in this work 
should help to explore this aspect of biological function of CD23. 
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CHAPTER 6: DISCUSSION 
6.1. Introduction 
The aim of this work was to generate recombinant soluble CD23 that could be used for 
both biophysical and functional studies of this protein. The recent progress of the 
knowledge about CD23 made both these studies not only possible but also rather 
necessary, since it raised a number of new questions and created models that needed 
further experimental evaluation. The biophysical studies carried out in this work are an 
attempt to provide the information about the native structure of CD23, as it has. been 
indicated for both murine (Dierks et al., 1993) and human system (Sutton and Gould, 
1993) that the structure-function relationship may be very important in the biology of 
CD23. The functional studies undertaken in this work have largely focused on the 
interaction of CD23 with CR2 and the role of this interaction in B cell development. The 
presented data have reinforced the significance of oligornerisation of CD23 for its 
function and pointed out at the crucial involvement of CD23-CR2 interaction in activation 
of B cells. It is the objective of this concluding Chapter to provide an interpretation of 
the obtained experimental data and to discuss the theoretical models that could be 
proposed on the basis of this and other studies on the subject. 
6.2. The native structure of soluble CD23 
The full length CD23 protein is a 45 kDa membrane glycoprotein that undergoes 
proteolytic processing to generate several soluble fragments ranging from 37 to 12 kDa 
(Delespesse et al., 1989). All of the cleavage fragments have been implicated in one or 
more biological functions, some of these IgE dependent (Pene et al., 1988; Sarfati et al., 
1988,1992a, 1992b; Capron et al., 1987; Kehry et al., 1989) and the others IgE 
independent (Gordon et al., 1984,1985; Liu et al., 1991). These proteolytic fragments 
differ in the length of the stalk region that is still retained with the lectin domain, with 
the 25,16 and 12 kDa fragments lacking the stalk completely. As mentioned before, die 
stalk region of the protein is thought to be responsible for the self-association of CD23 
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and this comes from the sequence analysis which provided the evidence for extensive a- 
helical coiled coil structure formation (Beavil et al., 1992). The protein crosslinking data 
of both membrane CD23 and its soluble fragments obtained for human CD23 (Beavil et 
al., 1995) and its murine counterpart (Dierks et al., 1993) confirmed this theoretical 
prediction in as much that they showed that protein trimers and dimers of CD23 can be 
formed and detected by crosslinking. As expected, the crosslinking of the full length 
protein and the 37 kDa fragment had yielded the highest proportion of protein trimer 
while the 25 kDa fragment 'z produced no detectable trimer and only small amount of 
dimer. it is possible that the short sequence that comprises 40 amino acid residues and is 
often called the "neck" region because it links the stalk and the lectin homology domain 
(see model published by Gould et al., 1991, also Figure 1-2 in this thesis, Chapter 1) is 
capable of forming (x-helical structure as indeed shown for the rat mannose binding 
protein (Weis an& Drickamer, 1994). Thus, the total amount of cc-helical structure in 
CD23 may be even higher then originally predicted in the model by Gould et al., 1991. 
The published evidence on the oligomeric structure ofCD23, apart from chemical 
crosslinking, is rather limited. In fact, only one report can be found that describes the 
biophysical characterisation of a recombinant soluble CD23 fragment expressed in insect 
cells (Graber et al., 1992). In that report the 37 kDa fragment of CD23 was shown to be 
monomeric as determined by gel filtration and native PAGE. This protein was able to bind 
IgE and also to promote the survival of germinal B cells from apoptosis suggesting that 
the monomeric form of CD23 may still be active, although no reference was made to the 
affinity of this product for binding to IgE. Several other studies on homologous C-type 
lectins have been published, but these studies were mostly carried out with either 
detergent solubilized preparations of the native protein or the recombinant soluble forms 
comprising the carbohydrate recognition domain (CRD) alone or together with the neck 
region, thus, providing little infon-nation on the contribution of the stalk region to the 
oligomerisation of the protein. In the case of native protein forms it has been shown that 
mannose binding protein is an 18-mer, the molecular organization of which is reminiscent 
of a hexamer of protein trimers (Drickamer and Taylor, 1993). The recombinant fragment 
of this protein comprising the CRD and the neck region can be crosslinked to form 
protein trimers and indeed does show this type of structure when crystallised while the 
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CRD alone forms protein dimers, (Weis and Drickamer, 1994; Weis et al., 1991). Other 
proteins from the type 2 subfamily of C-type animal lectins which are structurally related 
to CD23 also show tendency of extensive oligomerisation. For example, chicken hepatic 
lectin, CHL (Loeb and Drickamer, 1987), rat hepatic lectin, RHL, (Halberg et al., 1987) 
and rabbit hepatic lectin, RbHL, (Andersen et al., 1982) are all hexamers in solution, as 
shown by chemical crosslinking and/or hydrodynamic studies, but it is worth noticing that 
the crosslinking of membrane preparations of the former two proteins resulted in the 
formation of protein dimers and low amounts of trimers rather than high molecular weight 
oligomers. Interestingly, subtilisin treatment of detergent solubilised CHL that allowed 
release of a truncated soluble fragment that lacked the transmembrane region, had a 
dramatic negative effect on the oligornerisation capacity of this protein. This fragment was 
monomeric as shown by both croslinking and gel-filtration. However, due allowance 
should be given to the fact that this protein has a rather short stalk region consisted of 
only two heptad repeats and it is possible that subtilisin treatment has further reduced the 
length of the available coiled coil structure beyond the point of cc-helix stability. Apart 
from the quoted examples there is no other reported evidence for oligornerisation of 
soluble CD23. 
In this study an approach to this question has been developed that could combine use of 
several different molecular weight determination methods and in particular ones that could 
permit the analysis of the oligomerisation state of CD23 at different concentrations of the 
protein, ranging from 2 pg/ml to 2 mg/ml. These methods included SDS PAGE, native 
PAGE, HPLC, centrifugation in sucrose gradient, diffusion coefficient measurement, 
dynamic light scattering, crosslinking of the protein at several different concentrations and 
circular dichroism measurements. Some of the data obtained by application of these 
methods are summarised in Table 6-1, together with the data obtained for the two other 
described recombinant soluble CD23 fragments, one of which is the earlier mentioned 37 
kDa fragment expressed in insect cells (Graber et al., 1992; Beavil et al., (1995) and the 
other is CD23 expressed in 
I 
mammalian cell line NSO (J. Shi, PhD thesis). One common 
feature for all three CD23 preparations described in Table 6-1 is the fact that, in spite of 
being able to form protein trimers, that can be detected by crosslinking, none of them 
yielded a significant amount of protein trimer in any of the employed molecular weight 
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Table 6-1: Comparison of the structural properties of recombinant soluble forms of CD23 
from three different sources. 
Structural CD23 from CD23 from E. CD23 from 
characteristics insect cells COU NSO cells 
Protein fragment "37 KDa"cleave- Extracellular Extracellular 
age fragment portion portion 
Theoretical mol. weight 29000 30975 30975 
SDS PAGE mol. weight 34000 35000 43000 
Native PAGE mol. weight 35000-40000 70000-100000 unknown 
Sucrose gradient unknown 55000/32000 unknown 
Superdex-75 HPLC 39000 65000/39000 87000/44000 
CD spectrum 25 % a-helix 15 % cc-helix 
74 % O-sheet 56 % P-sheet unknown 
1% random 29 % random 
Crosslinking TnVMnVDm at MnVDnvTm at Trn at 0.05 
0.05 mg/mI 0.002 mg/ml; mg1mI 
TnVDm at 0.05 
mg/ml; 
cilycosylation o-glycosylated unglycosylated. 1 N-glycan, 2-3 
0-glycans (not 
shown) 
Degradation fragments 33,29,25 KDa 25 KDa mainly, 33,29,25,16 
a 
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detem-lination methods. A limited exception to this is the E. coli generated protein which 
showed the presence of a low amount (up to 20 %) of what n-dght be trimeric fraction in 
the HPLC experiments and native PAGE and also displayed a tetramer-like organisation 
at the concentration of 2 mg/mI and above, in the dynamic light scattering assay. On the 
other hand, the protein dimer is easily detectable in most of the applied experiments, at 
least in the case of E. coli and NSO expressed protein, often mixed with monomer rather 
than existing in a homogenous state. The molecular weight of the dimer of E. coli 
expressed CD23 (55000) was calculated from Swedberg's equation on the basis of 
measured sedimentation and diffusion coefficients. This is deemed to be the most rigorous 
way of calculating the native molecular weight of proteins, as it takes into consideration 
the hydrodynamic parameters that define the behaviour of non-spherical proteins in the 
solution. The expected molecular weight of the dimer of unglycosylated extracellular 
domain of CD23 is 60000. 
6.3. Concentration dependent oligomerisation of CD23 
An apparent discrepancy between the results obtained by chemical crosslinking that 
detected protein trimer as the predominant fraction and HPLC and sucrose gradient 
centrifugation experiments that have identified protein dimer as the major fmction has led 
to the hypothesis that CD23 or at least its soluble part may exist as an equilibrium of the 
three protein forms, i. e. monomer, dimer and trimer. To test this hypothesis several 
experiments were performed and the obtained evidence indeed supports this possibility. 
First it was observed that HPLC profile of CD23 shows the presence of more than one 
protein form, mainly dimer and monomer and small amount of trimer (Fig. 3-17 in Chapter 
3) and the same is true for the profile obtained on centrifugation of CD23 in sucrose 
gradient (Fig-3-19 in Chapter 3), but in this case no protein peak corresponding to the 
trimer was detected. These experiments were carried out at the concentration of CD23 
from 0.2 to 1.33 mg/ml and it was observed that four-fold increase in protein 
concentration (i. e. from 0.33 to 1.33 mg/n-d) produced a noticeable difference in the ratio 
dimer/monomer, in -. 
favour of the dimer (Fig. 3-17, Chapter 3). Therefore, it appears 
that there may exist a concentration dependent equilibrium, at least between monomer and 
dimer. 
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Further evidence in support of such a possibility comes from the crosslinking experiments 
performed at three different protein concentrations of CD23. When crosslinked at the very 
low concentration (2 pg/t-nl) CD23 mostly remains a monomer but significant amount of 
dimer begins to appear (Fig. 3-13, Chapter 3). As the further increase of the concentration 
of the crosslinker did not affect the yield of the formed dimer (not shown in this figure) 
these conditions were considered optimal for maximum efficiency crosslinking of CD23 
at a concentration of 2 pg1ml. If the hypothesis of concentration dependent 
oligomerisation of CD23 is to hold then one could expect that the addition of - 
unlabelled CD23 to the low concentration of labelled protein should result 
in the improved 
yield of the dimer and perhaps trimer upon crosslinking, at 
least for as long as the 
concentration of the unlabelled protein is not excessive compared to the concentration of 
the crosslinker. The obtained result shown in Fig. 3-14 in Chaptýr 3 does indeed support 
this assumption, as the yield of both dimer and trimer of CD23 increases with the 
addition of small amounts of unlabelled CD23 (lanes 2-5) but decreases again with - 
further increase of the amount of the unlabelled protein added (lanes 6-9), as the 
consequence of the crosslinker no longer being in excess. On the other hand, when 
crosslinked at the concentration of 50 pg/l (25 times higher concentration than in the 
previous experiment) CD23 gives entirely different pattern; the protein trimer is the major 
form with some dimer but no monomer present (Fig. 3-15, Chapter 3). Therefore, it is 
apparent that under these conditions CD23 can be almost completely converted to the 
trimeric form and this is consistent with the results obtained for a similar fragment of 
CD23 published elsewhere (Beavil et al., 1995). Further still increase in concentration 
of the protein did not produce . conclusive evidence as the significant amount of the 
protein was intermolecularily crosslinked in a structurally non-specific manner to form 
high molecular weight protein aggregates of CD23. 
Two further experiments demonstrated the concentration dependent oligomerisation of 
CD23, both performed at high protein concentration. First, the native PAGE revealed that 
CD23 migrates in the non-denaturing gel as a single although rather diffuse protein band 
(Fig. 3-1 1, Chapter 3). Since one of the features of the electrophoresis gels is concentrating 
rather than diluting the samples this can be an efficient method to study the effect of high 
protein concentration on the oligomerisation state and homogeneity of protein 
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preparations. A sample of CD23 at the concentration of 1 mg/ml (20 pl) was loaded onto 
the native PAGE gel with the gradient of polyacrylarnide concentration 5-20 % and the 
electrophoresis was performed as described in Chapter 2. From the dimensions of the 
excised gel slice containing the protein band stained with Coomassie blue it was measured 
that the volume of the gel containing CD23 was not greater than 15 pl, thus allowing for 
a further increase rather than decrease of protein concentration during the electrophoresis. 
As can be seen in Fig. 3-1 1, Chapter 3, there appears to be only one major protein form 
that migrates in the gel with a rate that falls between the migration rates of BSA monomer 
(Mr = 66000) and BSA dimer (Mr = 132000). 
Although the main purpose of the above experiment was to deten-nine the molecular 
homogeneity of CD23 preparation at high protein concentration and no attempt was made 
to measure the actual molecular weight of the native protein, this experiment is rather 
illustrative in demonstrating that at this concentration CD23 is not a monomer as it would 
appear very unlikely that CD23 monomer which is only 30 kDa migrates as a 70- 100 kDa 
protein, even allowing for the fact that the migration of proteins 
in native gels is rather 
anomalous, as it is based on the criteria other than those 
for denaturing gels. However, 
it is possible to make a more precise estimate of the molecular weight of proteins by 
native PAGE if gels with gradient of polyacrylamide concentration are used spanning a 
wide enough range of concentrations to include sufficiently high concentration of the 
polylinker that will prevent the further migration of the protein due to the small size of 
the pores. In other words, in such gels the migation rate of proteins will be initially 
dependent on their charge and size but as they approach the higher concentration of the 
gel the effect of charge diminishes and the size of the protein becomes the limiting factor 
for the migration rate. The final migration distance of a certain protein in such gels after 
they have been oveffun for several hours can be considered proportional to the molecular 
weight of the protein. In the case of CD23 a native gel with 3-30 % gradient of 
polyacrylan-dde was prepared and the gel run for 16 h. BSA (a mixture of monomer and 
dimer) was used as an intemal molecular weight marker. Fig. 6-1 (this Chapter) shows 
that the major molecular fonn of CD23 appears to be a dimer as it runs approximately 
like the BSA monomer the molecular weight of which is 66000 (theoretical molecular 
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Fig. 6-1 Native PAGE of CD23 on 3-30 % polyacrylarnide gradient gel. 
CD23 (20 pg was applied on to 3-30 % native polyacrylamide gel and the electrophoresis 
perfon-ned for 7 (A) or 16 (B) h. The positions of different CD23 forms (likely to 
represent protein trimer, dimer and monomer) are marked; the internal molecular weight 
standards were BSA monomer (66000) and BSA dirner (132000). 
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larger form of CD23 which runs ahead of BSA dimer and --- is, T. ý. -? likely to be the 
trimer of CD23, which has the theoretical molecular weight of 90000. 
The second experiment performed at the high protein concentration (2 mg/ml) was 
dynamic light scattering. From the obtained data it can be seen that CD23 at this 
concentration behaves as a monodisperse system (although one particular measurement 
gave significant polydispersity factor and it was exempted from the analysis). Mie 
interpretation of the data can be summarised as follows: the negligible polydispersity 
factor means that a possible contribution from minor components to the average value of 
the Stokes radius is less than 15 % (according to the manufacturer's manual); this reflects 
in the allowed experimental error for the estimated molecular weight of up to 20 %. The 
estimated molecular weight for CD23 was 126000 which falls close to the theoretical 
value for the protein tetramer (120000). This is somewhat unexpected in view of the 
previous observations that have indicated the protein dimer as the dominant form and the 
trimer as the minor fraction (native PAGE, also HPLC for lower concentrations of the 
protein). It is unlikely that this represents an experimental error in the estimation of the 
molecular weight of the trimer for at least two reasons: firstly, a 40 % error would exceed 
the maximum allowed error given for the equipment's apprehension of "negligible" 
polydispersity factor, and, secondly, the native PAGE experiment which was carried out 
at similar (slightly lower) concentration of the protein indicated that the trimer represents 
only a minor fraction while the dimer is the dominant form. However, it is possible that 
the apparent tetramolecular structure of CD23 reflects a higher level association state of 
CD23, i. e. dimer of a dimer. 
6.4 Higher order of self-association of CD23 
Higher level oligornerisation is common for other C-type lectins, notably for MBP 
(Drickamer and Taylor, 1993), CHL (Loeb and Drickamer, 1987), RHL (Halberg et at., 
1987) and RbHL (Andersen et al., 1982), but in each of these cases the transmembrane 
region is thought to be responsible for the interaction. Such evidence (though not on the 
same structural basis) already exists for CD23 as well, in the form of crosslinking data 
performed by Beavil et al., 1995, who showed that a crosslinker with sufficiently long 
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"spacer arm" could crosslink CD23 to form protein hexamers, as well as all the lower 
intermediate fon-ns. This was possible not only in the case of the 37 kDa fragment which 
contains a, large portion of the stalk region but also in the case of 25 kDa fragment 
which completely lacks the stalk region and is not expected to oligomerise through 
a-helix formation (although the possibility exists that the neck region may be capable of 
forming low amount of this type of structure on its own, as could be predicted by analogy 
to MBP (Weis and Drickamer, 1994). The ability of the lectin domain to self-associate 
has been demonstrated for MBP, for which it was shown that CRD domain alone is 
capable of forming protein dimers although it does not comprise any coiled coil structure 
(Weis and Drickamer, 1994). Therefore, it appears that the lectin domains of CD23 can 
interact on a higher level of oligornerisation to generate dimers of the dimer or indeed 
the dimer of a trimer although the later could not be detected in the described light 
scattering experiment. Nevertheless, the two parameters associated with the criteria for the 
distinction between the monomodal and bimodal system, the base line (represents the fit 
of the regression analysis applied) and the sum of squares, SOS (represents the amount 
of residual noise or error associated with the autocorrelation function), both have the 
border values that indicate possible "contamination" with a component of higher molecular 
weight, presumably, protein hexamer. This type of self-association of CD23 or other C- 
type lectins seems to be possible only in solution and not on the cell membrane, since the 
crosslinking experiments with the membrane associated proteins consistently failed to 
detect any oligomeric form higher than trimer (Loeb and Drickamer, 1987; Deavil et al., 
1995). A simple explanation for this discrepancy could be that the membrane associated 
protein lacks the required level of freedom of movement which could enable the protein 
dimers or trimers to dock against each other in a sterically feasible manner. 
There may be several questions arising from the possibility of higher level of self. 
association of CD23. Here are only two. How stable are these homocomplexes? What 
possible role (if any) this type of oligoinerisation might have? The answer to the first 
question would require identification of the domains and residues involved in this 
interaction, but the data presented in this work and the evidence from elsewhere published 
reports allow for a general conclusion that the interactions involved must be weak because 
very few methods seem to be appropriate to detect them. Chemical crosslinking is one of 
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these methods but its disadvantage Mýs in the fact that it does not reflect the actual 
dynamic state of the system. Ile answer to the second question may be even more 
difficult. There is no evidence in the published literature that would suggest a possible 
physiological role for this type of oligomerisation. However, one suggestion could be 
made on the basis of results obtained in a study of the effect of recombinant soluble 
CD23 described here on the internalisation of IgE immune complexes mediated by CD23 
on B cells (S. Karagianis, PhD thesis). This study had shown that addition of low amount 
of soluble CD23 enhances rather than inhibits the uptake of IgE and a possible mechanism 
by which this could happen may be the higher level self-association of CD23 and an 
increase in avidity of the receptor/ligand interaction. 
6.5. Model for concentration dependent oligomerisation of CD23: a summary 
Based on the experimental evidence presented in Chapter 3 and the interpretations of the 
experimental data as described above, a schematic model could be proposed depicting 
various stages and levels of oligomerisation and their dependence on the concentration of 
the protein. The model is designed on the basis of the data obtained for soluble CD23 and 
may not hold true or may require corrections for the cell membrane associated CD23. At 
low protein concentration (2 pgIml; 6.7 x 10-' M) CD23 is monomer with some dimer 
present. At 50 pg/ml (1.67 x 10-' M) CD23 can form protein trimer that can be detected 
by crosslinking with some dimer as an - intermediate. Since no evidence that the trimer 
of CD23 is the dominant form (at this or even higher protein concentration) was found 
by conventional molecular weight measurement methods it is likely that there exist an 
equilibrium between the dimer and the trimcr, as well as between the dimer and the 
monomer. The difference is, however, in the affinity of the association which in the 
former case appears to be low and in the later case higher. The transition of the dimer to 
a trimer seeins to be the limiting factor in the oligomerisation of CD23. At the 
concentration up to 1.33 mg/n-d (4.4 x 10' M) there is still a low amount of the protein 
monomer present but the proportion of the trimer increases up to 20 %. Further increase 
in concentration (> 4.4 x 10-5 M) eliminates the monomer completely but does not 
significantly increase the proportion of the trimer. At the concentration of 2 mg/mI (6.7 
x. 10-' M) and above there appears to begin higher level of association of CD23 in the 
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form of protein tetramers and hexamers. The ratio tetramer/hexamer may resemble the 
equilibrium between the dimer and the trimer. Therefore, the critical concentrations seem 
to be 10' M for the transition of monomer to dimer, 10*5 M for the transition of the dimer 
to trimer and above 10' M for' -higherorder -oligomerisation (formation of tetramer 
and hexamer). The limiting factor for the formation of the higher oligomers, i. e. trimers 
and hexamers that are thought to resemble the native structure of CD23 is the low 
association constant for the formation of the protein trimer. Schematically, this could be 
depicted as shown in Fig. 6-2. 
6.6. The interaction of CD23 with CR2 
The interaction of CD23 with CR2 was discovered in 1992 by Aubry et al., who showed 
that native CD23 when incorporated in fluorescent liposomes binds specifically to several 
B cell types and that this could be blocked by several antibodies to CR2 antigen. The 
binding of CD23 to CR2 was shown to be Ca' dependent and inhibited by the 
monosaccharide derivative fucose- I -phosphate, thus, implicating the lectin type nature of 
the interaction. This finding, together with the functional studies that followed, has solved 
several questions concerning the biological functions of CD23 and offered new 
interpretations of the existing experimental models. Probably most of all, it provided 
CD23 with a ligand for its lectin functions that have been somewhat ignored ever since 
the discovery that oligosaccharidesare not required for the interaction of CD23 with IgE 
(Vercelli et al., 1989). 
The first report on the interaction of CD23 and CR2 (Aubry et al., 1992) pointed out that 
recombinant soluble CD23 failed to bind CR2 in contrast to the intact protein and the 
explanation for this was the possibility that oligornerisation of the protein may be a 
requirement for the interaction. Indeed, the recombinant CD23 used in quoted report was 
a baculovirus expressed 37 kDa CD23 fragment, which has been previously shown by gel 
filtration to be monomeric (Graber et al., 1992). In the current work it was demonstrated 
that soluble CD23 expressed in E. coli is mainly a dimer, but also that there is an 
equilibrium between the dii-ner and trimer. It was also shown that this recombinant 
preparation of CD23 is able to bind CR2 on RPMI 8226 cells, as demonstrated by its 
Protein concentration [M 











Fig. 6-2 Concentration dependent oligomerisation of CD23. 
This schematic model for concentration dependent oligornerisation of soluble CD23 
depicts several concentrations that are thought to be critical for transition between the 
different molecular forms of CD23-, although it is based on experimental observations this 
model should be considered as an approximation rather than an accurate reflection of the 
true oligomerisation state of CD23 at the given concentrations. 
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capacity to inhibit the binding of native CD23. However, from the inhibition pattern 
obtained by varying the concentration of the recombinant CD23 in the assay and the 
incubation time it appears that the affinity of the recombinant protein is somewhat lower 
than that of the native protein. 
The binding of recombinant soluble CD23 to CR2 on RPMI 8226 cells has been subject 
of another study which failed to detect the interaction (Ishihara et al., 1994). The reason 
for this might be the inappropriateness of the experimental assay used (Western blotting 
type binding assay as opposed to the cell binding assay employed in this work); also the 
authors of the quoted report failed to demonstrate that under their experimental conditions 
the full length CD23 was able to bind CR2, (i. e. the positive control in the experiment) 
and no description of the recombinant CD23 fragment used was offered. It is clear that 
soluble CD23 fragments that lack most of the stalk region (such as the 25 kDa fragment) 
are not able to oligomerise in the same manner as the intact protein or the extracellular 
part, which might significantly influence the affinity for the interaction with CR2. 
However, it is true that 25 kDa fragment of CD23 appears to be the most stable 
intermediate in the proteolytic fragmentation pattern of CD23 (Cairns and Gordon, 1990) 
and probably the most relevant for the functional studies. In this work no attempt has been 
made to test all the degradation products of CD23 for their capacity to bind CR2, but the 
SPR data on 16 kDa CD23 fragment, which consists of the lectin domain alone with no 
extra sequences on either side Q. Shi, PhD thesis) still exhibited measurable although 
somewhat weaker binding of CR2 (not shown). Therefore, it is likely that the ability of 
soluble CD23 fragments to bind CR2 will depend on their respective sizes and 
oligomerisation capacity. 
6.7. The duality of the binding site for CD23 on CR2 
The recombinant CR2 secreted by insect cells was shown to bind weakly to recombinant 
CD23 (Ka was of the order of magnitude 10-1-10-1 M). The binding site on CR2 for the 
interaction with CD23 appears to be dual: the carbohydrates from the SCRs 5-8 (in 
particular the carbohydrate at the Asn position 370) as well as the peptide backbone of 
SCRs I and 2 contribute to the total binding. As the glycosylation of CR2 may indeed 
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vary from one cell type to another it is to be expected that some cell types will bind 
CD23 better than the others. In this work, a recombinant CR2 expressed in insect cells 
was used and shown to be able to bind CD23. Although the recombinant protein isolated 
from insect cell supernatants was confirmed to be glycosylated it is likely that the 
structure of the attached oligosaccharide significantly differed from those in animal cells. 
The insect cells largely do not synthesise complex type carbohydrates, but rather truncated 
high mannose type oligosaccharide. However, few examples demonstrate that other 
monosaccharides may be included as well, notably fucose attached to the primary 
glucosamine residue (Wathen et al., 1990). Moreover, evidence does exist that 
glycoproteins synthesised in insect cells can bind fucose-specific lectins (Russell and 
Consigly, 1985), a relevant observation with respect to apparent carbohydrate binding 
specificity of CD23 in the interaction with CR2 (Aubry et al., 1992). Insect cells are also 
capable of 0-type glycosylation but not sialiation of galactose residues (Wathen et al., 
1990); this leaves them accessible for interaction with lectins. Again, this was an 
important consideration with regard to secohd reported carbohydrate-binding specificity 
of CD23 (Kijimoto-Ochiai et al., 1994; Kijimoto-Ochiai and Uede, 1995). Thus, based on 
the available published evidence, it could not be predicted in advance whether 
recombinant CR2 expressed in insect cells would possess sufficiently correct carbohydrate 
structures for binding CD23. 
According to the obtained result it might be concluded that the glycosylation of CR2 in 
insect cells was sufficiently appropriate for binding CD23, although the measured affinity 
constant (4.6 x 10-5 M) was rather low and it cannot be excluded that the observed 
binding could be partly or entirely mediated through the glycosylation independent 
binding site within the SCRs I and 2. It is not possible to determine the actual 
contributions of these two binding sites to the total binding since it would be difficult to 
predict whether the carbohydrates on CR2 may affect the secondary structure of SCRs I 
and 2 (and in that way influence their contribution to binding), and also, whether these 
two SCRs may influence the glycosylation of the rest of the protein, due to die 
conformational requirements. Thus, if the binding site for CD23 on CR2 molecule is split, 
the key questions to be answered in the future experiments are: how do the two epitopes 
relate to each other, are they mutually dependent and how do they interact with CD23 
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molecule. The preliminary evidence on the stoichiometry of the interaction of CD23 with 
its other ligand, IgE, - indicates the possibility that CD23 itself may possess two binding 
sites for IgE (J. Shi et al, submitted for publication), thus giving further credibility to the 
theory that the interaction of CD23 and CR2 may involve dual binding sites on both 
proteins. 
6.8. CD23 is a co-stimulator of B cell activation 
The secondary immune response to antigen in the differentiation pathway of B 
lymphocytes is a requirement for affinity maturation of these cells which then give rise 
to either antibody secreting plasma cells or memory B cells. The ligation of the surface 
immunoglobulin (sIg) alone would normally require a relatively high concentration of 
antigen to activate the cell, a difficulty that the B cell resolves by simultaneous 
engagement of both the slg and the other membrane proteins such as CD19 (Carter and 
Fearon, 1992) and CR2 (Carter et al., 1988). The synergistic interaction between these and 
other membrane proteins and the antigen receptor leads to increased responsiveness of the 
cell to given antigen and in that way modulates the slg mediated B cell stimulation. 
However, little is known about natural ligands for these proteins on antigen presenting 
cells such as FDC. FDC are non-lymphoid cells present in secondary lymphoid tissues and 
are generally thought to play an important role at several stages of B cell activation and 
maturation. In addition to providing the antigen in immobilised and unprocessed form., the 
FDC are implicated in co-stimulation of the pre-activated B cells (Burton et al., 1993) and 
in survival and proliferation of the selected germinal center (GC) B cells (Lindhout et al., 
1993; Kosco et al., 1992). The means by which the FDC can achieve this are at least 
pple: (i) antigen specific dependent clonal selection of GC cells through matching the 
expressed antibody isotype with the antigen on FDC, (ii) direct cell contact with B cells 
through adhesion molecules, and (iii) secretion of stimulatory factors that promote the 
survival and clonal expansion of antigen specific cells. 
A particularly remarkable phenotypic feature of FDC is high level expression of CD23. 
one possible role for CD23 on FDC has already been suggested, based on the evidence 
that a soluble fragment of this protein in synergy with IL-Ict provides the rescue signal 
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for GC B cells that would otherwise undergo apoptosis (Liu et al., 1991). In the current 
work, evidence was sought for the role of membrane associated CD23 on FDC in the 
context of B cell activation, with particular regard for the possibility that the CD23-CR2 
adhesion pair may be involved in FDC-B cell interactions. A hypothesis has been 
previously proposed, which envisages the CD23-CR2 interaction as one of the critical sites 
of the interaction, alongside the FcyR-antibody/antigen-slg interaction, between the antigen 
presenting and B cell (Sutton and Gould, 1993). The model also predicts a synergistic type 
interaction between CD32 (FcyRII, the low affinity receptor for IgG) and CD23, by 
analogy to the synergistic effects of CD19 or CR2 co-ligation in combination with the 
antigen receptor ligation. To test this hypothesis and to further clarify the role of CD23 
in B cell activation and differentiation, a fibroblast cell line that expresses both CD32 and 
CD23 was generated and could in that respect n-dmic FDC in B cell, proliferation assay. 
Highly purified resting B cells from human tonsils were stimulated with incremental 
concentrations of anti-IgM antibody, in the presence of mitomycin treated fibroblast cells 
and IL-4. The sensitivity of B cell to the ligation of sIg was increased by a factor of 10- 
100 if the B cells were co-cultured with CD32/CD23" fibroblasts as compared to 
CD32"/CD23, cells. CD23 also displayed a significant response enhancement effect in the 
presence of sub-optimal concentration of anti-IgM and this was particularly obvious when 
the cells were cultured in the absence of IL-4. Therefore, in addition to synergistic 
interaction with CD32 that leads to increased sensitivity of the cell for a given antigen, 
CD23 is also mitogenic for pre-activated cells. This is consistent with a previous report 
that had suggested such a role for CD23 based on the capacity of purified intact protein 
to stimulate the phorbol-ester pre-activated cells (Cairns and Gordon, 1990), and in fact, 
further extends this suggestion by demonstration of mitogenic activity of the cell 
membrane associated CD23. 
6.9. CD23-CR2 interaction is responsible for B cell stimulatory activity of CD23 
CR2 was the obvious choice of the candidate for the role of counter-structure for CD23 
on B cell, not only because it has been already known as the second ligand for CD23 but 
also because CR2 itself displays stimulatory effect on B cell response when co-ligated 
with sIg (Carter et al., 1988; Luxembourg et al., 1994). Besides that, this protein has been 
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implicated in the rescue of GC cells from apoptosis upon engagement with a subset of 
monoclonal antibodies, thus providing a rationale for theý capacity of soluble CD23 to 
promote the survival of these cells (Bonnefoy et al., 1993). Recombinant soluble CR2 
expressed in insect cells was added to thý culture of B cells and CD32*/CD23- or 
CD3Z'/CD23' fibroblasts, together with incremental concentrations of anti-IgM and EL-4. 
As shown in Fig. 5-8, the stimulatory effect of CD23 is completely diminished in the 
presence of recombinant CR2. In fact, soluble CR2 not only displaced its membrane 
associated counterpart from the interaction with CD23 but also exhibited, somewhat 
inhibitory effect on sIg mediated stimulation of the cells, presumably a consequence of 
its engagement in interactions with other surface proteins that may be activated by ligation 
of sIg and its inability to transduce the signals into the cell because of the lack of 
intracellular domain that is responsible for signalling through CR2. Thus, CD23 must now 
be added to the list of CR2 ligands (Od, EBV) and antibodies that are capable of 
triggering B cell activation through this receptor, particularly in combination with antigen 
receptor ligation. A very recent report (Dempsey et al., 1996) revealed a dramatic effect 
of Od attachment to a model antigen in stimulating the immune response in vivo; only 
3 copies of Od attached to the antigen enhanced the response in immunised mice by a 
factor of 10000. This was shown to be mediated through CR2 which is the receptor for 
this complement fragment, and crosslinking of the antigen receptor and CR2 by C3dg may 
be considered as a molecular bridge between the innate and acquired immunity. CD23 
binding to CR2 further reinforces this notion and in fact is a unique example of a direct 
interaction between the acquired immune and complement system without participation 
of C3dg as a crosslinker. Thus, CR2, together with CD19, emerges as a major modulator 
of'B,, cell response; it interacts with the antigen/receptor complex through Odg, it 
participates in cellular contact between the B and the antigen presenting through CD23 
and finally, it associates with CD19 and modulates the signalling through this molecule. 
6.10. CD23 modulates B cell response to CD19 ligation 
The simultaneous engagement of CD 19 on B cells by a monoclonal antibody and CR2 by 
CD23 on fibroblast cells significantly enhanced B cell response to IgM ligation (Fig. 5-9). 
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Moreover, it was shown that the engagement of these two membrane proteins was already 
sufficient to activate the cell in the absence of antibody/antigen. Thus, it is possible that 
simultaneous engagement of CR2 (with CD23 and possibly other ligands) and CD 19 (with 
unknown ligand), both of which are members of closely associated membrane protein 
complex that has great signal transducing capacity (Fearon and Carter, 1995) is sufficient 
alone to activate the cell. Although the iigand for CD19 and its possible expression on B 
cells and FDC are not yet known, the role of CD19 as the modulator of cellular response 
to antigen receptor ligation is well established, as shown by both in vitro (Carter et al., 
1988) and in vivo studies (Sato et al., 1995). Moreover, CD19 appears to be a regulator 
of other membrane proteins; for example, engaging of CD 19 by a monoclonal antibody 
induces the binding of B cells to the interfollicular stroma of tonsils via integrin (x4/P1 
(VLA-4) (Behr and Schriever, 1995). In turn, the VLA-4 adhesion pathway, together with 
the LFA-1 integrin dependent pathway, is shown to prevent apoptosis of GC B cells 
(Koopman et al., 1994), the role which is closely associated with soluble CD23. Indeed, 
the only published report that places CD19 and CD23 into the same perspective showed 
that in addition to other factors, an anti-CD19 antibody was a potent inhibitor of IL, 4 
promoted CD23 synthesis and surface expression in B cells, and that this inhibitory effect 
could be overridden by engagement of CD40 (Gordon et al., 199 1). If this is so, then one 
could speculate that the engagement of CD19 on B cells results in the inhibition of CD23 
expression which in turn decreases the probability for homotypic B cell interactions 
through CD23 and CR2 and favours the stimulatory FDC-B cell contact. 
6.11. Concluding remarks and implications for future studies 
This and other reports further delineate the difference in biological function of membrane 
associated CD23 and its soluble fragments and also emphasize the duality of the nature 
of this protein. Its role as the low affinity receptor for IgE and the modulator of IgE 
synthesis has been well documented. The role of CD23 as aB cell differentiation marker 
and an autocrine growth factor began to emerge with the discovery of its second ligand, 
CR2. This work has demonstrated that the membrane associated CD23 is co-stimulatory 
for B cells and that this function is mediated by two types of interactions, the synergistic 
interaction with CD32 and the adhesion type interaction with CR2. The later interaction 
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appears to form a link between the two distinct biological activities of CD23 with respect 
to binding IgE and CR2, since it has been shown previously that this interaction, in 
addition to having other possible functions also up-regulates IgE synthesis (Aubry et aL, 
1992; Bonnefoy et aL, 1995). It would be therefore of considerable interest to study the 
molecular mechanism for the regulation of IgE synthesis by CD23-CR2 interaction. It has 
been observed previously that in contrast to its soluble fragmenm the membrane associated 
CD23 down-regulates IgE synthesis (reviewed by Sutton and Gould, 1993). It is very 
likely that the engagement of CD23 with CR2 is responsible for the increase in IgE 
synthesis and the mechanism by which this is achieved may well resemble the one 
described in this work in the context of B cell activation. In other words, it is possible 
that ligation of CD23 on an antigen presenting cell with CR2 on IgE committed B cell, 
in the presence of IL-4, may lead to increase of IgE production and amplification of the 
cellular response to the allergen. Also, the in vitro crosslinking of IgE and CR2 with 
oligomeric soluble CD23 which has been demonstrated in this work may have important 
functional consequences in the context of allergic response. These and other studies that 
have been already initiated as the continuation of current work should further clarify the 
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